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Bryostatin 1 is a highly complex marine natural product originally isolated by Pettit 
in the 1960s.  Since its structural elucidation in 1982 bryostatin 1 has attracted 
considerable attention for the treatment of several human diseases such as cancer, HIV, 
and Alzheimer’s.  Bryostatin 1 exerts it effect by binding to and activating Protein Kinase 
C (PKC) isozymes with nanomolar affinity.  Bryostatin 1 is unique among the many 
known activators in that it is nontumor promoting.  Contrastingly, the Phorbal ester PMA, 
which shares the same binding pocket, is one of the most potent tumor promoters known. 
Despite intense medical interest, the development of bryostatin 1 as a therapeutic has 
been impeded by its extremely low natural abundance.  To address this problem 
numerous groups have developed elegant syntheses of the natural bryostatins.  Another 
and perhaps more attractive solution however is the synthesis of simplified bryostatin 
analogues.  Towards this end the Keck group synthesized the analogue Merle 23, which 
in cell assays demonstrated either a PMA like response or a bryostatin like response 
depending on the cell line.  This paradoxical behavior illustrates the complexity of PKC 
activation as therapeutic strategy, and Merle 23 provides a valuable tool for probing the 
subtle differences between tumor promoting and nontumor promoting PKC ligands.  
Described within is the scaled synthesis of Merle 23 and it use for further probing the 






as two less lipophilic analogues Merle 35 and Merle 37 are also shown to be potent 
activators of latent HIV reservoirs. 
Central to the Keck group’s analogue work is identifying strategies by which the 
synthetic burden can be reduced.  In order to simplify the synthesis of new analogues the 
use of simple aromatic building blocks as surrogates for the A and B ring pyrans was 
explored.  Using phenyl rings to replace the pyrans resulted in an analogue that failed to 
maintain high affinity binding in spite of it still containing all of the elements previously 
believed to be responsible for binding.   
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SCALED SYNTHESIS OF THE BRYOSTATIN ANALOGUE MERLE 23, AND 
IDENTIFYING A STRATEGY FOR SOLUBILIZING ANALOGUES 
 
Introduction to Bryostatins 
Bryostatins are a family of 20 marine macrolides isolated in 1970 from the bryozoan 
Bugula neritina, collected from the Gulf of Mexico.1 Crude extracts from Bugula 
neritina, a moss like animal, which grows worldwide and is known to attach to the hull of 
ships, first attracted attention when they were shown to have considerable cytotoxicity 
against the murine p388 lymphocytic leukemia cell line, as well as moderate effects 
against other NCI 60 cancer cell lines.  The active component of these extracts, bryostatin 
1 (Bryo 1), was purified and characterized in 1982.2 Since the initial collection and 
isolation, 19 other bryostatins,3 as well as another closely related natural product,4 have 
been discovered (Figure 1.1).  All bryostatins contain three pyran rings A, B, and C 
embedded within a 20-membered ring, and most differ only in their C7 (R1) and C20 (R2) 
ester substituents.  Bryostatins 3, 19, and 20 contain an additional ring that results from 
the fusion of the C21 exocyclic enoate to the C-ring.  Bryostatins 16 and 17 lack both the 












ester.  Neristatin is another member of the bryostatin family; however, it contains a 
rearranged C- ring.    
 
Bryostatin and cancer 
As a result of bryostatin 1’s potent antineoplastic properties against the murine p388 
lymphocytic leukemia cell line, it has been the focus of numerous in-vitro and in-vivo 
studies.  In 2002 Pettit et al. published a comprehensive review of these studies.5 In spite 
of potent activity in cell assays and mouse models, bryo 1 has shown limited activity in 
clinical trials as a single agent.  To date only one patient, a 41-year-old woman who had 
stage 4 follicular small-cell-cleaved non-Hodgkin’s lymphoma, has been cured by bryo 
1.6 More promising has been the use of bryostatin in combination with other anticancer 
treatments such as paclitaxel,7 vincristine,8 interleukin II,9 fludarabine,10 and dolastatin 
10,11 among others.  In the approximately 80 completed or ongoing clinical trials, bryo 1 
has been so potent that only 1 mg has been required for an entire 6-week cycle, and the 
only negative side effect observed was mild to severe myalgia.12 To some degree the 
observed synergism with other oncotic agents can be attributed to bryo 1’s ability to 
activate T lymphocytes, platelets and neutrophils,13 thus enhancing the body’s inherent 
ability to fight cancer and diminish the often severe side effects of other 
chemotherapeutics. 
 
Bryostatin and HIV 
Concomitant with bryostatin 1 potentiating the immune system is its ability to 




antiretroviral therapy (HAART) has become a manageable yet chronic disease.14 There 
exist two significant drawbacks to HAART therapies.  First is the expense and logistics 
of distributing a lifetime supply of the drugs to the areas of world that are most in need, 
and second is that if HAART is discontinued the disease will return.  The HIV virus 
establishes residency in CD4+ memory T cells, which contain an integrated yet 
transcriptionally silent infection allowing it to evade treatment by HAART therapy.15 
Bryostatin 1 has not only been shown to induce transcription of viral DNA, but also to 
downregulate the expression of the HIV-1 co-receptors CD4 and CXCR4, preventing de-
novo infection.15 Thus, bryo 1 is an attractive agent for achieving a total cure when 
combined with a HAART regiment in a strategy referred to as “Shock and Kill.”16 The 
Wender group has recently demonstrated in addition to bryo 1 simplified analogues are 
also capable of activating latent HIV reservoirs in vitro.17 
 
Bryostatin and neuroregeneration/ neurodegenerative disorders 
Another emerging area of bryostatin research is in the field of neuroregeneration and 
the treatment of neurodegenerative diseases.  Alkon and co-workers have demonstrated 
that treatment with bryostatin 1 stimulates synaptogenesis, presynaptic ultrastructural 
specialization, and protein synthesis leading to enhanced spatial learning and memory in 
rats.18 Bryo 1 is also capable of preventing neuronal loss by maintaining and restoring 
synapses when administered within 24 h following induced cerebral ischemia/ hypoxia in 
rats.19 Alzheimer’s is a neurodegenerative disease that is characterized by memory loss.  
In the early stages of the disease, learning and storage of recent information are affected 




shown to reverse an Alzheimer’s phenotype in AD double-transgenic mouse model at 
nanomolar concentration,20 and has since been advanced into phase II clinical trials. 
 
Bryostatin and protein kinase C 
All of the advantageous biological properties reported for the bryostatins are a direct 
result of their ability to bind to the protein kinase C (PKC) family of signaling enzymes 
with nanomolar affinity.  The PKC family of kinases consists of 10 isozymes, which play 
a central role in signaling cascades that regulate many cellular functions such as 
mitogenesis, differentiation, cell proliferation, and apoptosis.21 All PKCs possess a highly 
conserved C-terminal kinase domain and a pseudosubstrate which occupies the catalytic 
pocket when the enzyme is inactive (Figure 1.2).22 Differences in the C1 and C2 
regulatory domains divide the 10 isozymes into three subclasses based upon their 
requirement for second messengers. Conventional PKCs respond to both diacylglycerol 
(DG) and calcium, novel PKCs contain a mutated C2 domain that no longer requires 
calcium, and atypical PKCs lack a C2 domain along with a mutated C1 domain making 
them insensitive to both DG and calcium.  The C1 and C2 regulatory domains have 
multiple functions. In addition to maintaining the enzyme in an autoinhibited 
conformation when not active, they mediate protein-protein interactions targeting the 
enzyme to specific cellular membranes.  Binding of DG anchors the enzyme to a 
membrane and produces a conformational change removing the pseudosubstrate to give 
the catalytically competent enzyme.  Due to their central role in cell signaling, 





Figure 1.2. PKC isozymes 
 
Tumor promoting vs. nontumor promoting PKC ligands 
In addition to binding DG, the C1 domain is also the binding pocket for the tumor 
promoting natural product phorbol-12-myristate-13-acetate (PMA) (Figure 1.3). 
Bryostatin 1 also binds to the C1 domain inducing PKC activation; however in contrast to 
PMA, bryostatin 1 is antitumorigenic.  Furthermore, bryo 1 will block any effects it itself 
does not induce in a dose dependent manner, therefore functioning to antagonize PMA 
when co-administered.   Several other natural and synthetic compounds are known to 
bind the PKC C1 domain and display a range of tumor promoting ability (Figure 1.3).23 
Although the exact structural features that determine tumor-promoting ability are 
somewhat nebulous, a few trends exist.  The most distinct trend is that tumor-promoting 
ligands often contain a long hydrocarbon chain whereas nontumor promoting ligands 
either lack that chain or have it replaced by a shorter more polar group, i.e., PMA vs. 
prostratin.  It is also important to observe that high affinity binding to PKC does not 
correlate well with tumor promotion.  The co-crystal structure of phorbol 13-acetate 
bound to the C1 domain indicates that binding of a ligand occurs in a hydrophilic cleft 





Figure 1.3. PKC C1 domain ligands 
 
interacts with other proteins and cell membranes.  Thus, a reasonable hypothesis is that 
tumor-promoting ability is not dictated by binding to PKC, but rather by the interactions 
of the newly formed surface with other cellular components.  Understanding these 
interactions is of paramount importance for the successful development of PKC 
activators as pharmaceuticals.   The bryostatins are extremely interesting in this regard as 
they appear to be naturally optimized for inducing the beneficial effects of PKC 







Figure 1.4. Phorbol 13-acetate bound to the C1 domain (PDB id: 1PTR) 
 
The supply problem 
Despite intense interest in bryostatin 1 as a therapeutic for treatment of many serious 
human ailments, the issue of limited supply remains a significant obstacle.  Following the 
initial screening of Bugula neritina a second much larger scale collection was 
undertaken.  This harvest yielded 18 grams of bryostatin 1 from approximately 13,000 
kilograms of organism.  To date, this 18 grams had been sufficient to supply all clinical 
trials and research efforts; however, continuing to obtain bryo 1 from its natural source is 
both costly and environmentally unsustainable.  Due to the intriguing biology and 
developing clinical relevance of bryo 1 many approaches have been pursued to solve the 
problem of limited supply.  In conjunction with the Scripps Institution of Oceanography, 
CalBioMarine Technologies attempted to aquaculture Bugula neritina with high nutrient 
serums to increase the organism’s natural production.25 Although this attempt failed, it 
did help to identify the symbiotic bacterium Candidatus Endobugula sertula (E. sertula) 




presumably because bryostatins are only produced as a chemical defense against 
predation.  The final approach taken by Dr. Haygood’s team at Scripps was the 2007 
identification of the putative bryostatin polyketide synthase gene cluster in E. sertula;27  
but there have yet to be any subsequent reports concerning the expression of these genes 
in a suitable host. As an alternative approach, chemical synthesis has attracted attention 
from numerous groups and resulted in the syntheses of bryostatins 228, 329, 730, 931, and 
1632.  Bryostatin 1 finally succumbed to total synthesis by the Keck group in 2010.33 
Each of these syntheses represents a tremendous accomplishment in synthetic chemistry; 
however, all of them still fall short as a means of providing significant amounts of 
material for biological and clinical study.  Currently, the most feasible solution to the 
supply problem may be the synthesis of structurally simplified analogues. This approach 
has the added benefit of potentially improving upon the biological profile and substrate 
specificity of compounds that were not naturally designed for medical use. 
 
Initial Analogue Work 
Early analogue work was pioneered by a collaboration between George Pettit, Peter 
Blumberg and Paul Wender who compared the structural features of natural and semi-
synthetic bryostatins to identify the pharmacophoric elements (Figure 1.5).34 First, by 
looking at the natural bryostatins it is clear that changing the ester substituents at C7 and 
C20 has little effect on PKC affinity; however, if the C20 ester and C19 ketal are missing 
the binding affinity drops by two orders of magnitude, i.e., bryostatins 16 and 17.  
Comparison of the semisynthetic analogues (Figure 1.6) indicated that hydrogenation 







Bryostatin R1 R2 Ki (nM) 
1 O2CCH3  1.35 ± 0.17 
2 OH  5.86 ± 1.13 
4 O2CC(CH3)3 O2CH2CH2CH3 1.30 ± 0.19 
5 O2CC(CH3)3 O2CCH3 1.04 ± 0.10 
6 O2CH2CH2CH3 O2CCH3 1.18 ± 0.29 
7 O2CCH3 O2CCH3 0.84 ± 0.07 
8 O2CH2CH2CH3 O2CH2CH2CH3 1.72 ± 0.10 
9 O2CCH3 O2CH2CH2CH3 1.31 ± 0.00 
10 O2CC(CH3)3 H 1.56 ± 0.16 
 












effect on binding.  However, further hydrogenation of the C21- C34 exocyclic enoate had 
a much more dramatic effect.  The C13-C30 olefin was also manipulated through 
epoxidation, which showed minimal effects implying that substituents on the B- ring are 
unlikely to play any substantial role in determining PKC affinity.  Inversion of the C26 
stereocenter of bryostatin 1 or acetylating it on bryostatin 4 both had detrimental effects. 
These comparisons indicate that the functionalities surrounding the C-ring are the 
major factors in binding to PKC, and of particular importance are the C26 oxygen, an 
olefin at C21- C34, and a C19 ketal in combination with an ester at C20.  The identity of 
the C20 ester does however appear to be flexible, and is therefore an attractive position 
for synthetic diversification.  
Utilizing computer modeling to compare the energy-minimized structure of bryostatin 
1 to diacylglycerol (DAG), and phorbol-12-myristate-13-acetate (PMA), Wender and Co-
workers were able to make spatial correlations between the C26 hydroxyl, C19 ketal and 
C1 carbonyl to that of an oxygen atom triad on the other ligands (Figure 1.7).  The A-, 
and B-ring portion of the molecule was then hypothesized to function as a ‘spacer 
domain’ to hold the three pharmacophoric oxygen’s on the C-ring ‘binding domain’ in 
the correct position. 
 
Wender’s Analogue Design 
Wender’s original analogues called for significant changes to the A- and B-ring 
portion while leaving the C-ring ‘binding domain’ completely intact.  In general, the 
retrosynthetic plan was to disconnect the novel B-ring through a trans-acetylation 





Figure 1.7. PKC ligand binding hypothesis 
 
(Figure 1.8).  This strategy was chosen to allow for the utilization of multiple spacer 
domains in a combinatorial approach. 
Many of Wender’s early analogues are represented in Figure 1.9, and a few additional 
ones will be discussed later.  Through the synthesis of these analogues, several new 
structure-function relationships were probed.  First was the role of the C3 hydroxyl group 
that when absent (1.4) or inverted (1.6) binding affinity suffered by ~100 fold.34c, 35 This 
was hypothesized to be due to the loss of the internal hydrogen bonding network created 
by the C3 hydroxyl, C19 ketal, and the pyran oxygen of the B-ring.  Similar to what was 
observed for (26-acetoxy)-bryostatin 4, when the C26 hydroxyl was acylated, binding 
was almost completely inhibited.35a Analogues 1.8-1.11 demonstrate that removal of the 
A- ring was well tolerated; however, better PKC affinity was achieved when the sterically 
bulky t-Butyl group was used at R1 as opposed to a hydrogen.
34c, 36 Diversification at C20 
yielded some interesting results.  While the C20 was amenable to a variety of long 
hydrocarbon chains and a phenyl group, introducing an acetate ester had a detrimental 
effect on Wender’s analogues. In contrast, this modification had no effect on the 





Figure 1.8. Wender’s analogue strategy 
 
necessary, presumably to help arrange the three pharmacophoric oxygens correctly.34c In 
addition to obtaining Ki values, analogues 1.5 and 1.11 were evaluated for activity against 
a number of human cancer cell lines (Figure 1.9).35b In general, analogue 1.5 yielded 
similar activity to that of bryostatin 1. Analogue 1.11 demonstrated reduced 
growthinhibition indicating that while the A-ring may not be responsible for PKC binding 
it still plays a role in biological potency. 
In subsequent publications, the Wender group revealed a first- and second- generation 
synthesis as well as biological evaluation against the NCI panel of 60 human cancer lines 
for their most potent analogue 1.16, which has subsequently been named ‘picolog’ 
(Figure 1.10).38 In general, picolog demonstrates similar growth inhibitory effects as 
bryostatin 1 and in some cell lines such as MOLT-4 human acute lymphoblastic leukemia 
and NCI-H460 human lung cancer it was orders of magnitude more potent.  The only 
difference between picolog and other analogues is the lack of a C27 methyl group, and as 
the most potent and easily synthesized analogue, it has become Wender’s most well-











Analogue, GI50 in ng/mL 
1.5                              1.11  
Pancreas BXPC-3 6 80 
Lung NCI-H460 120 3100 
Pharynx FADU 1.8 290 
Prostate DU-145 170 3000 
 






Figure 1.10. ‘Picolog’ 
 
Keck’s Analogue Design 
The Keck group has had a long-standing program directed at the total synthesis of 
bryostatin 1.  Towards this end, a novel reaction termed ‘pyran-annulation’ was 
developed to access the A- and B-ring pyrans.  This methodology allows for the 
convergent union of two aldehydes across the four-carbon allyl stannane/silane 1.18 
resulting in a stereo-defined 2,6- tetrahyropyran (Figure 1.11).40 The first step in the 
process is the catalytic asymmetric allylation of the first aldehyde 1.17 with stannane 
1.18, which is available from commercial sources in three steps.41 The resulting chiral β-
hydroxyallylsilane 1.19 is then treated with the second aldehyde 1.20 under Lewis acidic 
conditions to give the 2,6-tetrahydropyran through a proposed six-member transition 
state.  When this methodology is utilized in an iterative fashion bis-pyran 1.25, which 
represents a simplified spacer domain, can be accessed rapidly. 
 
Pyran annulation approach to analogues 
The development of the pyran annulation allowed for the synthesis of the group’s first 





Figure 1.11. Pyran annulation strategy 
 
reactions to construct the A- and B-rings.  The C-ring would then come from linear 
precursor 1.30 which itself was elaborated from (R)-(+)-isobutyl lactate 1.31 through a 
series of chelation controlled allylation reactions (Figure 1.12).  Analogue 1.26 contains 
all three oxygen hypothesized to dictate PKC binding, but was simplified at C20, and 
C21 of the C-ring as well as the replacement of the high oxygenated A- and B-rings with 
pyrans containing only an exocyclic methylene.  This design was chosen for three 
reasons: first, to test the applicability of the pyran annulation to complex substrates; 
second, at that time, the role of the C20, and C21 substituents were still not well-defined; 






Figure 1.12. First analogue retrosynthesis 
 
In the forward direction (Figure 1.13), commercially available (R)-(+)-isobutyl lactate 
provided the first stereocenter, which was protected as the BOM ether, followed by 
DIBAl-H reduction to the aldehyde.  The first 1,2 chelation-controlled allylation 
proceeded in high yield to give homoallylic alcohol 1.33 as a single, NMR observable, 
diastereomer.43 The free alcohol was protected as the PMB ether and the olefin was 
cleaved with ozone to provide aldehyde 1.34.   The C23 stereocenter was established 





Figure 1.13. Synthesis of the C16-C27 segment 
 
a 5:1 mixture of diastereomers, which were separable following protection of the alcohol 
with TBSCl.  The terminal olefin was converted to the one carbon homologated aldehyde 
using Buchwald’s hydroformylation conditions.45 Prenyl indium addition46 was used to 
install the gem-dimethyl and the resulting racemic alcohol was oxidized using PCC47 to 
give 1.30 in 10 steps and ~46% yield.  
With an efficient route to olefin 1.30 in hand, attention was turned to elaborating 1.30 
to the desired C-ring aldehyde 1.41 for the first pyran annulation.  The first generation 
plan (Figure 1.14) was to remove the TBS protecting group, close the C- ring, and then 
oxidize the resulting glycal olefin to give ketone 1.39.  Cleavage of the terminal olefin 
was accomplished with ozone.  However, the C17 aldehyde was slow to react in 
subsequent transformations.  Wender and Trost32 have also reported similar observations 





Figure 1.14. Attempted functionalization of the C17 aldehyde 
 
In order to circumvent the reactivity issue, the C17 aldehyde was extended prior to 
cyclization (Figure 1.15).  Cleavage of olefin 1.30 proceeded with a dramatically 
improved yield over the cyclized compound 1.39 and a Horner-Wadsworth-Emmons 
olefination with a thioester phosphonate provided the α,β-unsaturated thioester 1.44.48 
Cleavage of the TBS protecting group followed by dehydrative cyclization accessed 
glycal 1.45.  Finally, the thioester was reduced to the aldehyde with DIBAl-H to give C-
ring 1.46 in a remarkable 27% overall yield from (R)-(+)-isobutyl lactate.  Unfortunately, 





Figure 1.15. Completing the C-ring 
 
the C20 alcohol to undergo Michael addition into the α,β-unsaturated thiolester, as well 
as poor selectivity for reducing the thiol ester in the presence of a C20 ketone.  Attempts 
to use the C-ring as the β-hydroxyallyl silane halve were also meet with limited success 
due to the instability of the glycal to catalytic asymmetric allylation conditions. 
Pyran annulation of the C-ring aldehyde 1.46 with β-hydroxyallyl silane 1.24 
provided 1.47 (Figure 1.16), which after removal of the TBDPS group and oxidation to 
an aldehyde, under Ley conditions,49 was ready for the second pyran annulation with β-
hydroxyallyl silane 1.28.  The C-ring of coupled product 1.48 was oxidized with m-
CPBA, the C1 TBDPS was removed and the free alcohols at C1 and C20 were both 
oxidized.49 Further oxidation of the C1 aldehyde using Pinnick conditions,50 and 
deprotection of the PMB ether gave seco-acid 1.50, which was cyclized using Yamaguchi 
conditions.51 Finally, simultaneous deprotection of the BOM ether and methyl ketal was 
achieved in one step with LiBF4.











pharmacophoric oxygens, was sent to Dr. Peter Blumberg at the NIH for biological 
testing regarding binding affinity.  Analogue 1.26 exhibited a Ki of 546 nM for purified 
PKC-α.  Such a dramatically higher Ki compared to that of bryostatin 1 (Ki = 1.35 nM) or 




At this stage the project was continued by Dr. Carina Sanchez who installed the 
missing C-ring functionalities.  To accomplish this, Dr. Sanchez started with TBS 
protection of the C3 alcohol on intermediate 1.51.  The C21 enoate was added through an 
aldol reaction with methyl glyoxylate followed by elimination.  The exocyclic enoate was 
obtained as a single isomer in which olefin geometry was dictated by developing 1,3-
allylic strain from the vicinal ketone.53 Luche reduction and esterification with benzoic 
anhydride provided a separable 4:1 mixture of diastereomers.  Global deprotection 
completed the analogue ‘Carina 1’ (Figure 1.17), which exhibited a Ki = 0.70 nM 
confirming the necessity of the C21 enoate and a C20 ester in order to maintain single 
digit nanomolar affinity for PKC. 
 
Second-generation route to pyran analogues 
Building on the success of Carina 1, Dr. Matt Kraft and Dr. Wei Li designed a more 
convergent route in order to create a series of bryostatin analogues that would further 
probe the role of the C20 ester and C21 exocyclic enoate (Figure 1.18).54 The two major 





Figure 1.17. Synthesis of Carina 1 
 
associated with the acid sensitive glycal, and the convergent union of two equally 
complex subunits. Both modifications allowed for greater throughput of material 
compared to the previous completely linear route. 
Synthesis of the A- and C-ring fragments was divided between Dr. Kraft, C-ring, and 
Dr. Wei, A-ring.  The C-ring, up to intermediate 1.45, was made in a linear fashion as 
previously described. Glycal 1.45 was epoxidized with m-CPBA. In-situ opening of the 
epoxide through oxonium ion formation and trapping by MeOH addition to the axial 
position gave a C20 alcohol that was oxidized to ketone 1.58 using Ley conditions49 
(Figure 1.19). Low yields in these steps were attributed to the tendency of the 





Figure 1.18. Second-generation retrosynthesis 
 
thioester.  The PMB protecting group was then exchanged for a TBS in order to avoid a 
difficult purification encountered in the previous route when both PMB ethers were 
removed prior to macrolactonization.  The final step was to selectively reduce the 
thioester to an aldehyde in the presence of the C20 ketone.  After extensive screening of 
conditions, Dr. Kraft discovered that conditions developed in the Evans group (Lindlar’s 
catalyst, Et3SiH, 1-hexene)






Figure 1.19. Synthesis of second-generation C-ring 
 
Synthesis of the A-ring portion (Figure 1.20) commenced with Michael addition of 
benzyl alcohol into acrylonitrile, followed by a Reformatsky reaction with ethyl 
bromoacetate.56 Keto-ester 1.62 was then subjected to a Noyori asymmetric 
hydrogenation to give chiral alcohol 1.63 in 95% ee.57 The C11 free alcohol was 
protected as the TBS ether, the benzyl grouped cleaved, and the resulting C9 alcohol was 
oxidized to the aldehyde.  Pyran annulation of aldehyde 1.57 with the known β-
hydroxyallylsilane 1.28 provided the A-ring in excellent yield and as a single 
diastereomer.  Removal of the C13 TBS protecting group resulted in a mixture of the 
mono alcohol 1.66 and the diol 1.65 from loss of the C1 TBDPS, which could be 
selectively replaced.  The free C13 alcohol was then protected as a TMS ether and a 
Bunnelle reaction was used to access the desired β-hydroxyallylsilane 1.56.58  
Pyran annulation between C-ring aldehyde 1.60 and A-ring β-hydroxyallylsilane 1.56 













and general this reaction is (Figure 1.21).  Selective removal of the primary TBDPS 
group at C1 in the presence of the C25 TBS was accomplished with TBAF in 
AcOH/DMF,59 and the free alcohol was oxidized to the acid over two steps.  Cleavage of 
the C25 TBS with HFPyr provided the seco-acid, which was carried directly into the 
Yamaguchi macrolatonization.51 
Once again the C21 enoate was added through an aldol reaction with methyl 
glyoxylate followed by elimination (Figure 1.22). Luche reduction with a dr =  4:1, 
esterification with the appropriate anhydride, and global deprotection completed two new 
 
 





Figure 1.22. Completion of Merle 21, 22, and 23 
 
analogues, Merle 22 and Merle 23, as well as Carina 1 (Merle 21).  All three analogues 
exhibited Ki values comparable to that of bryostatin 1 (Ki = 1.35 ± 0.17 nM).  
Waiting to install the C20 ester and C21 enoate until the end allowed for the 
individual assessment of each of these groups’ contribution to binding affinity to be done 
without significant deviations to the synthetic route (Figure 1.23).  The C20 ketone could 
be reduced to give either the axial or equatorial alcohol by using NaBH4 or L-selectride. 





Figure 1.23. Synthesis Merle 24, and 25 
 
global deprotection provided two new analogues, Merle 24 and Merle 25.  Both of the 
new analogues had significantly improved binding as compared to analogue 1.26 but still 
fell well short of the high binding affinities observed for Merle 21-23 or the natural 
bryostatins.  Additionally, by also comparing with Bryostatin 10 (Figure 1.5), which 
lacks a C20 ester but contains a C21 enoate, it appears that an analogue can tolerate 
removing one of the C-ring substituents but not both.  Of the two substituents, the C21 
enoate seems to have a greater effect. 
 
Biology of Merle 23 
Merle 23 differs from bryostatin 1 at four positions across the A- and B-rings (Figure 





Figure 1.24. Structural differences 
 
the C8 gem-dimethyl and C9 alcohol are omitted. If the A- and B-rings are to serve 
merely as a spacer domain holding the three-pharmacophoric oxygens in place then these 
changes should not affect bryostatins 1’s highly attractive biology. 
Merle 21-23 all represent potent PKC ligands with binding affinities equal to or 
greater than Bryostatin 1; however, since strong binding does not solely dictate tumor 
promoting vs. nontumor promoting behavior it was prudent to examine whether or not the 
Merle compounds were true bryostatin mimics biologically.  To accomplish this goal, a 
more extensive collaboration was formed with Peter Blumberg’s group at the NIH.  The 
new analogues were tested in a number of human cell lines in which tumor promoting 
PMA and nontumorigenic bryostatin 1 have contrasting effects. The first test was the 
U937 leukemia cell attachment and proliferation assay. In U937 cells PMA inhibits 
proliferation and induces attachment, while bryostatin 1 has little effect on either.  
Furthermore, bryostatin 1 will antagonize the response induced by PMA in a dose 
dependent manner.60 In this assay (Figure 1.25), Merle 23 (purple bars) displays PMA 

















were mirrored when cell growth was measured in the K562 chronic myelogenous 
leukemia cell line indicating that the A- and B-rings do not simply act as a spacer 
domain, but instead play a critical role in the analogue’s biological profile. 
In the LNCaP human prostate cancer cell line, PMA inhibits proliferation and induces 
apoptosis while Merle 23, like Bryostatin 1, fails to induce either response (Figures 1.26, 
and 1.27).61 Additional studies using the LNCaP cell line have demonstrated that the 
biological response of Merle 23 in LNCaP cells was more complex, showing either a 
bryo 1 like, PMA like, or a novel response depending on what biological end point was 
observed. When Merle 23 was co-administered with the proteasome inhibitor MG-132 it, 
like PMA, inhibited proliferation and induced apoptosis while bryostatin 1 was 
unaffected by the presence of MG-132. When phosphorylation of known PKC substrates 
MARCKS and PKD1 were observed, Merle 23 showed duration of response intermediate 
between that of bryostatin 1 and PMA, but closer to the long activation time seen for 
PMA. Activation, down regulation, and translocation of PKC isozymes, alpha and delta, 
was another observable endpoint in which all three compounds exhibit distinct responses. 
Merle 23 was the least potent compound for activation of PKC delta through 
phosphorylation at Ser299; however Merle 23 showed intermediate potency for 
phosphorylation at Tyr311. Merle 23 was the most efficient down-regulator of PKC delta, 
but the least efficient down-regulator of PKC alpha. Bryostatin 1 induced a biphasic 
down-regulation of PKC delta and was the most potent against PKC alpha, while PMA 
down-regulated both with equal efficiency. Translocation of PKC isoforms to either 











Figure 1.27. LNCaP apoptosis assay 
PMA: 0.1, 1, 10, 100, 1000 nM 
Bryostatin 1: 0.1, 1, 10, 100, 1000 nM 
Merle 23: 0.1, 1, 10, 100, 1000, 10000 nM 
PMA: 0.1, 1, 10, 100, 1000 nM 
Bryostatin 1: 0.1, 1, 10, 100, 1000 nM 




phosphorylation and therefore what signaling pathways are activated. Merle 23 
demonstrated a PMA like response of translocating PKC alpha and epsilon to the plasma 
membrane, but showed bryo 1 like behavior in directing PKC delta and PKD1 primarily 
to internal membranes. Our current understanding of Merle 23 is that it is not simply 
bryostatin 1 or PMA like but that it is a distinct compound with a unique biological 
profile that provides an invaluable tool for understanding the role of PKC isozymes in 
cellular processes. Unfortunately, at this point all of the material previously synthesized 
had been consumed, and for continued testing of Merle 23 a larger scale synthesis was 
needed. 
 
Results and Discussion 
Scaled synthesis of Merle 23 
In order to produce substantial quantities of Merle 23, a third-generation approach 
(Figure 1.28) was developed.  For the third approach, we wanted to utilize a fully 
functionalized C-ring in the B-ring pyran annulation so that difficult manipulations on a 
complex substrate could be avoided.  The new fully functionalized C- ring was 
envisioned to come from linear precursor 1.75 through an olefinic ester metathesis 
reaction developed by the Rainier group,62 followed by a series of stereo- and regio-
selective oxidations.  Metathesis precursor 1.75 would then be tracked back to two nearly 
equal size fragments 1.76 and 1.77 that could be united through an EDCI mediated 
coupling. The A-ring β-hydroxyallylsilane 1.56 was produced on gram scale following 
the route previously described by Dr. Li (Figure 1.20) without any deviation and 





Figure 1.28. Third-generation retrosynthesis 
 
The 3rd-generation C-ring also began with (R)-(+)-isobutyl lactate, which was 
elaborated to homoallyl alcohol 1.77 through the same series of chelation controlled 
allylations described previously (Figure 1.13).  At this point, rather than expanding 
linearly, 1.77 was coupled to acid 1.76, which was constructed in six steps from methyl 
isobutyrate (Figure 1.29).  Deprotonation with LDA and alkylation with allyl bromide 
provided terminal olefin 1.79 in 70 % yield on a 1-mole scale.  Wohl-Ziegler radical 





Figure 1.29. Synthesis of acid 1.76 
 
Removal of the acetate through transesterification with K2CO3/MeOH accessed the free 
alcohol, which was protected with TBSCl, and hydrolysis of the methyl ester under basic 
conditions provided acid fragment 1.76.  Having produced each C-ring fragment on 
large-scale, attention was focused on coupling and elaborating to glycal 1.85. 
Acid piece 1.76 was coupled to alcohol 1.77 with EDCI to provide ester 1.82 in 92 % 
yield (Figure 1.30). A three-step hydroboration,64 oxidation,65 and Wittig-olefination66 
sequence was employed to prepare the one carbon homologated olefin 1.75. Use of the 
Rainer metathesis reaction62 to form glycal 1.85 was facilitated by the presence of the 
C18 gem-dimethyl, which directs the titanium catalyst towards reacting with the olefin 
first, whereas reaction with the ester first leads to olefination without cyclization. The 3rd-
generation route for the C-ring accessed gram quantities of glycal 1.85 in 11 linear steps, 
a 3-step improvement over the previous routes. Furthermore, having a TBS protected 
alcohol at C15, as opposed to the previously used thioester, allowed for functionalization 
of the glycal. The unsaturated thioester (Figure 1.19) was prone to cyclization though 






Figure 1.30. Synthesis of glycal 1.85 
 
Analogous to previous routes, glycal 1.85 was epoxidized with magnesium 
monoperoxy phthalate (MMPP) with in-situ opening of the epoxide, followed by 
oxidation of C20 to the ketone using Ley conditions49 (Figure 1.31).  Aldol addition of 
methyl glyoxylate at C21 with K2CO3 in MeOH allowed for in-situ elimination to 
provide exocyclic enoate 1.87 in one-step,38b and reduction using Luche conditions67 
gave the axial alcohol as a single diastereomer by 1H NMR. The high level of selectivity 
during the reduction can be rationalized by considering the C20-C21 portion of the ring 
as highly planar, and approach of the hydride from the face opposite the bulky substituent 





Figure 1.31. Functionalization of the C-ring 
 
when the reduction is carried on the macrocylcic structure 1.72 (Figure 1.22).  
Subsequent esterification with (2E,4E)-octa-2,4-dienoic anhydride provided the fully 
functionalized C-ring 1.88. Cleavage of the C15 TBS ether was accomplished with 
HF•Pyr, and the resulting alcohol was oxidized to an aldehyde. Finally, protecting group 
exchange of PMB for TBS was done to avoid later complications when the PMB 




Pyran annulation between the A- and C-ring fragments proceeded in 75 % yield to 
give the full carbon skeleton 1.91, and at this point the synthesis intercepted known steps 
to finish the analogue (Figure 1.32).  Selective removal of the C1 TBDPS,59 double 
oxidation of the resulting alcohol to the C1 acid,50, 65 and Yamaguchi 
macrolactonization51 accessed macrolactone 1.73.  Deprotection over two steps to remove 
first the PMB then BOM ether and methyl ketal52 provided Merle 23 in 28 linear steps, 
50 total.  The 3rd-generation route only represents a 3-step improvement over the previous 
route; however, the true advantage was the convergent route to the fully functionalized C-
ring.  The new C-ring route resolved issues associated with functionalizing the C-ring 
with the thioester present at C15 allowing for quantities in excess of 10 grams to be 
prepared.  The other serious advantage is that after the pyran annulation to form the B-
ring only 7 steps remained to finish the analog as opposed to 11.  Through the 3rd-
generation route, 15 mg of Merle 23 have been produced to date as well as significant 
amounts of materials that could readily be converted to Merle 23 or to other new 
analogues. 
 
Transcriptional response of Merle 23 
Building on the previous result where Merle 23 was seen to act like the phorbol ester 
PMA when tested for cell proliferation and attachment in U937 cells, but bryostatin 1 like 
when looking at cell growth and TNFα induced apoptosis in LNCaP cells, we sought to 
examine the effects of all three agents from a more comprehensive view.68 Using qPCR, 
we examined the effects of the compounds as a function of dose and time on the levels of 












based on its marked regulation by PMA as described by Caino,69 as well as their 
relevance to known growth regulating pathways.  We sought to answer three questions: 
how do each of the three compounds compare in the activation of individual genes? Does 
each gene show a similar pattern of response to the compounds?  Finally, how do the 
patterns of response compare and contrast for the two cell lines given that a different 
biological outcome is reached?   
For the LNCaP cells the time course for modulation of all 18 genes at 2, 6, 12, and 24 
h windows is illustrated in (Figure 1.33) at 100 nM PMA, a fully effective dose.  The 
maximal response for most genes examined was observed at 6 h or later. For several 
genes (e.g., CXCL8, CCL2, TNFa, TRAF1, BIRC3), elevated levels were maintained 
past the 24 h time frame, while others (e.g., ALOXE3, ETS2, SMAD6) had largely 
returned to baseline.  Next, the pattern of response to PMA was compared to that of 
bryostatin 1 and Merle 23 (Figure 1.34 and 1.35).  At the 2 h time point, the average 
PMA response had risen to 26-fold over the control.  Bryostatin 1 had induced only 52% 
of the PMA response while Merle 23 induced 73%.  After 6 h the PMA response had 
climbed 87-fold over control. Bryostatin 1 now only exhibited 11% of this response and 
Merle 23 58%.  At the 12 and 24 h time points PMA continued to display elevated 
mRNA levels of 71- and 83-fold over control.  The bryostatin 1 response fell to 6.9% of 
PMA at 12 h then rebounded slightly up to 9.8% at 24 h.  The Merle 23 response 
followed a similar pattern dropping to 23% before rebounding to 35% of the PMA 
response.  
To answer the first question “how do each of the three compounds compare in the 





Figure 1.33. Activation of genes by PMA 
 
similar pattern of response; however, the degree of transience was dramatically different.  
The second question can be answered by observing that the degree of transience was not 
conserved for the different genes. In particular, SERPINB2 showed dramatic induction 
by bryostatin 1 at 2 h, which was entirely lost by 24 h.  Contrastingly, PPP1R15A 
experienced an approximate 10-fold increase that was maintained through the entire 24 h 
time course.  It is also important to once again note that the transient response of 
bryostatin 1 was not due to instability as bryo 1 was capable of antagonizing the effects 
of PMA throughout the full 24 h when co-administered.   
Merle 23 demonstrated contrasting biological outcomes in U937 cells where it 
resembled PMA in its ability to inhibit proliferation and induce attachment whereas in 
LNCaP cells it was bryostatin 1 like, not inhibiting proliferation nor inducing apoptosis.  
Therefore we compared the pattern of transcriptional response in these two cell lines to 























showed the most significant response were used again (Figure 1.36, and 1.37).  The first 
difference of note is that in U937 cells the maximum level of stimulation was not as high 
as for LNCaP cells.  The average changes in gene response due to PMA were 4.8, 9.1, 
and 17-fold at 2, 8, and 24 h compared to average increases of 26- and 83-fold at 2 and 
24 h in LNCaP cells.  Likewise, the response to bryo 1 and Merle 23 were considerably 
reduced.  The bryostatin 1 responses were 75.4%, 43.4% and 11.5% of the PMA 
response, and the corresponding values for Merle 23 were 45.4%, 60.9% and 48.2%, 
respectively.   
To adress the third question, the two cell lines showed dramatically different levels of 
activation in response to the three compounds, suggesting that the different biological 
outcome may be a result of the cells sensitivity to PKC activation.  U937 cells having a 
smaller range seem to be more susceptible to modest changes in degree and duration of 
mRNA activation. 
The major difficulty in understanding the rationale for a bryostatin like response 
compared to PMA are the multiple mechanistic differences such as isozyme 
translocalization, modification, and down regulation.  These studies sought to look at the 
net effect of these factors on what genes are activated and for how long.  For both cell 
lines, the dominant difference in PMA vs. bryostatin like behavior was the degree of 
transiency following the initial activation.  Merle 23 gave a transiency level intermediate 
between that of PMA and bryostatin for both cell lines.  We now believe that tumor-
promoting behavior is likely a result of two factors:  first, the duration of gene activation 












Figure 1.37. Transcriptional response in U937 cells at 24 h  
 
Merle 23 and HIV 
 
Having a sufficient supply of Merle 23, we looked to explore new areas in which 
bryostatin 1 has previously demonstrated beneficial effects.  To evaluate Merle 23’s 
ability to activate latent HIV, we submitted both Merle 23 and bryostatin 7, synthesized 
by Dr. Poudel, to Dr.Kazmierski’s HIV Medicinal Chemistry group at GlaxoSmithKline.  
Both compounds were exposed to a Human Osteosarcoma (HOS) long terminal repeat 
(LTR) stimulation assay.  The concept of the assay is that HOS cells are transfected with 
a luciferase reporter under the control of the HIV LTR promoter.  Therefore, compounds 
that stimulate the HIV LTR promoter will produce the luciferase enzyme in a dose 
dependent manner.  Both Merle 23 and bryostatin 7 display potent EC50’s with Merle 23 















Merle 23 0.002 166 0.07 39.57 
Bryostatin 7 0.006 250 0.07 6.24 
Bryostatin 1 0.002 187 2.51 >5 
Prostratin 1.08 274 27.78 >50 
 
compounds have minimal cytotoxicity with CCEC50’s in the low micro molar range, 
which is very similar to bryostatin 1.  Prostratin, which is also in development as an 
activator, is three orders of magnitude less potent.  Based on these initial findings GSK 
has expressed interest in conducting further studies aimed at determining 
pharmacokinetic properties.  
 
Identifying a Strategy for Solubilizing Analogues 
 
Owing to an inability to detect low levels of bryostatin 1 in patients there exist very 
little pharmacokinetic data in humans.  Mouse studies conducted with a rapid i.v. 
injection of [C26-3H] labeled bryo 1 revealed a two-compartment model of plasma 
disappearance with half-lives of 1.05 and 22.97 h. Bryo 1 was widely distributed with 
particularly high levels in the lungs, liver, gastrointestinal tract, and fatty tissue.  
Radioactivity associated with the intact compound was observed for up to 24 h and it was 
eliminated primarily through urinary secretion.70 In the clinic, the low aqueous solubility 
of bryo 1 necessitated infusion initially in 60% ethanol, which caused venous sclerosis.  




60/30/10 v/v) also caused significant injection site issues that were not believed to be 
associated with bryostatin itself.71 Rather than dealing with problems related to 
formulating an i.v. injection a couple of groups have explored making structural 
modifications to bryo 1 in order to increase the aqueous solubility.  
The first attempt at modifying bryo 1 structurally to improve aqueous solubility was 
the synthesis of 26-succinylbryostatin 1 by Kraft (Figure 1.38).71 Addition of the 
carboxylate increased solubility by 100-fold.  Unfortunately this compound was no 
longer a good ligand for PKC because the requisite C26 oxygen was now blocked.  
Additionally, the compound showed very little biological activity, and what was observed 
was most likely the result of the succinate side chain undergoing hydrolysis and reverting 
back to bryostatin 1. 
In the course of the Wender group’s analogue work they recognized that the C20 
position might be a more attractive position to attach a solubilizing group.  To test the 
feasibility of using this position for tuning pharmacokinetic properties, they developed a 
strategy based on a late stage diversification of a C20 aniline with a variety of different 
 
 





anhydrides (Figure 1.39).72 The aniline linkage was chosen due to difficulties 
encountered when directly esterifying the C20 alcohol with more complex anhydrides.  
All analogues synthesized demonstrated double-digit nanomolar PKC affinity; however, 
none were tested for biological activity. 
 
Synthesis and biology of Merle 35 and Merle 36 
Merle 23 has demonstrated interesting biology and considerable promise as an 
activator of latent HIV.  Unfortunately, Merle 23 is even more lipophilic than bryostatin 
1, and if it were to ever progress in its development, a strategy by which aqueous 
solubility could be enhanced would need to be developed.  Based on knowledge of 
structure function relationships as well as Wender’s success using the C20 position, we 
also chose to use C20 for attaching solubilizing groups.  In contrast to previous work, we 
felt that attaching directly to the C20 alcohol, rather than through an aniline appendage, 








The first analogue we targeted was Merle 35 where the (2E,4E)-octa-2,4-dienoic ester 
was to be replaced by an acetate.  This simple modification is analogous to the difference 
between bryostatin 1 and bryostatin 7, which is less lipophilic and which we have already 
demonstrated to have comparable binding and biology.73 The synthesis began with Luche 
reduction of previously used ketone 1.87, followed by esterification with acetic 
anhydride.  Removal of the C15 TBS protecting group, oxidation to the aldehyde, and 
exchange of the PMB protecting group for a TBS provided the acetate containing C-ring 
(Figure 1.40). 
Pyran annulation with the A-ring gave the full carbon skeleton, and the TBDPS group 
was removed.  Oxidation of the free alcohol to the acid, as previously described, was 
followed by TBS removal and macrolactonization.  The PMB, BOM and methyl ketal 
groups were removed in two steps to furnish Merle 35 (Figure 1.41). 
 
 












Merle 35 was not only designed as a less lipophilic analogue but was also envisioned 
as a late stage intermediate for more dramatic changes.  The first solubilizing group we 
wanted to install was a carboxylic acid.  To accomplish this the C20 acetate of 
macrocycle 1.102 was removed with K2CO3/MeOH and the free alcohol was esterified 
with succinic anhydride.74 The free carboxyl was protected with a BOM group to help 
facilitate efficient purification of the C3 alcohol after PMB removal with DDQ.  The final 
deprotection with LiBF4 afforded Merle 36, which was converted to the morpholine salt 
(Figure 1.42). 
Both new analogues were submitted to the Blumberg group to test if these changes 
would affect their biology.  Merle 35 was even more potent than Merle 23 with a Ki = 0.6  
 
 




nM, and Merle 36 was nearly 100 times less potent with a Ki = 92.5 nM.  In the U937 
proliferation assay Merle 35 behaved like Merle 23 in that it inhibited proliferation and 
was unable to antagonize the action of PMA (Figure 1.43).  In contrast Merle 36 failed to 
induce a biological response until the highest compound concentration (5 μM) was 
reached.  A possible explanation for this is that the negatively charged carboxylate was 
preventing the compound from traversing the cell membrane efficiently. 
 
Synthesis and biology of Merle 37 
To avoid having a negative charge directly on the analogue, we decided instead to 
utilize a quaternary ammonium salt.  Once again the acetate ester of macrocycle 1.102  
 
 




was cleaved; however, esterification with the previously used anhydride/DMAP 
procedure failed to effectively couple 6-(dimethylamino)hexanoic acid to the C20 
alcohol.  This problem was fixed by using a Shiina esterification,75 and the analogue 
could be deprotected using our standard two-step protocol (Figure 1.44). 
Merle 37 (M37), submitted as the TFA salt, has a Ki = 5.08 nM and was biologically 
active demonstrating Merle 23 like behavior albeit two orders of magnitude less potent 
(Figure 1.45).  Lower potency has also been observed for bryostatin 7 compared to 
bryostatin 1 and may be a due to reduced membrane association and increased cytosolic 
concentration as implicated by translocation studies performed with bryostatin 773.  Merle 
37 also resembled PMA in its ability to induce TNFα secretion (Figure 1.46). 
 
 























Comparison of relative lipophilicity 
After having successfully developed a strategy for attaching solubilizing groups to 
our bis-pyran scaffold that maintained binding and similar biology we wanted to evaluate 
how dramatic a change in lipophilicity the acetate and amine produced. To achieve this 
goal we chose to use the reverse phase HPLC method76 relating retention time to the 
relative lipophilicity (Figure 1.47).  This method is not a highly accurate way of 
calculating Log P values; however, it was ideal for us because it only requires ~ 0.01 mg 
of compound and provides us an excellent way to compare our analogues to each other.  
As expected Merle 23 was more lipophilic than bryo 1, and Merle 37 was by far the lest 
lipophilic compound.  Interestingly, simply exchanging the eight carbon 20 side chain for 
an a acetate had a very dramatic effect for both the Merle and bryostatin series indicating 
that this modification alone may be sufficient to improve pharmacokinetic properties. 
 
Activation of latent HIV by Merle 35 and 37  
After having demonstrated that modification of the C20 ester endowed Merles 35 and 
Merle 37 with dramatically improved aqueous solubility while maintaining single digit Ki 
values for PKC, and without changing the biological response in U937 cells, the two new 
analogues were submitted to GSK for HIV activation analysis.  Merle 35 activated HIV 
in Jurkat cells with an EC50 = 10 nM and cell cytotoxicity 50 (CC50) = 50 nM.  Merle 
37 had an EC50 = 80 nM and a CC50 = 550 nM.  Both compounds compare very 
favorably to prostratin which as an EC50 = 130 nM and CC50 = 370 nM.  Merle 23 
however is still the best compound in the Jurkat cells with an EC50 = 0.2 nM and a CC50 
















































































































































































































































Merle 23 is a valuable tool for understanding the fundamental difference between 
tumor promoting and nontumor promoting PKC ligands.  The scaled synthesis utilized a 
more convergent strategy that allowed for approximately 15 mg of Merle 23 to be 
synthesized to date as well as significant quantities of intermediate compounds that can 
be readily advanced to Merle 23 or other analogues.  The most significant of the 
improvements was the use of a fully functionalized C-ring that circumvented the need for 
challenging manipulations on complex and delicate advanced intermediates.  Use of a 
Rainier metathesis reaction facilitated a multigram synthesis of the C-ring in a highly 
efficient and convergent manner.  The Merle 23 produced through this route has already 
helped to expand our understanding of bryostatin related biology through transcriptional 
response studies, and is sufficient in quantity to conduct the first direct tumor promotion 
studies in mice.  Additionally, we have demonstrated Merle 23’s potent activity in the 
HOS-LTR HIV activation cell assay. 
The large-scale C-ring synthesis also enabled us to amend solubilizing groups to the 
Merle bis-pyran scaffold through the C20 ester.  Merle 35 and 37 both demonstrate 
reduced lipophilicity while maintaining single digit nanomolar affinity for PKC and 
Merle 23 like biology in the U937 proliferation and attachment assay.  
 
Experimental Section 
General experimental procedures  
Solvents were purified according to the guidelines in Purification of Common 




Diisopropylamine, diisopropylethylamine, pyridine, triethylamine, EtOAc, and CH2Cl2, 
were distilled from CaH2.  Reagent grade DMF, DMSO and acetone were purchased, 
stored over 4Å molecular sieves and used without further purification. Et2O, THF, and 
toluene were distilled from Na under an atmosphere of N2. MeOH was distilled from dry 
Mg turnings. The titer of n-BuLi was determined by the method of Eastham and 
Watson.78 TiCl4 was distilled prior to use. Zn was activated with aqueous HCl solution 
prior to use. All other reagents were used without further purification. Yields were 
calculated for material judged homogenous by thin layer chromatography and nuclear 
magnetic resonance (NMR).  Thin layer chromatography was performed on Merck 
Kieselgel 60 Å F254 plates or Silicycle 60Å F254 eluting with the solvent indicated, 
visualized by a 254 nm UV lamp, and stained with an ethanolic solution of 12-
molybdophosphoric acid, or an aqueous potassium permanganate solution. Flash column 
chromatography was performed with Silicycle Flash Silica Gel 40 – 63 µm or Silicycle 
Flash Silica Gel 60 – 200 µm, slurry packed with hexanes in glass columns. Glassware 
for reactions was oven dried at 125 C and cooled under a dry atmosphere prior to use.  
Liquid reagents and solvents were introduced by oven-dried syringes through septum-
sealed flasks under a nitrogen atmosphere.  Nuclear magnetic resonance spectra were 
acquired at 300, 500 MHz for 1H and 75, 125 MHz for 13C.  Chemical shifts for proton 
nuclear magnetic resonance (1H NMR) spectra are reported in parts per million relative to 
the signal of residual CDCl3 at 7.27 ppm. Chemicals shifts for carbon nuclear magnetic 
resonance (13C NMR and DEPT) spectra are reported in parts per million relative to the 
centerline of the CDCl3 triplet at 77.23 ppm.  Chemical shifts of the unprotonated carbons 




abbreviations s, d, dd, ddd, dddd, dq, t, and m stand for the resonance multiplicity singlet, 
doublet, doublet of doublets, doublet of doublet of doublets, triplet and multiplet 
respectively.  Optical rotations (Na D line) were obtained using a microcell with 1 dm 
path length.  Specific rotations ([α] , Unit: °cm2/g) are based on the equation α = 
(100·α)/(l·c) and are reported as unit-less numbers where the concentration c is in g/l00 
mL and the path length l is in decimeters.  Mass spectrometry was performed at the mass 
spectrometry facility of the Department of Chemistry at The University of Utah on a 
double focusing high-resolution mass spectrometer.  Compounds were named using 
ChemDraw 12.0.0. 
 
Synthesis of reagents 
 Preparation of ((chloromethoxy)methyl)benzene: To a stirring 
solution of paraformaldehyde (9.6 g, 319 mmol, 1 equiv) and benzyl alcohol (33.0 mL, 
319 mmol, 1 equiv) in a 250 mL three-neck rb flask equipped with a dropping funnel, at 
0 ºC, was added thionyl chloride (23.2 mL, 319 mmol, 1 equiv) dropwise over a period of 
30 min.  The reaction was warmed to rt, stirred for an additional 1 h, then diluted with 
pentane (200 mL).  The solution of ((chloromethoxy)methyl)benzene was washed with 
brine (2 × 50 mL), dried over MgSO4, and concentrated.  The crude 
((chloromethoxy)methyl)benzene (50 g, 320 mmol, 100%) was obtained as an off white 
liquid which was used without purification. 300 MHz 1H NMR (CDCl3)  7.40 (s, 5H), 





 Preparation of 1-(bromomethyl)-4-methoxybenzene: To a stirring 
solution of phosphorus tribromide (7.50 mL, 80.0 mmol, 0.5 equiv) in Et2O (150 mL) in a 
500 mL three-neck rb flask equipped with a dropping funnel, at 0 ºC, was added 4-
methoxybenzyl alcohol dropwise over a period of 45 min. The reaction was warmed to rt, 
stirred for an additional 1 h, then quenched by pouring over a stirring solution of 
saturated aqueous sodium bicarbonate and ice.  The aqueous phase was extracted with 
Et2O (3 × 30 mL), the combined organic phases were dried over MgSO4, and 
concentrated. The crude 1-(bromomethyl)-4-methoxybenzene (32.9 g, 164 mmol, 100%) 
was obtained as a white liquid, solid at -20 ºC, which was used without purification. 300 
MHz 1H NMR (CDCl3)  7.34 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 4.52 (s, 2H), 
3.82 (s, 2H). 
 
 Preparation of allyltributylstannane:  To a stirring suspension of 
magnesium turnings (14.8 g, 609 mmol, 1.3 equiv) and iodine (160 mg) in THF (450 mL) 
at reflux in a 2 L three-neck rb flask equipped with a dropping funnel and an efficient 
reflux condenser was added a premixed solution of allyl bromide (50.1 mL, 579 mmol, 
1.2 equiv) and tributyltin chloride (129 mL, 475 mmol, 1 equiv) in THF (75 mL) 
dropwise over a period of 2 h.  The reaction mixture was maintained at reflux for an 
additional 16 h, then cooled to rt, filtered through a coarse glass frit and partitioned 
between 10% EtOAc/hexanes (1 L) and saturated aqueous NaHCO3 solution (200 mL).  
The phases were separated and the organic layer was washed with brine (2 × 200 mL), 




distillation using a 1-piece distillation apparatus with a 3.0 × 14.0 cm vigruex column.  
Pure allytributylstannane (151.2 g, 455 mmol, 95%) as a clear liquid was stored in two 
100 mL Aldrich sure-seal bottles: bp 90 ºC at 0.2 mm Hg, 300 MHz 1H NMR (CDCl3)  
6.03- 5.86 (m, 1H), 4.79 (d, J = 16.9 Hz, 1H), 4.65 (d, J = 9.5 Hz, 1H), 1.79 (d, J= 8.8 Hz, 
2H), 1.57- 1.43 (m, 6H), 1.39- 1.24 (m, 6H), 0.91 (t, J = 7.2 Hz, 9 H), 0.90 (q, J = 7.2 Hz, 
6H). 
 
Preparation of magnesium bromide diethyletherate: To a stirring suspension of 
magnesium turnings (15.5 g, 638 mmol, 1.1 equiv) in Et2O (600 mL) at reflux in a 1 L 
three-neck rb flask equipped with a dropping funnel and an efficient reflux condenser 
was added 1,2-dibromoethane (50.0 mL, 580 mmol, 1 equiv) dropwise over a period of 3 
h.  The reaction was heated at reflux for an additional 2 h, cooled to rt, and filtered 
through a coarse glass frit under N2. The filtrate was sealed with a septum and placed in a 
-20 ºC freezer overnight.  The Et2O was removed via cannula, the grey crystals were 
triturated with Et2O (4 × 100 mL), and the now off-white crystals were kept under 
vacuum (0.2 mm Hg) overnight.  Magnesium bromide diethyletherate (127 g, 493 mmol, 
85%) was stored in amber bottles under N2 and in a desiccator. 
 
 Preparation of methyl glyoxylate: To a stirring solution of dimethyl 
maleate (5.00 mL, 39.9 mmol, 1 equiv) in CH2Cl2 (50 mL) in a 250 mL rb flask, at -78 
ºC, was passed O3 until a blue color developed.  Excess O3 was purged with O2, dimethyl 




to rt overnight.  The solution was concentrated, and the crude methyl glyoxylate was 
distilled under aspirator pressure using a 1-piece distillation apparatus with a 5 cm 
column.  Pure methyl glyoxylate was weighed, then immediately diluted with THF to 
make a cloudy 3M solution, which was used directly and not stored. 
 
Experimental procedures for Merle 23 
 Preparation of (R)-2-((benzyloxy)methoxy)propanal (1.32):79 To a stirring 
solution of (R)-(+)- isobutyl lactate (14.6 mL, 85.6 mmol, 1 equiv)  and DIEA (40.0 mL, 
229.6 mmol, 2.7 equiv) in a 500 mL rb flask, at 0 ºC, was added 
((chloromethoxy)methyl)benzene (27.0 mL, 194.8 mmol, 2.3 equiv).  The reaction 
mixture was allowed to warm to rt as it stirred overnight, then quenched with an aqueous 
1.0 M HCl solution (15 mL), and partitioned between Et2O (1000 mL) and water (100 
mL).  The phases were separated and the aqueous layer was extracted with Et2O (3 × 50 
mL).  The combined organic phases were dried over Na2SO4, concentrated, and purified 
by flash column chromatography using a 7.5 × 22.0 cm silica gel column, eluting with 
10% EtOAc/hexanes, collecting 125 mL fractions.  The product containing fractions (12-
25) were concentrated to give protected (R)-(+)-isobutyl lactate as an impure yellow oil 
that was taken on without further purification. 
The aforementioned lactate ester in a 1 L rb flask was taken up in CH2Cl2 (500 mL), 
and cooled to -78 C. A solution of DIBAL 1.0 M in hexanes (103 mL, 103 mmol, 1.2 
equiv) was added down the side of the flask using a syringe pump (20 mL/h).  The 




(50 mL) added by a syringe pump (25 mL/hr).  The cloudy solution was warmed to rt, 
poured into a stirring aqueous sodium potassium tartrate solution (500 mL), and kept at rt 
overnight.  The phases were separated and the aqueous layer was extracted with CH2Cl2 
(3 × 300 mL).  The combined organic layers were dried over Na2SO4, concentrated, and 
purified by flash column chromatography using a 10.0 × 18.0 cm silica gel column, 
eluting with 8% EtOAc/hexanes, collecting 125 mL fractions.  The product containing 
fractions (24-65) were concentrated to give pure (R)-2-((benzyloxy)methoxy)propanal 
(1.32) (15.07 g, 90 s%, 2 steps) as clear oil. Rf = 0.50 (30% EtOAc/hexanes); 300 MHz 
1H NMR (CDCl3)  9.66 (s, 1H), 7.44–7.25 (m, 5H), 4.88 (s, 2H), 4.69 (ABq, J = 11.8, 
 = 14.5 Hz, 2H), 4.13 (dq, J = 6.7, 1.2 Hz, 1H), 1.34 (d, J = 7.0 Hz, 3H); 75 MHz 13C 
NMR (CDCl3)  202.5, 137.4, 128.6, 127.9, 127.8, 94.2, 78.2, 70.0, 15.3. 
 
 Preparation of (2R,3R)-2-((benzyloxy)methoxy)hex-5-en-3-ol (1.33):79  
To a stirring solution of aldehyde 1.32 (7.28 g, 38.3 mmol, 1 equiv) in CH2Cl2 (300 mL) 
in a 500 mL rb flask, at rt, was added MgBr2Et2O (19.3 g, 74.8 mmol, 2 equiv).  The 
cloudy solution was stirred for 5 min, then cooled to -15 C.  After 15 min at -15 C a 
solution of allyl tributyltin (19.5 g, 58.7 mmol, 1.5 equiv) in CH2Cl2 (10 mL) was added 
slowly via cannula over 30 min.   The transfer was made complete with two CH2Cl2 (3 
mL) washes, and the flask allowed to warm slowly to rt as it stirred overnight.  The 
reaction was quenched by carefully pouring into a stirring three-part mixture of CH2Cl2 
(200 mL), a saturated aqueous NaHCO3 solution (200 mL), and a saturated aqueous KF 




separated, and the aqueous layer was extracted with CH2Cl2 (3 x 100 mL).  The 
combined organic phases were washed with brine (100 mL), dried over Na2SO4, and 
concentrated to a viscous oil.  The oil was taken up in Et2O (200 mL) and stirred with an 
insoluble solid mixture of KF/Celite (1:1, 15 g) for 2 h.  KF/Celite was removed by 
filtration, Et2O was removed by rotavap, and the resulting crude product was purified by 
flash column chromatography using a 7.5 × 20.0 cm silica gel column, eluting with 5-
10% EtOAc/Hexanes, collecting 125 mL Erlenmeyer flask fractions.  The product 
containing fractions (19-38) were concentrated to provide pure homoallyl alcohol 1.33 
(8.07 g, 89%) as a colorless oil. Rf = 0.40 (30% EtOAc/Hexanes); 500 MHz 
1H NMR 
(CDCl3)  7.42-7.27 (m, 5H), 5.92 (dddd, J = 17.1, 10.2, 7.0, 6.4 Hz, 1H), 5.18-5.10 (m, 
2H), 4.86 (ABq, J = 7.0,  = 20.9 Hz, 2H), 4.66 (ABq, J = 11.84,  = 10.0 Hz, 2H), 
3.68 (dq, J = 6.2, 6.2 Hz, 1H), 3.56 (ddd, J = 7.7, 5.7, 4.1, 1H), 2.66 (s, 1H), 2.43-2.34 
(m, 1H), 2.31-2.17 (m, 1H), 1.24 (d, J = 6.7, 3H); 75 MHz 13C NMR (CDCl3)  137.8, 
134.9, 128.7, 128.1, 128.0, 117.7, 94.1, 77.3, 74.4, 70.0, 37.9, 16.9. 
 
 Preparation of (3R,4R)-4-((benzyloxy)methoxy)-3-((4-
methoxybenzyl)oxy)pentanal (1.34):79  To a 1 L rb flask was added 35% by wt. KH in 
mineral oil (3.93 g, 98.3 mmol, 1.5 equiv).  The majority of the excess mineral oil was 
removed by pipet, and the KH was triturated with hexanes (3 × 100 mL) under a strict N2 
atmosphere.  THF (400 mL) was added, and the flask was cooled to 0 C.  Homoallylic 
alcohol 1.33 (15.5 g, 65.5 mmol, 1 equiv) was added via cannula, and the solution was 




98.3 mmol, 1.5 equiv) dropwise via cannula.  The reaction mixture was stirred at rt for 1 
h, quenched with NH4OH (100 mL), and stirred overnight.  The solution was transferred 
to a separatory funnel and extracted with Et2O (3 × 200 mL).  The combined organic 
layers were dried over Na2SO4, concentrated and purified by flash column 
chromatography using a 10.0 × 15.0 cm silica gel column, eluting with 20% 
EtOAc/hexanes, collecting 125 mL fractions.  The product containing fractions (9-20) 
were concentrated to give the crude PMB protected alcohol as a yellow oil. Rf = 0.51 
(30% EtOAc/hexanes). 
The yellow oil was taken up in a 4:1 solution of CH2Cl2/MeOH (400 mL), NaHCO3 
(31.45 g, 374.4 mmol, 6.7 equiv.) was added, and the resulting solution was cooled to -78 
C.  While stirring, O3 was bubbled through the solution until a faint blue color was 
observed.  Excess O3 was purged by bubbling O2 through the solution for 20 min, DMS 
(45 mL, 608 mmol, 11 equiv) was added, and this solution was allowed to stir overnight 
at rt. The solution was filtered through a medium glass frit, concentrated, and purified by 
flash column chromatography using a 7.5 × 30.0 cm silica gel column, eluting with 10% 
EtOAc/hexanes, collecting 125 mL Erlenmeyer flask fractions.  The product containing 
fractions (19-34) were concentrated to give pure aldehyde 1.34 (19.43 g, 83%, 2 steps) as 
a yellow oil. Rf = 0.38 (30% EtOAc/hexanes); 500 MHz 
1H NMR (CDCl3)  9.75 (t, J = 
2.0 Hz, 1H), 7.41-7.29 (m, 5H), 7.23 (d, J = 8.8 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 4.79 
(ABq, J = 7.7,  = 21.6 Hz, 2H), 4.59 (s, 2H), 4.53 (ABq, J = 11.2 Hz,  = 11.2 Hz, 
2H), 4.05-3.96 (m, 2H), 3.79 (s, 3H), 2.70-2.58 (m, 2H), 1.20 (d, J = 6.6, 3H); 13C NMR 
(CDCl3)  201.6, 159.6, 138.0, 130.3, 129.8, 128.7, 128.1, 128.0, 114.1, 93.8, 75.7, 73.2, 




 Preparation of (4S,6R,7R)-7-((benzyloxy)methoxy)-6-((4-
methoxybenzyl)oxy)oct-1-en-4-ol (1.73):79 To a stirring solution of aldehyde 1.34 (3.56 
g, 9.93 mmol, 1 equiv) in CH2Cl2 (80 mL), at rt, was added MgBrEt2O (5.13 g, 19.9 
mmol, 2 equiv).  The cloudy solution was stirred at rt for 5 min, then cooled to -15 C. 
After 25 min a solution of allyltributyltin (4.98 g, 14.9 mmol, 1.5 equiv) in THF (10 mL) 
was added over 15 min via cannula, and this solution was maintained at -15 C for 8 h.  
The completed reaction mixture was poured into stirring saturated aqueous NaHCO3 
solution (50 mL) and saturated aqueous KF solution(50 mL).  This solution was stirred 
for 3 h, diluted with CH2Cl2 (100 mL), the phases were separated, and the aqueous layer 
was extracted with CH2Cl2 (3 × 50 mL).  The combined organic layers were dried over 
Na2SO4, concentrated, and purified by flash column chromatography using a 5.0 × 15.0 
cm silica gel column, eluting with 10% EtOAc/hexanes, collecting 18 x 150 mm test tube 
fractions.  The product containing fractions (15-54) were concentrated to give pure 
homoallyl alcohol 1.73 (3.44 g, 87%) as an inseparable 7:1 mixture of diastereomers, and 
as a clear oil. Rf = 0.25 (30% EtOAc/hexanes); 500 MHz 
1H NMR (CDCl3)   7.41-7.28 
(m, 5H), 7.26 (d, J = 9.3 Hz, 2H), 6.86 (d, J = 9.3 Hz, 2H), 5.87-5.76 (m, 1H), 5.11 (d, J 
= 13.6 Hz, 2H), 4.84 (q, J = 14.0, 6.8 Hz, 2H), 4.64-4.60 (m, 2H), 4.61 (d, J = 11.0 Hz, 
1H) 4.52 (d, J = 11.0 Hz, 1H), 4.00 (quintet, J = 5.9, 1H), 3.87-3.81 (m, 1H), 3.79 (s, 
3H), 3.77-3.70 (m, 1H) 2.34 (s, 1H), 2.27-2.17 (m, 2H), 1.68-1.62 (m, 2H), 1.20 (d, J = 
5.9 Hz, 3H); 125 MHz 13C NMR (CDCl3)  159.5, 138.1, 135.2, 130.8, 129.9, 128.7, 





 Preparation of Methyl 2,2-dimethylpent-4-enoate (1.79):33  To a 
stirring solution of diisopropylamine (169 mL, 1.25 mol, 1.1 equiv) in THF (800 mL) in a 
2 L rb flask, at -78 C, was added a 2.5 M solution of n-BuLi (500 mL, 1.250 mol, 1.1 
equiv.) in hexanes dropwise by cannula.  The reaction was allowed to warm to rt and stir 
for 30 min before being returned to -78 C.  Methyl isobutyrate (130 mL, 1.13 mol, 1 
equiv) in THF (100 mL) was added slowly via cannula, and the mixture was stirred for 
1.5 h at -78 C.  The solution was brought to 0 C, stirred for 30 min, and a solution of 
allylbromide (113 ml, 1.31 mol, 1.2 equiv) in THF (100 mL) was added via cannula.  
This solution was allowed to reach rt as it stirred overnight.  The crude reaction mixture 
was filtered through a medium glass frit, concentrated, and distilled under atmospheric 
pressure to give pure olefin 1.79 (119 g, 70%) as clear oil.  BP = 133 C, Rf = 0.75 (10 % 
EtOAc/hexanes); 500 MHz 1H NMR (CDCl3)  5.75-5.66 (m, 1H), 5.04 (dd, J = 1.3,1.3 
Hz, 1H), 5.03-5.00 (m, 1H), 3.64 (s, 3H), 2.26 (dt, J = 7.4, 1.1 Hz, 2H), 1.16 (s, 6H). 
 
  Preparation of (E)-methyl 5-bromo-2,2-dimethylpent-3-enoate 
(1.80):33  To a stirring solution of olefin 1.79 (119.4 g, 839.6 mmol, 1 equiv), and N-
bromosuccinimide (190 g, 1.07 mol, 1.3 equiv) in CCl4 (700 mL) in a 1 L rb flask 
equipped with a reflux condenser was added benzoyl peroxide (5.0 g, 21 mmol, 0.25 
equiv). The flask was submerged in a preheated 105 C oil bath, and heated at reflux for 
2 h.  Another portion of benzoyl peroxide (1 g) was added, and the reaction mixture was 




through a coarse glass frit, concentrated, and purified by flash column chromatography 
using a 9.5 × 17.0 cm silica gel column, eluting with 5% EtOAc/hexanes, and collecting 
125 mL Erlenmeyer flask fractions.  The product containing fractions (7-30) were 
concentrated to give a crude allyl bromide 1.80 (177.3 g, 96%) as yellow oil. Rf = 0.48 
(5% EtOAc/hexanes); 500 MHz 1H NMR (CDCl3)  5.97 (d, J = 15.1 Hz, 1H), 5.74 (dt, J 
= 15.1 Hz, 1H), 3.95 (dd, J = 7.4, 1.1 Hz, 2H), 3.68 (s, 3H), 1.31 (s, 6H). 
 
 Preparation of (E)-methyl 5-hydroxy-2,2-dimethylpent-3-enoate 
(1.105):  To a stirring solution of allyl bromide 1.80 (177.3 g, 801.8 mmol, 1 equiv) in 
MeOH (1.0 L) in a 2 L rb flask, at rt, was added KOAc (400.0 g, 4.075 mol, 5 equiv).  
The flask was equipped with a reflux condenser and heated at 50 C for 2 days.  The 
reaction was concentrated to approximately 100 mL, filtered through a medium glass frit 
washing with EtOAc (500 mL).  The filtrate was transferred to a separatory funnel, 
washed with brine (3 × 200 mL), dried over Na2SO4, and concentrated to give the crude 
allylacetate as a brown oil,  Rf = 0.22 (25 % EtOAc/hexanes). 
 This brown oil was taken up in MeOH (1.0 L), K2CO3 (115.0 g, 0.832 mol, 1 
equiv) was added, and the white solution was stirred for 20 h at rt.  The mixture was 
concentrated to approximately 100 mL, and partitioned between EtOAc (500 mL) and 
water (500 mL).  The organic layer was washed with water (2 × 200 mL), dried over 
Na2SO4, concentrated, and purified by flash column chromatography using a 9.5 × 18.0 
cm silica gel column, eluting with 5% EtOAc/hexanes, collecting 125 mL Erlenmeyer 




allyl alcohol 1.105 (66.04 g, 52 %) as a clear oil. Rf = 0.10 (25 % EtOAc/hexanes); 500 
MHz 1H NMR (CDCl3)  5.89 (dt, J = 15.7, 1.3 Hz, 1H), 5.69 (dt, J = 15.7, 5.5 Hz, 1H), 
4.15 (dd, J = 5.7, 1.3 Hz, 2H), 3.67 (s, 3H), 1.74 (s, 1H), 1.31 (s, 6H). 
 
Preparation of (E)-methyl 5-((tert-butyldimethylsilyl)oxy)-2,2-
dimethylpent-3-enoate (1.81):33  To a stirring solution of allyl alcohol 1.105 (29.37 g, 
185.6 mmol, 1 equiv) in CH2Cl2 (500 mL) in a 2 L rb flask, at rt, was added triethylamine 
(50.0 mL, 360 mmol, 2 equiv), followed by TBSCl (50.80 g, 337.0 mmol, 1.9 equiv).  
After 20 h at rt the mixture was diluted with Et2O (1 L), and quenched with saturated 
aqueous NH4Cl solution (250 mL).  The phases were separated, and the organic layer was 
washed with brine (2 × 200 mL), dried over Na2SO4, and concentrated.  Purification was 
accomplished by flash column chromatography using a 9.5 × 18.0 cm silica gel column, 
eluting with 5% EtOAc/hexanes, collecting 125 mL Erlenmeyer flask fractions.  The 
product containing fractions (3-22) were concentrated to give pure TBS ether 1.81 (56.65 
g, 99%) as a yellow oil. Rf = 0.80 (25% EtOAc/hexanes). 500 MHz 
1H NMR (CDCl3)  
5.85 (dt, J = 15.6, 1.6 Hz, 1H), 5.60 (dt, J = 15.8, 5.4 Hz, 1H) 4.19 (dd, J = 5.4, 1.9, 2H), 
3.67 (s, 3H), 1.31 (s, 6H), 0.91 (s, 9H), 0.07 (s, 6H). 
 
 Preparation of (E)-5-((tert-butyldimethylsilyl)oxy)-2,2-
dimethylpent-3-enoic acid (1.76):33  To a stirring solution of methyl ester 1.81 (35.14 g, 




was added NaOH (21.0 g, 525 mmol, 4 equiv) in a single portion.  This solution was 
stirred at 0 C for 16 h, quenched at 0 C with glacial acetic acid (20 mL), and partitioned 
between EtOAc (500 mL) and brine (500 mL).  The organic layer was washed with brine 
(2 × 200 mL), dried over Na2SO4, and concentrated.  Purification was accomplished by 
flash column chromatography using a 9.5 × 6.0 cm silica gel column, eluting with 5-20% 
EtOAc/hexanes, collecting 125 mL Erlenmeyer flask fractions.  The product containing 
fractions (8-22) were concentrated to give acid 1.76 (31.89 g, 93% yield) as a yellow oil. 
Rf = 0.20 (25% EtOAc/hexanes). 500 MHz 
1H NMR (CDCl3)   5.87 (dt, J = 15.6, 1.8 
Hz, 1H), 5.65 (dt, J = 15.6, 5.0 Hz, 1H), 4.20 (dd, J = 5.0, 1.8 Hz, 2H) 1.33 (s, 6H), 0.91 
(s, 9H), 0.07 (s, 6H). 
 
 Preparation of (E)-(4R,6R,7R)-7-((benzyloxy)methoxy)-
6-((4-methoxybenzyl)oxy)oct-1-en-4-yl 5-((tert-butyldimethylsilyl)oxy)-2,2-
dimethylpent-3-enoate (1.82):33  To a stirring solution of acid 1.76 (8.10 g, 31.3 mmol, 
2 equiv) in CH2Cl2 (20 mL) in a 100 mL rb flask, at rt, was added DMAP (3.23 g, 26.5 
mmol, 1.5 equiv), DMAPHCl (2.80 g, 17.6 mmol, 1 equiv), and EDCHCl (6.76 g, 35.3 
mmol, 2 equiv).  After 5 min, a solution of alcohol 1.77 (7.06 g, 17.6 mmol, 1 equiv) in 
CH2Cl2 (3 mL) was added via cannula. CH2Cl2 (2 mL) was used to rinse the alcohol flask 
and was added to the reaction mixture, which was allowed to stir overnight at rt.  The 
reaction mixture was partitioned between 50% EtOAc/hexanes (50 mL) and brine (50 




concentrated. Purification was accomplished by flash column chromatography using a 5.0 
× 10.0 cm silica gel column, eluting with 5% EtOAc/hexanes, collecting 18 × 150 mm 
test tube fractions.  The product containing fractions (7-27) were concentrated to give 
ester 1.82 (10.34 g, 92%) as a yellow oil. Rf = 0.58 (35% EtOAc/hexanes). 500 MHz 
1H 
NMR (CDCl3)  7.38-7.29 (m, 5H), 7.27 (d, J = 8.9 Hz, 2H), 6.86 (d, J = 8.9 Hz, 2H), 
5.86 (dt, J = 15.6, 1.9 Hz, 1H), 5.79-5.69 (m, 1H), 5.60 (dt, J = 15.6, 5.4 Hz, 1H), 5.24-
5.16 (m, 1H), 5.08-5.02 (m, 2H), 4.80 (Aq, J = 7.2 Hz,  = 17.8 Hz, 2H), 4.62 (Aq, J 
= 11.9 Hz,  = 20.1 Hz, 2H), 4.52 (d, J = 10.7 Hz, 1H), 4.35 (d, J = 10.7 Hz, 1H), 4.16 
(dd, J = 5.0, 1.6 Hz, 2H), 3.95 (dq, J = 6.2, 6.2 Hz, 1H), 3.79 (s, 3H), 3.42 (ddd, J = 10.3, 
5.0, 2.1 Hz, 1H), 2.41-2.26 (m, 2H), 1.84-1.77 (m, 1H), 1.70-1.63 (m, 1H) 1.29 (d, J =2.7 
Hz, 6H), 1.18 (d, J = 6.4 Hz, 3H), 0.92 (d, J = 11.7 Hz, 9H), 0.09 (d, J = 24.4, 6H); 125 
MHz 13C NMR (CDCl3)  176.0, 159.6, 138.2, 134.9, 133.8, 130.8, 130.1, 128.8, 128.2, 
128.1, 128.0, 118.3, 114.2, 93.6, 73.5, 73.3, 70.6, 69.7, 64.1, 55.6, 44.3, 39.8, 34.7, 26.3, 
26.0, 25.5, 25.2, 18.7, 18.3, 15.5, -3.3. 
 
 Preparation of (E)-(4R,6R,7R)-7-((benzyloxy)methoxy)-
1-hydroxy-6-((4-methoxybenzyl)oxy)octan-4-yl 5-((tert-butyldimethylsilyl)oxy)-2,2-
dimethylpent-3-enoate (1.83):33  To a stirring solution of olefin 1.82 (10.34g, 16.13 
mmol, 1 equiv) in THF (80 mL), in a 250 mL rb flask, at rt, was added a 0.5 M solution 




mixture was stirred at rt for 10 min, sonicated in a water bath at 60 Hz for 45 min, then 
cooled to 0 C.  A 2 M aqueous solution of NaOH (40 mL) was added slowly followed 
by the careful addition of a 30% aqueous solution of H2O2 (20 mL).  After 1 h the 
mixture was diluted with EtOAc (100 mL) and water (100 mL), the phases were 
separated, and the aqueous layer was extracted with EtOAc (3 × 50 mL). The combined 
organic layers were dried over Na2SO4, concentrated, and purified by flash column 
chromatography using a 5.0 × 10.0 cm silica gel column, eluting with 10% 
EtOAc/hexanes, collecting 18 × 150 mm test tube fractions.  The product containing 
fractions (12-35) were concentrated to give alcohol 1.83 (8.18 g, 77% yield) as a clear 
oil. Rf = 0.21 (30% EtOAc/hexanes). 500 MHz 
1H NMR (CDCl3)  7.39-7.29 (m, 5H), 
7.27 (d, J = 8.0 Hz, 2H), 6.86 (d, J = 8.0 Hz, 2H), 5.86 (dt, J = 15.8, 2.0 Hz, 1H), 5.61 
(dt, J = 15.6, 5.0 Hz, 1H), 5.21-5.14 (m, 1H), 4.80 (Aq, J = 7.4 Hz,  = 18.1 Hz, 2H), 
4.62 (Aq, J = 11.9 Hz,  = 19.8 Hz, 2H), 4.53 (d, J = 10.4 Hz, 1H), 4.36 (d, J = 10.4 
Hz, 1H), 4.17 (dd, J = 5.0, 1.6 Hz, 2H), 3.96 (dq, J = 6.1, 6.1 Hz, 1H), 3.79 (s, 3H), 3.61 
(t, J = 6.5 Hz, 2H), 3.42 (ddd, J = 10.4, 4.9, 2.1 Hz, 1H), 1.81 (ddd, J = 14.5, 9.8, 2.4, 
1H), 1.68-1.50 (m, 6H), 1.30 (d, J = 2.2, 6H), 1.18 (d, J = 7.2 Hz, 3H), 0.91 (s, 9H), 0.07 
(s, 6H); 125 MHz 13C NMR (CDCl3)  176.4, 159.7, 138.2, 135.0, 130.8, 130.2, 128.8, 
128.3, 128.1, 128.0, 114.2, 93.7, 77.8, 73.5, 73.3, 71.4, 69.8, 64.1, 62.8, 55.6, 44.4, 35.1, 





 Preparation of (E)-(4R,6R,7R)-7-((benzyloxy)methoxy)-
6-((4-methoxybenzyl)oxy)-1-oxooctan-4-yl 5-((tert-butyldimethylsilyl)oxy)-2,2-
dimethylpent-3-enoate (1.84):33  To a stirring solution of alcohol 1.83 (8.18 g, 12.4 
mmol, 1 equiv) in CH2Cl2 (124 mL, 0.1 M) in 250 mL rb flask, at 0 C, was added i-
Pr2EtN (15.2 mL, 86.9 mmol, 7 equiv) and DMSO (8.80 mL, 124 mmol, 10 equiv).  The 
reaction mixture was stirred for 10 min, then SO3Pyr complex (7.90 g, 49.6 mmol, 4 
equiv) was added in three equal aliquots 5 min apart.  The cloudy solution was stirred at 0 
C for 1 h, then quenched by the addition of saturated aqueous NaHCO3 solution (50 
mL).  The biphasic solution was stirred for 10 min, partitioned between water (100 mL) 
and CH2Cl2 (100 mL), and the aqueous layer was extracted with CH2Cl2 (3 × 100 mL).  
The combined organic layers were dried over Na2SO4, concentrated, and purified by flash 
column chromatography using a 5.0 × 12.5 cm silica gel column, eluting with 5% 
EtOAc/hexanes, collecting 18 × 150 mm test tube fractions.  The product containing 
fractions (16-45) were concentrated to give aldehyde 1.84 (6.91 g, 85%) as a clear oil. Rf 
= 0.40 (30% EtOAc/hexanes). 500 MHz 1H NMR (CDCl3)  9.73 (s, 1H), 7.39-7.33 (m, 
5H), 7.27 (d, J = 9.1 Hz, 2H), 6.86 (d, J = 9.1 Hz, 2H), 5.86 (dt, J = 15.9, 1.5 Hz, 1H), 
5.62 (dt, J = 15.6, 4.9 Hz, 1H), 5.20-5.14 (m, 1H), 4.80 (Aq, J = 7.1 Hz,  = 19.7 Hz, 
2H), 4.62 (Aq, J = 11.9 Hz,  = 19.8 Hz, 2H), 4.52 (d, J = 10.6 Hz, 1H), 4.34 (d, 10.6 
Hz, 1H), 4.17 (dd, J = 4.9, 1.7 Hz, 2H), 3.97 (dq, J = 4.9, 6.3 Hz, 1H), 3.80 (s, 3H), 3.42 




2H), 1.66-1.50 (m, 1H), 1.31 (s, J = 2.9 Hz, 6H), 1.18 (d, J = 6.4 Hz, 3H), 0.90 (s, 9H), 
0.06 (s, 6H); 125 MHz 13C NMR (CDCl3)  201.6, 176.3, 159.6, 138.2, 134.6, 130.7, 
130.2, 128.8, 128.6, 128.1, 128.0, 114.2, 93.7, 77.6, 73.2, 73.1, 70.9, 69.8, 64.0, 55.6, 
44.3, 40.1, 35.1, 27.6, 26.3, 25.5, 25.3, 18.7, 15.4, -4.8. 
 Preparation of (E)-(5R,7R,8R)-8-((benzyloxy)methoxy)-
7-((4-methoxybenzyl)oxy)non-1-en-5-yl 5-((tert-butyldimethylsilyl)oxy)-2,2-
dimethylpent-3-enoate (1.75):33  To a stirring solution of methyltriphenylphosphonium 
bromide (7.52 g, 21.0 mmol, 2 equiv) in THF (105 mL) in a 250 mL rb flask, at -5 C, 
was added n-BuLi (5.47 mL, 13.7 mmol, 1.3 equiv).  The yellow solution was warmed to 
rt and stirred for 30 min, then returned to -5 C, and aldehyde 1.84 (6.91 g, 10.5 mmol, 1 
equiv) was added slowly via cannula along with a THF rinse (5 mL).  After 5 min the 
reaction mixture was quenched by the addition of an aqueous pH 7 buffer (100 mL), and 
the aqueous layer was extracted with 25% EtOAc/hexanes.  The combined organic layers 
were dried over Na2SO4, concentrated, and purified by flash column chromatography 
using a 5.0 × 10.0 cm silica gel column, eluting with 5% EtOAc/hexanes, collecting 18 × 
150 mm test tube fractions.  The product containing fractions (9-30) were concentrated to 
give olefin 1.75 (5.72 g, 83%) as a clear oil. Rf = 0.70 (35% EtOAc/hexanes). 500 MHz 
1H NMR (CDCl3)  7.40-7.30 (m, 5H), 7.28 (d, J = 9.0 Hz, 2H), 6.68 (d, J = 9.0 Hz, 2H), 
5.88 (dt, J = 15.7, 1.5 Hz, 1H), 5.83-5.73 (m, 1H), 5.62 (dt, J = 15.7, 5.2 Hz, 1H), 5.22-




= 11.8 Hz,  = 21.4 Hz, 2H), 4.52 (d, J = 10.5 Hz, 1H), 4.38 (d, J = 10.5 Hz, 1H), 4.17 
(dd, J = 5.0, 1.5 Hz, 2H), 3.95 (dq, J = 4.8, 6.4 Hz, 1H), 3.80 (s, 3H), 3.42 (ddd, J = 10.3, 
4.9, 2.2 Hz, 1H), 2.05 (q, J = 8.2 Hz, 2H), 1.84-1.77 (m, 1H), 1.73-1.59 (m ,3H), 1.31 (d, 
J = 2.8 Hz, 6H), 1.18 (d, J = 6.3 Hz, 3H), 0.91 (s, 9H), 0.064 (s, 6H); 125 MHz 13C NMR 
(CDCl3)  176.2, 159.6, 138.2, 138.2, 134.8, 130.8, 130.2, 128.8, 128.3, 128.1, 128.0, 
115.2, 114.1, 93.6, 77.8, 73.5, 73.3, 71.3, 69.7, 64.1, 55.6, 44.3, 35.2, 34.6, 29.7, 26.3, 
25.5, 25.3, 18.7, 15.5, -4.8. 
 
 Preparation of (((E)-4-((S)-2-((2R,3R)-3-
((benzyloxy)methoxy)-2-((4-methoxybenzyl)oxy)butyl)-3,4-dihydro-2H-pyran-6-yl)-
4-methylpent-2-en-1-yl)oxy)(tert-butyl)dimethylsilane (1.85):33  To a stirring solution 
of TiCl4 (13.6 mL, 124 mmol, 15 equiv) in CH2Cl2 (500 mL) in a 2 L three neck rb flask 
equipped with a reflux condenser and a 250 mL dropping funnel, at 0 C, was added THF 
(70 mL).  The solution turned yellow and was stirred for 10 min prior to the addition of 
TMEDA (119.0 mL, 798.7 mmol, 96 equiv) dropwise via cannula, which turned the 
solution brown.  This mixture was warmed to rt, stirred for 30 min, and then PbCl2 (4.63 
g, 16.7 mmol, 2 equiv) and activated zinc dust (19.58 g, 299.4 mmol, 36 equiv) were 
added in a single portion causing the reaction mixture to transition to a deep blue color.  
A premixed solution of olefin 1.75 (5.45 g, 8.32 mmol, 1 equiv) and 1,1-dibromoethane 
(12.1 mL, 133 mmol, 16 equiv) in CH2Cl2 (100 mL) was added dropwise using the 250 




and quenched by the slow addition of saturated aqueous K2CO3 solution (100 mL).  The 
resulting black mud was filtered through a 3 cm pad of alumina, washing with CH2Cl2 
(500 mL).  The filtrate was concentrated to a yellow solid, which was suspended in 50% 
EtOAc/hexanes (250 mL) and filtered through a coarse glass frit.  The filtrate was 
concentrated to a yellow oil and purified by flash column chromatography using a 9.5 × 
12.0 cm silica gel column, eluting with 10% EtOAc/hexanes, collecting 125 mL 
Erlenmeyer flask fractions.  The product containing fractions (4-18) were concentrated to 
give glycal 1.85 (4.26 g, 82%) as a clear oil. Rf = 0.39 (5% EtOAc/Toluene). 500 MHz 
1H NMR (CDCl3)  7.37 (m, 5H), 7.25 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 8.5 Hz, 2H), 5.75 
(dt, J = 15.6, 1.5 Hz, 1H), 5.52 (dt, J = 15.8, 5.5 Hz, 1H), 4.83 (Aq, J = 7.0 Hz,  = 6.3 
Hz, 2H), 4.64 (Aq, J = 11.7 Hz,  = 11.5 Hz, 2H), 4.62 (d, J = 10.9 Hz, 1H), 4.55 (dd, 
J = 4.3, 2.6 Hz, 1H), 4.52 (d, J = 10.9, 1H), 4.14 (dd, J = 5.6, 1.6 Hz, 2H), 4.04-3.08 (m, 
1H), 3.95 (dq, J = 5.3, 6.2 Hz, 1H), 3.83 (ddd, J = 10.4, 4.9, 2.0 Hz, 1H), 3.80 (s, 3H), 
2.12-2.03 (m, 1H), 2.01-1.94 (m, 1H), 1.83-1.71 (m, 2H), 1.65-1.57 (m, 1H), 1.35-1.2 (m, 
1H), 1.20 (d, J = 6.4 Hz, 3H), 1.17 (d, J = 4.3, 6H), 0.90 (s, 9H), 0.05 (s, 6H); 125 MHz 
13C NMR (CDCl3)  159.6, 159.4, 139.0, 138.4, 131.3, 129.8, 128.8, 128.2, 128.0, 126.1, 
114.2, 93.8, 93.4, 78.2, 74.3, 73.8, 71.9, 69.8, 64.7, 55.6, 40.7, 36.6, 28.5, 26.4, 26.3, 
26.1, 20.7, 18.8, 16.0, -4.3. 
 






3(4H)-one (1.86):33  To a stirring solution of glycal 1.85 (1.11 g, 1.78 mmol, 1 equiv) in 
CH2Cl2 (20 mL) in a 100 mL rb flask, at 0 C, was added MeOH (8 mL) and NaHCO3 
(0.370 g, 4.40 mmol, 2.5 equiv).  After 10 min, MMPP (2.11 g, 3.42 mmol, 1.9 equiv) 
was added and stirring continued for an additional 1 h at 0 C.  The reaction mixture was 
quenched by the addition of a saturated aqueous NaHCO3 solution (10 mL), partitioned 
between EtOAc (20 mL) and water (20 mL), and the aqueous layer was extracted with 
EtOAc (3 × 10 mL).  The combined organic layers were washed with brine (2 × 10 mL), 
dried over Na2SO4, and concentrated to give the crude alcohol as a clear oil which was 
taken on without further purification. Rf = 0.21 (20% EtOAc/ hexanes) 
The crude alcohol was taken up in CH2Cl2 (30 mL), and powdered 4 Å molecular 
sieves (600 mg) were added.  TPAP (0.062 g, 0.177 mmol, 0.1 equiv) and NMO (0.624 g, 
5.32 mmol, 3 equiv) were added in a single portion, and the black suspension was stirred 
at rt for 1 h.  The reaction mixture was diluted with EtOAc (20 mL) and filtered through a 
3 cm plug of florisil washing with copious amounts of EtOAc.  The filtrate was 
concentrated and purified by flash column chromatography using a 2 × 8.0 cm silica gel 
column, eluting with 10% EtOAc/hexanes, collecting 13 × 100 mm test tube fractions.  
The product containing fractions (7-25) were concentrated to give ketone 1.86 (0.789 g, 
66%) as a clear oil. Rf = 0.30 (20% EtOAc/hexanes). 500 MHz 
1H NMR (CDCl3)  7.38-
7.34 (m, 5H), 7.21 (d, J = 9.2 Hz, 2H), 6.84 (d, J = 9.2 Hz, 2H), 5.97 (dt, J = 16.1, 1.7, 
1H), 5.50 (dt, J = 15.8, 5.1 Hz, 1H), 4.85 (Aq, J = 6.8 Hz,  = 7.7 Hz, 2H), 4.66 (s, 
2H), 4.62 (d, J = 10.9 Hz, 1H), 4.44 (d, J = 10.9 Hz, 1H), 4.16-4.07 (m, 2H), 4.13 (dd, J 




(dd, J = 8.6, 5.7 Hz, 2H), 1.98-1.85 (m, 3H), 1.69-1.59 (m, 1H), 1.41 (s, 3H) 1.21 (d, J = 
6.7 Hz, 3H), 1.13 (s, 3H) 1.09 (s, 3H), 0.91 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H); 125 MHz 
13C NMR (CDCl3)  207.8, 159.6, 138.2, 136.5, 130.9, 129.6, 128.8, 128.2, 128.1, 128.0, 
114.2, 104.4, 93.7, 77.3, 72.8, 72.4, 70.3, 69.8, 64.4, 55.6, 52.5, 44.3, 37.9, 36.6, 30.4, 
26.3, 23.1, 18.7, 15.1, -4.8. 
 
 Preparation of (E)-methyl 2-((2S,6S)-6-((2R,3R)-3-
((benzyloxy)methoxy)-2-((4-methoxybenzyl)oxy)butyl)-2-((E)-5-((tert-
butyldimethylsilyl)oxy)-2-methylpent-3-en-2-yl)-2-methoxy-3-oxodihydro-2H-
pyran-4(3H)-ylidene)acetate (1.87):33  To a stirring solution of ketone 1.86 (514 mg, 
0.766 mmol, 1 equiv) in MeOH (11.0 mL) in a 25 mL rb flask, at rt, was added K2CO3 
(529 mg, 3.83 mmol, 5 equiv) and a 3 M solution of freshly distilled methyl glyoxylate 
(1.3 mL, 380 mmol, 5 equiv) in THF.  After 1 h, during which time the solution 
developed a vibrant yellow color, it was quenched by the addition of saturated aqueous 
NH4Cl solution (10 mL), and the aqueous layer was extracted with Et2O (3 × 20 mL).  
The combined organic layers were dried over Na2SO4, concentrated and purified by flash 
column chromatography using a 2.5 × 13.0 cm silica gel column, eluting with 10% 
EtOAc/hexanes, collecting 12 × 75 mm test tube fractions.  The product containing 
fractions (9-37) were concentrated to give ester 1.87 (431 g, 76%) as a yellow oil. Rf = 




= 8.4 Hz, 2H), 6.82 (d, J = 84 Hz, 2H), 6.53 (dd, J = 3.2, 1.7 Hz, 1H), 5.81 (dt, J = 16.1, 
14 Hz, 1H), 5.40 (dt, J = 15.8, 5.0 Hz, 1H), 4.85 (Aq, J = 7.3 Hz,  = 9.7 Hz, 2H), 
4.66 (s, 2H), 4.61 (d, J = 10.9 Hz, 1H), 4.41 (d, J = 10.9 Hz, 1H), 4.15-4.10 (m, 2H), 
4.07-4.04 (m, 2H), 3.91-3.86 (m, 1H), 3.78 (s, 3H), 3.75 (s, 3H), 3.31 (dt, J = 18.3, 1.8 
Hz, 1H), 3.21 (s, 3H), 2.85 (ddd, J = 18.7, 12.6, 3.3 Hz, 1H), 1.96 (ddd, J = 14.8, 9.2, 2.4 
Hz, 1H), 1.78-1.72 (m, 1H), 1.21 (d, J = 6.7 Hz, 3H), 1.10 (s, 3H), 1.04 (s, 3H), 0.90 (s, 
9H), 0.04 (s, 6H); 125 MHz 13C NMR (CDCl3)  197.8, 166.2, 159.4, 148.2, 138.1, 
134.8, 130.6, 129.3, 128.8, 128.7, 128.0, 127.9, 122.7, 114.0, 104.8, 93.6, 76.9, 72.4, 
71.8, 69.7, 69.5, 64.1, 55.4, 52.2, 52.0, 44.7, 36.2, 36.1, 26.1, 22.5, 22.0, 18.5, 14.7, -5.0 
 
 Preparation of (2E,4E)-(2S,3S,6S,E)-6-((2R,3R)-3-
((benzyloxy)methoxy)-2-((4-methoxybenzyl)oxy)butyl)-2-((E)-5-((tert-
butyldimethylsilyl)oxy)-2-methylpent-3-en-2-yl)-2-methoxy-4-(2-methoxy-2-
oxoethylidene)tetrahydro-2H-pyran-3-yl octa-2,4-dienoate (1.88):80  To a stirring 
solution of ketone 1.87 (740 mg, 0.999 mmol, 1 equiv) in MeOH (100 mL) in a 250 mL 
rb flask, at rt, was added CeCl37H2O (7.45 g, 20.0 mmol, 20 equiv), and the suspension 
was stirred until the CeCl37H2O was completely solvated before being cooled to -42 C.  
NaBH4 (378 mg, 10.0 mmol, 10 equiv) was added in a single portion. The reaction 




quenched by the addition of saturated aqueous NH4Cl solution (30 mL).  The aqueous 
layer was extracted with 40% EtOAc/hexanes (3 × 50 mL).  The combined organic layers 
were washed with brine (2 × 20 mL), dried over Na2SO4, and concentrated to give the 
intermediate alcohol as a clear oil. Rf = 0.10 (20% EtOAc/hexanes) 
The crude alcohol was taken up in CH2Cl2 (25 mL), and DMAP (611 mg, 5.00 mmol, 
5 equiv), pyridine (2.42 mL, 30.0 mmol, 30 equiv) and (2E,4E)-octa-2,4-dienoic 
anhydride (5.25 g, 20.0 mmol, 20 equiv) were added.  This solution was stirred at rt for 
20 h before first quenching with MeOH (5 mL), stirring for 30 min, then quenching with 
saturated aqueous NaHCO3 solution (20 mL).  The phases were separated, and the 
aqueous layer was extracted with 40% EtOAc/hexanes (3 × 25).  The combined organic 
layers were washed with brine (2 × 10 mL), dried over Na2SO4, and concentrated.  
Purification was accomplished by flash column chromatography using a 2.0 × 7.0 cm 
silica gel column, eluting with 10% EtOAc/hexanes, collecting 13 × 100 mm test tube 
fractions.  The product containing fractions (5-22) were concentrated to give ester 1.88 
(654 mg, 74%) as a clear oil. Rf = 0.38 (20% EtOAc/hexanes). 500 MHz 
1H NMR 
(CDCl3)  7.38-7.33 (m, 5 H), 7.21 (d, J = 9.0 Hz, 2H), 6.84 (d, J = 9.0 Hz, 2H), 6.18-
6.10 (m, 2H), 5.96 (d, J = 15.8 Hz, 1H), 5.91 (s, 1H), 5.75 (d, J = 15.8 Hz, 1H), 5.48 (s, 
1H), 5.37 (dt, J = 15.9, 5.7 Hz, 1H), 4.86 (Aq, J = 6.6 Hz,  = 6.5 Hz, 2H), 4.68 (Aq, 
J = 11.8 Hz,  = 9.1 Hz, 2H), 4.62 (d, J = 11.1 Hz, 1H), 4.44 (d, J = 11.1 Hz, 1H), 4.15-
4.01 (m, 4H), 3.90 (ddd, J = 10.1, 4.4, 2.0 Hz, 1H), 3.79 (s, 3H), 3.68 (s, 3H), 3.51 (dd, J 
= 15.4, 2.5 Hz, 1H), 3.26 (s, 3H), 2.36-2.24 (m, 1H), 2.19-2.12 (m, 2H) 1.92 (ddd, J = 
14.2, 9.6, 2.1 Hz, 1H), 1.74 (ddd, J = 14.2, 9.6, 2.1 Hz, 1H), 1.59 (s, 1H), 1.47 (q, J = 7.2 




(s, 9H), 0.05 (s, 6H); 125 MHz 13C NMR (CDCl3)  166.9, 165.8, 159.5, 152.9, 146.6, 
145.8, 138.3, 138.2, 130.9, 129.6, 128.8, 128.7, 128.1, 128.0, 125.2, 118.9, 117.7, 114.1, 
103.0, 93.7, 77.2, 72.8, 72.3, 72.1, 69.8, 68.6, 64.9, 55.6, 51.9, 51.4, 46.1, 36.7, 35.4, 
32.9, 26.4, 24.6, 23.9, 22.2, 18.8, 15.2, 14.0, -4.7. 
 
 Preparation of (2E,4E)-(2S,3S,6S,E)-6-((2R,3R)-3-
((benzyloxy)methoxy)-2-((4-methoxybenzyl)oxy)butyl)-2-((E)-5-hydroxy-2-
methylpent-3-en-2-yl)-2-methoxy-4-(2-methoxy-2-oxoethylidene)tetrahydro-2H-
pyran-3-yl octa-2,4-dienoate (1.106):80  To a stirring solution of TBS ether 1.88 (114 
mg, 0.132 mmol, 1 equiv) in a 5:4:1 solution of THF/MeOH/pyridine (2.6 mL) in a 
plastic bottle, at 0 C, was added HFPyr (20%, 1 mL).  The reaction mixture was stirred 
at 0 C for 10 min, then at rt for 2 h, then quenched by pipetting it into a stirring solution 
of 50% EtOAc/hexanes (10 mL) and saturated aqueous NaHCO3 solution (10 mL).  The 
phases were separated and the aqueous layer was extracted with 50% EtOAc/hexanes (3 
x 10 mL).  The combined organic layers were dried over Na2SO4, concentrated and 
purified by flash column chromatography using a 1.5 × 8.5 cm silica gel column, eluting 
with 20% EtOAc/hexanes, collecting 10 × 75 mm test tube fractions.  The product 
containing fractions (10-38) were concentrated to give pure alcohol 1.106 (92.0 mg, 
93%) as a yellow oil. Rf = 0.50 (50% EtOAc/hexanes). 500 MHz 
1H NMR (CDCl3)  




5.99 (d, J = 15.9 Hz, 1H), 5.91 (s, 1H), 5.75 (d, J = 15.6 Hz, 1H), 5.51 (s, 1H), 5.46 (dt, J 
= 15.8, 6.1 Hz, 1H), 4.87 (Aq, J = 6.6 Hz,  = 5.9 Hz, 2H), 4.68 (s, 2H), 4.62 (d, J = 
11.0 Hz, 1H), 4.43 (d, J = 11.0 Hz, 1H), 4.15 (dq, J = 6.4, 4.6 Hz, 1H), 4.10-4.03 (m, 
1H), 4.02-3.99 (m, 2H), 3.92 (ddd, J = 10.2, 4.6, 2.2 Hz, 1H), 3.79 (s, 3H), 3.68 (s, 3H), 
3.50 (dd, J = 15.6, 2.3 Hz, 1H), 3.25 (s, 3H), 2.35 (ddd, J = 13.4, 11.8, 1.8 Hz, 1H), 2.19-
2.14 (m, 2H), 1.94 (ddd, J = 14.5, 9.8, 2.0 Hz, 1H), 1.75 (ddd, J = 14.0, 10.2, 2.5 Hz, 
1H), 1.62 (s,1H), 1.47 (q, J = 7.5 Hz, 3H), 1.23 (d, J = 6.0 Hz, 3H), 1.12 (d, J = 15.6 Hz, 
6H), 0.93 (t, J = 7.5 Hz, 3H); 125 MHz 13C NMR (CDCl3)  167.0, 165.9, 159.6, 152.8, 
147.1, 146.4, 140.1, 138.2, 130.8, 129.6, 128.8, 128.6, 128.2, 128.1, 125.2, 118.7, 117.7, 
114.2, 103.0, 93.7, 77.0, 72.6, 72.1, 72.1, 69.8, 68.7, 64.6, 55.6, 51.8, 51.6, 46.4, 36.6, 
35.5, 33.0, 24.4, 24.2, 22.2, 15.0, 14.1. 
 
 Preparation of (2E,4E)-(2S,3S,6S,E)-6-((2R,3R)-3-
((benzyloxy)methoxy)-2-((4-methoxybenzyl)oxy)butyl)-2-methoxy-4-(2-methoxy-2-
oxoethylidene)-2-((E)-2-methyl-5-oxopent-3-en-2-yl)tetrahydro-2H-pyran-3-yl octa-
2,4-dienoate (1.88):80  To a stirring solution of alcohol 1.106 (177 mg, 0.24 mmol, 1 
equiv) in CH2Cl2 (8 mL) in 25 mL rb flask, at rt, was added powdered 4 Å  molecular 
sieves (300 mg), followed by  TPAP (11.0 mg, 0.02 mmol, 0.1 equiv) and NMO (83.0 
mg, 0.705 mmol, 3 equiv) in a single portion.  After 1 h the reaction mixture was diluted 




amounts of EtOAc.  The filtrate was concentrated to a dark oil, and purified by flash 
column chromatography using a 1.5 × 9.5 cm silica gel column, eluting with 15% 
EtOAc/hexanes, collecting 10 × 75 mm test tube fractions.  The product containing 
fractions (10-40) were concentrated to give aldehyde 1.88 (157.0 mg, 89%) as a clear oil. 
Rf = 0.66 (50% EtOAc/hexanes). 500 MHz 
1H NMR (CDCl3)  9.44 (d, J = 7.8 Hz, 1H), 
7.37-7.34 (m, 4H), 7.33-7.29 (m, 1H), 7.21 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 8.6 Hz, 2H), 
6.16-6.11 (m, 2H), 5.90 (dd, J = 16.5, 7.4 Hz, 1H), 5.89 (s, 1H), 5.60 (s, 1H), 5.57 (d, J = 
15.2 Hz, 2H), 4.86 (Aq, J = 7.0 Hz,  = 10.9 Hz, 2H), 4.67 (s, 2H), 4.63 (d, J = 10.9 
Hz, 1H), 4.41 (d, J = 10.9 Hz, 1H), 4.17 (dd, J = 6.2, 4.5 Hz, 1H), 4.16-4.12 (m, 1H), 
3.90 (ddd, J = 10.0, 4.4, 1.9 Hz, 1H), 3.79 ( s, 3H), 3.81-3.78 (m, 1H), 3.69 (s, 3H), 3.50 
(dd, J = 16.4, 2.0 Hz, 1H), 3.28 (s, 3H), 2.44 (dd, J = 14.9, 11.3 Hz, 1H), 2.16 (q, J = 7.0 
Hz, 2H), 1.97 (ddd, J = 14.4, 9.7, 1.9 Hz, 1H), 1.78 (ddd, J = 14.2, 10.2, 2.6 Hz, 1H), 
1.47 (q, J = 7.7 Hz, 2H), 1.23 (d, J = 6.5 Hz, 3H), 1.16 (s, 3H), 1.13 (s, 3H), 0.93 (t, J = 
7.4, 3H); 125 MHz 13C NMR (CDCl3); 194.7, 166.8, 166.4, 165.2, 159.4, 152.1, 147.4, 
146.6, 137.9, 130.5, 129.4, 128.6, 128.3, 127.9, 127.9, 127.2, 117.8, 117.4, 114.0, 102.8, 
93.6, 76.7, 72.2, 71.8, 70.7, 69.7, 69.0, 55.5, 51.4, 47.6, 46.4, 36.3, 35.3, 33.4, 23.7, 22.3, 
22.0, 14.7, 13.9 
 






pyran-3-yl octa-2,4-dienoate (1.74):80  To a stirring solution of PMB ether 1.88 (177 
mg, 0.236 mmol, 1 equiv) in CH2Cl2 (3.4 mL) and t-BuOH (2.4 mL) in a 25 mL rb flask, 
at rt, was added a 1 M aqueous pH 7 buffer (2.4 mL).  The mixture was cooled to 0 C 
and DDQ (134 mg, 0.590 mmol, 2.5 equiv) was added in a single portion.  This reddish 
mixture was stirred for 1 h at 0 C, then another portion of DDQ (134 mg, 0.590 mmol, 
2.5 equiv) was added, and stirring continued for an additional 1 h. The reaction mixture 
was quenched by the addition of saturated aqueous NaHCO3 solution (5 mL), the phases 
were separated, and the aqueous layer was extracted with CH2Cl2 (3 × 5 mL).  The 
combined organic layers were dried over Na2SO4, and concentrated to give the crude 
alcohol as a red oil which was taken on to the next step without further purification. 
The crude alcohol was taken up in CH2Cl2 (4.7 mL), cooled to 0 C, and 2,6-lutidine 
(165 L, 1.42 mmol, 6 equiv) was added followed by TBSOTf (136 L, 0.590 mmol, 2.5 
equiv).  The reaction mixture was stirred for 30 min at 0 C, then quenched first with 
MeOH (200 L) and then with a saturated aqueous NaHCO3 solution (1 mL).  The layers 
were separated and the aqueous layer was extracted with CH2Cl2 (3 × 5 mL). The 
combined organic layers were dried over Na2SO4, concentrated, and purified by flash 
column chromatography using a 1.5 × 10.5 cm silica gel column, eluting with 5% 
EtOAc/hexanes, collecting 10 × 75 mm test tube fractions.  The product containing 
fractions (5-45) were concentrated to give TBS ether 1.74 (150.2 mg, 86%) as a yellow 
oil. Rf = 0.58 (30% EtOAc/hexanes); 500 MHz 
1H NMR (CDCl3)  9.43 (d, J = 7.9 Hz, 
1H), 7.34-7.30 (m, 5H), 7.29-7.26 (m, 1H), 6.18-6.06 (m, 2H), 5.93-5.86 (m, 2H), 5.66 




4.17-4.07 (m, 2H), 3.89-3.76 (m, 1H), 3.67 (s, 3H), 3.50 (dd, J = 16.6, 2.7 Hz, 1H), 3.39 
(s, 3H), 2.42 (dd, J = 16.1, 11.9 Hz, 1H), 2.14 (q, J = 7.4 Hz, 2H), 2.04 (ddd, J = 14.4, 
8.8, 2.7, 1H), 1.64 (ddd, J = 14.1, 8.6, 3.0 Hz, 1H), 1.45 (sextet, J = 7.4 Hz, 2H), 1.19 (s, 
3H), 1.15 (s, 3H), 1.13 (s, 3H), 0.91 (t, J = 7.4 Hz, 3H), 0.87 (s, 9H), 0.06 (d, J = 10.5 Hz, 
6H); 125 MHz 13C NMR (CDCl3)   195.0, 167.1, 166.6, 165.5, 152.4, 147.7, 146.8, 
138.1, 128.8, 128.5, 128.1, 128.1, 127.5, 117.9, 117.6, 103.1, 93.5, 75.3, 70.5, 70.5, 69.7, 
69.2, 51.9, 51.5, 47.7, 38.9, 35.5, 33.7, 26.2, 23.7, 22.5, 22.2, 18.4, 14.0, 14.0, 1.4, -3.6, -
4.3. 
 
Preparation of (R)-ethyl 5-
(benzyloxy)-3-((tert-butyldimethylsilyl)oxy)pentanoate (1.107):80  To a stirring 
solution of alcohol 1.63, provided by Dr. Li (213 mg, 0.844 mmol, 1 equiv), in DMF (1 
mL) in a 10 mL rb flask, at rt, was added imidazole (69 mg, 1.0 mmol, 1.2 equiv) and 
TBSCl (140 mg, 0.928 mmol, 1.1 equiv).  After 3 h the solution was diluted with 40% 
EtOAc/hexanes (5 mL), and quenched with water (5 mL).  The phases were separated 
and the organic layer was washed with water (3 × 3 mL), dried over Na2SO4, and 
concentrated. Purification was accomplished by flash column chromatography using a 1.5 
× 12.0 cm silica gel column, eluting with 5% EtOAc/hexanes, collecting 10 × 75 mm test 
tube fractions.  The product containing fractions (9-22) were concentrated to give pure 
silyl ether 1.107 (254 mg, 85%) as a clear oil. Rf = 0.60 (20% EtOAc/hexanes); (500 
MHz 1H NMR (CDCl3)  7.29-7.26 (m, 5H), 4.43 (Aq, J = 12.0 Hz,  = 13.4 Hz, 2H), 
4.26 (quintet, J = 6.1 Hz, 1H), 4.11-4.00 (m, 2H), 3.49 (t, J = 6.5 Hz, 2H), 2.42 (d, J = 




6.7 Hz, 6H); 125 MHz 13C NMR (CDCl3)  171.9, 138.8, 128.6, 127.9, 127.8, 73.2, 67.3, 
66.8, 60.6, 43.3, 37.7, 26.1, 18.3, 14.5, -4.4, -4.5. 
 
 Preparation of (R)-ethyl 3-((tert-butyldimethylsilyl)oxy)-5-
oxopentanoate (1.57):54  To a stirring solution of benzyl ether 1.107 (1.37 g, 3.74 mmol, 
1 equiv) in EtOAc (20 mL) in a 100 mL rb flask, at 0 C, was added palladium on carbon 
(50 mg, 10% wt.).  The flask was equipped with a hydrogen balloon and allowed to stir at 
rt for 4 days.  The black solution was filtered through a plug of celite washing with 
copious amounts of EtOAc, and concentrated to give a crude alcohol Rf = 0.10 (20% 
EtOAc/hexanes) as a dark oil that was used without purification. 
The crude alcohol was taken up in CH2Cl2 (40 mL), cooled to 0 C, and i-Pr2EtN (4.6 
mL, 26 mmol, 7 equiv) and DMSO (2.65 mL, 37.4 mmol, 10 equiv) were added.  The 
mixture was stirred for 10 min, then SO3Pyr complex (2.38 g, 14.9 mmol, 4 equiv) was 
added in three equal aliquots 5 min apart.  The cloudy solution was stirred at 0 C for 1.5 
h, then quenched by the addition of saturated aqueous NaHCO3 solution (20 mL).  The 
biphasic solution was stirred for 10 min, partitioned between water (50 mL) and CH2Cl2 
(50 mL), and the aqueous layer was extracted with CH2Cl2 (3 × 30 mL).  The combined 
organic layers were dried over Na2SO4, concentrated, and purified by flash column 
chromatography using a 2.0 × 9.0 cm silica gel column, eluting with 5% EtOAc/hexanes, 
collecting 13 × 150 mm test tube fractions.  The product containing fractions (14-30) 
were concentrated to give aldehyde 1.57 (839 mg, 82%) as a clear oil. Rf = 0.35 (20% 




4.64 (dq, J = 5.6, 6.4 Hz, 1H), 4.14-4.09 (m, 2H), 2.67 (ddd, J = 16.8, 5.7, 2.2 Hz, 1H), 
2.62 (ddd, J = 16.8, 5.7, 2.2 Hz, 1H), 2.56 (dd, J = 15.1, 6.3 Hz, 1H), 2.53 (dd, J = 15.1, 
6.3 Hz, 1H), 1.27 (t, J = 7.7 Hz, 3H), 0.86 (s, 9H), 0.09 (d, J = 1.5 Hz, 6H); 125 MHz 13C 
NMR (CDCl3)  201.5, 171.2, 65.4, 61.0, 51.3, 43.0, 26.0, 18.2, 14.5, -4.5. 
 
 Preparation of (S)-5-((tert-
butyldiphenylsilyl)oxy)-3-((4-methoxybenzyl)oxy)pentanal (1.108):80  To a stirring 
solution of homoallyl alcohol, provided by Dr. Li (1.99 g, 5.62 mmol, 1 equiv), in THF 
(50 mL) in a 250 mL rb flask, at rt, was added PMBBr (4.0 mL, 27 mmol, 5 equiv) and 
Et3N (11.9 mL, 85.3 mmol, 15 equiv).  The mixture was cooled to -78 C, KHMDS (0.5 
M, 33.4 mL, 16.7 mmol, 3 equiv) was added dropwise by syringe, and this solution was 
stirred for 1 h at -78 C then for 1.5 h at -15 C.  The reaction mixture was then quenched 
by the addition of saturated aqueous NH4OH solution (20 mL) and allowed to stir 
overnight at rt.  The phases were separated and the aqueous layer was extracted with Et2O 
(3 × 40 mL).  The combined organic layers were dried over Na2SO4, concentrated and 
filtered through a 3 cm plug of silica to give the crude PMB ether (2.09 g) as a yellow oil.  
The crude oil was taken up in a 4:1 solution of CH2Cl2/MeOH (75 mL), NaHCO3 
(1.85 g, 22.0 mmol, 5 equiv) was added, and the mixture was cooled to -78 C.  A stream 
of O3 was bubbled through the solution until a light blue color developed (~3 min.).  
Excess O3 was purged by bubbling O2 through the solution for 15 min.  PPh3 (2.3 g, 8.8 
mmol, 2 equiv) was added and this mixture was stirred at rt for 1 h.  The cloudy solution 




chromatography using a 4.0 × 9.0 cm silica gel column, eluting with 10% 
EtOAc/hexanes, collecting 13 × 150 mm test tube fractions.  The product containing 
fractions (12-49) were concentrated to give aldehyde 1.108 (2.02 g, 75%, 2 steps) as a 
clear oil. Rf = 0.25 (20% EtOAc/hexanes); 500 MHz 
1H NMR (CDCl3)  9.76 (t, J = 2.2 
Hz, 1H), 7.71-7.65 (m, 4H), 7.48-7.38 (m, 6H), 7.20 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.4 
Hz, 2H), 4.47 (s, 2H), 4.20 (quintet, J = 6.0 Hz, 1H), 3.88-3.81 (m, 1H), 3.81 (s, 3H), 
3.79-3.73 (m, 1H), 2.69 (ddd, J = 16.3, 7.1, 2.8 Hz, 1H), 2.63 (ddd, J = 16.3, 7.1, 2.8 Hz, 
1H), 1.99-1.75 (m, 2H), 1.08 (s, 9H); 125 MHz 13C NMR (CDCl3)  102.0, 159.6, 135.9, 
133.9, 133.9, 130.1, 129.9, 129.8, 129.7, 128.1, 114.2, 71.6, 71.4, 60.4, 55.6, 48.9, 37.5, 
27.2, 19.5. 
 
 Preparation of (4S,6S)-8-((tert-butyldiphenylsilyl)oxy)-6-((4-
methoxybenzyl)oxy)-2-((trimethylsilyl)methyl)oct-1-en-4-ol (1.28):54  To a stirring 
solution of aldehyde 1.108 (1.92 g, 4.04 mmol, 1 equiv) in CH2Cl2 (32 mL) in a 100 mL 
rb flask, at rt, was added MgBrEt2O (2.08 g, 8.06 mmol, 2 equiv) in a single portion.  
The cloudy mixture was cooled to -78 C and stirred for 30 min.  Trimethyl(2-
((tributylstannyl)methyl)allyl)silane (2.87 g, 6.88 mmol, 1.7 equiv) was added in CH2Cl2 
(5 mL) along with a CH2Cl2 (2 mL) rinse.  This solution was maintained at -78 C for 5 
h, then quenched by the addition of saturated aqueous NaHCO3 solution (15 mL) and 
brine (20 mL). The phases were separated and the aqueous layer was extracted with 




concentrated, and purified by flash column chromatography using a 4.0 × 11.0 cm silica 
gel column, eluting with 5% EtOAc/hexanes, collecting 13 × 150 mm test tube fractions.  
The product containing fractions (21-54) were concentrated to give -hydroxyallylsilane 
1.28 (1.60 g, 65%) as a clear oil. Rf = 0.51 (25% EtOAc/hexanes); 500 MHz 
1H NMR 
(CDCl3)  7.70-7.65 (m, 4H), 7.46-7.36 (m, 6H), 7.20 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 8.6 
Hz, 2H), 4.65 (d, J = 8.6 Hz, 2H), 4.47 (s, 2H), 4.03-3.94 (m, 2H), 3.80 (s, 3H), 3.84-3.71 
(m, 2H), 2.65 (d, J = 2.5 Hz, 1H), 2.12 (dd, J = 13.7, 8.1 Hz, 1H), 2.06 (dd, J = 13.7, 81 
Hz, 1H), 1.92 (dq, J = 12.8, 6.1 Hz, 1H), 1.78 (dq, J = 13.8, 6.1 Hz, 1H), 1.71-1.58 (m, 
2H), 1.53 (Aq, J = 13.4 Hz,  = 14.7 Hz, 2H), 1.06 (s, 9H), 0.03 (s, 9H); 125 MHz 13C 
NMR (CDCl3)  159.5, 144.9, 136.0, 134.2, 134.1, 131.0, 130.0, 129.9, 128.0, 128.0, 
114.2, 110.3, 74.2, 71.7, 66.4, 60.9, 55.6, 47.1, 41.0, 37.5, 27.2, 27.1, 19.5, -1.0. 
 
 Preparation of (3R)-ethyl 3-((tert-
butyldimethylsilyl)oxy)-4-(6-((S)-4-((tert-butyldiphenylsilyl)oxy)-2-((4-
methoxybenzyl)oxy)butyl)-4-methylenetetrahydro-2H-pyran-2-yl)butanoate 
(1.64):80  To a stirring solution of -hydroxyallylsilane 1.28 (2.48 g, 4.10 mmol, 1.2 
equiv) and aldehyde 1.57 (839 mg, 3.06 mmol, 1 equiv) in Et2O (30 mL) in a 100 mL rb 
flask, at -78 C, was added  a 1.0 M TMSOTf solution (3.7 mL, 3.7 mmol, 1.2 equiv) in 
THF dropwise by syringe.  After1 h at -78 C the reaction mixture was quenched first by 
i-Pr2EtN (1 mL) then with saturated aqueous NaHCO3 solution (10 mL).  The mixture 




Et2O (3 × 20 mL). The combined organic layers were dried over Na2SO4, concentrated 
and purified by flash column chromatography using a 2.0 × 10.0 cm silica gel column, 
eluting with 5% EtOAc/hexanes, collecting 12 × 75 mm test tube fractions.  The product 
containing fractions (15-52) were concentrated to give pyran 1.64 (2.31 g, 95%) as a 
clear oil. Rf = 0.62 (20% EtOAc/hexanes). 500 MHz 
1H NMR (CDCl3)  7.70-7.67 (m, 
4H), 7.46-7.36 (m, 6H), 7.17 (d, J = 8.5 Hz, 2H), 6.83 (d, J = 8.5 Hz, 2H), 4.70 (d, J = 
10.8 Hz, 2H), 4.41 (Aq, J = 10.8 Hz,  = 25.4 Hz, 2H), 4.38-4.33 (m, 1H), 4.12-3.99 
(m, 2H), 3.91-3.85 (m, 1H), 3.82-3.75 (m, 2H), 3.79 (s, 3H), 3.54-3.47 (m, 1H), 3.46-
3.40 (m, 1H), 2.54-2.45 (m, 2H), 2.23 (d, J = 13.1 Hz, 1H), 2.16 (d, J = 13.1 Hz, 1H), 
1.99-1.89 (m, 2H), 1.89-1.77 (m, 3H), 1.69-1.61 (m, 3H), 1.18 (t, J = 13.1 Hz, 3H), 1.06 
(s, 9H), 0.86 (s, 9H), 0.08 (s, 3H), 0.04 (s, 3H); 125 MHz 13C NMR (CDCl3)  171.9, 
159.3, 144.9, 135.9, 134.2, 134.1, 131.1, 129.8, 129.6, 127.9, 127.9, 114.0, 108.8, 75.2, 
75.1, 73.1, 71.9, 67.0, 60.8, 60.5, 55.6, 44.1, 42.9, 42.6, 41.4, 41.3, 37.9, 27.2, 26.1, 19.5, 
18.4, 14.4, -4.1, -4.5. 
 
 Preparation of (3R)-ethyl 4-(6-((S)-4-((tert-
butyldiphenylsilyl)oxy)-2-((4-methoxybenzyl)oxy)butyl)-4-methylenetetrahydro-2H-
pyran-2-yl)-3-hydroxybutanoate (1.66):80  To a stirring solution of TBS ether 1.64 (685 
mg, 0.867 mmol, 1 equiv.) in benzene (28 mL) and MeOH (12 mL) in a 100 mL rb flask, 
at rt, was added p-toluenesulfonic acid (331 mg, 1.73 mmol, 2 equiv).  After stirring for 3 




concentrated.  Purification was accomplished by flash column chromatography using a 
2.0 × 13.0 cm silica gel column, eluting with 10% EtOAc/hexanes, collecting 12 × 75 
mm test tube fractions.  Fractions (5-18) were concentrated to give starting material 1.64 
(308 mg, 45%) as a clear oil, and product containing fractions (20-35) were concentrated 
to give alcohol 1.66 (319 mg, 54%) as a clear oil that was carried on without complete 
characterization.  Rf = 0.30 (20% EtOAc/hexanes); 500 MHz 
1H NMR (CDCl3)  7.69-
7.65 (m, 4H), 7.45-7.36 (m, 6H), 7.19 (d, J = 8.8 Hz, 2H), 6.85 (d, J = 8.8 Hz, 2H), 4.71 
(d, J = 11.0 Hz, 2H), 4.39 (Aq, J = 11.2 Hz,  = 41.2 Hz, 2H), 4.28-4.21 (m, 1H), 4.14 
(ddd, J = 14.5, 7.2, 2.4 Hz, 2H), 3.80 (s, 3H), 3.79-3.72 (m, 4H), 3.56-3.48 (m, 2H), 2.52 
(dd, J = 15.7, 7.5 Hz, 1H), 2.44 (dd, J = 15.7, 7.5 Hz, 1H), 2.22 (d, J = 13.4 Hz, 1H), 2.16 
(d, J = 13.4 Hz, 1H), 1.99 (t, J = 12.4 Hz, 1H), 1.92 (t, J = 12.4 Hz, 1H), 1.85-1.62 (m, 
6H), 1.24 (t, J = 6.9 Hz, 3H), 1.06 (s, 9H). 
 
 Preparation of (3R)-ethyl 4-(6-((S)-4-((tert-
butyldiphenylsilyl)oxy)-2-((4-methoxybenzyl)oxy)butyl)-4-methylenetetrahydro-2H-
pyran-2-yl)-3-((trimethylsilyl)oxy)butanoate (1.109):80  To a stirring solution of 
alcohol 1.66 (391 mg, 0.579 mmol, 1 equiv) in CH2Cl2 (10 mL) in a 50 mL rb flask, at rt, 
was added TMSCl (0.11 mL, 0.87 mmol, 1.5 equiv) and Et3N (0.24 mL, 1.7 mmol, 3 
equiv).  After 3.5 h the reaction mixture was quenched with water (50 mL), the phases 
were separated, and the aqueous layer was extracted with CH2Cl2 (3 × 5 mL).  The 




column chromatography using a 1.5 × 8.5 cm silica gel column, eluting with 10% 
EtOAc/hexanes, collecting 10 × 75 mm test tube fractions.  The product containing 
fractions (6-26) were concentrated to give pure silyl ether 1.109 (415 mg, 97%) as a 
yellow oil. Rf = 0.60 (20% EtOAc/hexanes); 500 MHz 
1H NMR (CDCl3)  7.72-7.68 (m, 
4H), 7.47-7.37 (m, 6H), 7.18 (d, J = 8.2 Hz, 2H), 6.85 (d, J = 8.5 Hz, 2H), 4.72 (dd, J = 
8.2, 1.6 Hz, 2H), 4.42 (Aq, J = 10.8 Hz,  = 28.2 Hz, 2H), 4.37 (dt, J = 6.5, 65 Hz, 
1H), 4.15-4.02 (m, 2H), 3.90 (dt, J = 5.9, 6.0 Hz, 1H), 3.82-3.76 (m, 2H), 3.80 (s, 3H), 
3.56-3.48 (m, 1H), 3.44-3.37 (m, 1H), 2.50 (d, J =1.3 Hz, 1H), 2.49 (s, 1H), 2.27 (d, J = 
13.1 Hz, 1H), 2.18 (d, J = 13.1 Hz, 1H), 1.94 (q, J = 12.8 Hz, 2H), 1.89-1.79 (m, 3H), 
1.68-1.61 (m, 3H), 1.21 (t, J = 7.2 Hz, 3H), 1.08 (s, 9 H), 0.13 (s, 9H); 125 MHz 13C 
NMR (CDCl3)  177.8, 159.3, 144.9, 135.9, 134.2, 131.4, 129.9, 129.6, 128.0, 114.1, 
108.9, 75.2, 75.2, 72.9, 71.9, 66.9, 60.9, 60.6, 55.6, 44.4, 43.1, 42.6, 41.4, 41.2, 38.0, 
27.2, 19.5, 14.5, 0.6. 
 
 Preparation of (S)-1-((2R,6S)-6-((S)-4-((tert-
butyldiphenylsilyl)oxy)-2-((4-methoxybenzyl)oxy)butyl)-4-methylenetetrahydro-2H-
pyran-2-yl)-4-((trimethylsilyl)methyl)pent-4-en-2-ol (1.56):80  Powdered CeCl37H2O 
(674 mg, 1.81 mmol, 10 equiv) in a 15 mL rb flask was dried at 170 C under a vacuum 
of 0.3 mm of Hg for 16 h.  The dry CeCl3 has a slight grey appearance.  The flask was 
cooled to rt, flushed with N2, THF (1.5 mL) was added, and the thick suspension was 




a 1 M solution of the TMSCH2MgCl was prepared:  Mg turnings (125 mg) along with a 
single crystal of I2 were heated using a heat gun in a flame dried 25 mL 2 neck rb flask 
equipped with a reflux condenser.  After purple vapors filled the flask THF (4.6 mL) was 
added in single portion, and was brought to reflux using the heat gun.  TMSCH2Cl (0.4 
mL) was added dropwise to the reddish brown THF solution along with continuous 
heating.  The THF solution first turned clear and then developed a mild metallic silver 
color at which point heating was discontinued.  The self-maintained reaction solution was 
stirred for 1.5 h, during which time a deep grey color developed and most of the Mg was 
consumed.  The flask containing the CeCl3 was cooled to -78 C and the 1 M 
TMSCH2MgCl (1.81 mL, 1.81 mmol, 10 equiv) solution was added in a single portion.  
This solution was stirred at -78 C for 1 h, a brown color developed, then ethyl ester 
1.109 (135 mg, 0.181 mmol, 1 equiv) was added along with a THF (0.5 mL) rinse.  This 
solution was stirred at -78 C for 2 h then allowed to reach rt as it stirred overnight.  The 
mixture was transferred to 25 mL rb flask, diluted with THF (10 mL), and cooled to -78 
C.  To this vigorously stirred solution was added a 1 N aqueous HCl solution 5 drops at 
a time until only a single spot, blue in PMA, was observed by TLC.  The acidic solution 
was immediately quenched with a saturated aqueous NaHCO3 solution (5 mL) and 
allowed to warm to rt.  This solution was partitioned between CH2Cl2 (10 mL) and water 
(5 mL), and the aqueous layer was extracted with CH2Cl2 (3 × 5 mL).  The combined 
organic layers were dried over Na2SO4, concentrated and purified by flash column 
chromatography using a 1.5 × 11.0 cm silica gel column, eluting with 5% 
EtOAc/hexanes, collecting 10 × 75 mm test tube fractions.  The product containing 




clear oil. Rf = 0.55 (30% EtOAc/hexanes). 500 MHz 
1H NMR (CDCl3)  7.69-7.65 (m, 
4H), 7.45-7.36 (m, 6H), 7.19 (d, J = 8.5 Hz, 2H), 6.84 (d, J = 8.5 Hz, 2H), 4.70 (dd, J = 
10.7, 1.6 Hz, 2H), 4.64 (d, J = 14.3 Hz, 2H), 4.39 (Aq, J = 11.1 Hz,  = 30.8 Hz, 2H), 
3.99-3.93 (m, 1H), 3.79 (s, 3H), 3.79-3.74 (m, 3H), 3.52-3.51 (m, 3H), 2.25-2.14 (m, 
3H), 2.08-1.90 (m, 3H), 1.79 (q, J = 6.5 Hz, 2H), 1.69-1.57 (m, 4H), 1.55 (s, 2H), 1.05 (s, 
9H), 0.02 (s, 9H); 125 MHz 13C NMR (CDCl3)  159.4, 144.8, 144.3, 135.9, 134.2, 
134.2, 131.3, 129.9, 129.8, 129.7, 128.0 114.1, 110.2, 109.2, 79.5, 75.7, 73.0, 71.7, 69.8, 
60.7, 55.6, 46.8, 42.8, 42.1, 41.4, 41.3, 37.7, 27.3, 27.1, 19.5, -1.0. 
 





pyran-3-yl octa-2,4-dienoate (1.91):  To a stirring solution of aldehyde 1.74 (24.1 mg, 
0.032 mmol, 1 equiv) and silane 1.56 (33.5 mg, 0.047 mmol, 1.5 equiv) in Et2O (1.0 mL) 
in a 5 mL rb flask, at -78 C, was added a 1.0 M TMSOTf  solution (1.0 M, 47 L, 0.047 
mmol, 1.5 equiv) in THF dropwise by syringe.  After 9 h the reaction mixture was 




aqueous NaHCO3 solution (1 mL).  The mixture was warmed to rt, the phases were 
separated, and the aqueous layer was extracted with Et2O (3 × 1 mL).  The combined 
organic layers were concentrated, dried over Na2SO4, concentrated, and purified by flash 
column chromatography using a 1.5 × 8.0 cm silica gel column, eluting with 5% 
EtOAc/hexanes, collecting 10 × 75 mm test tube fractions.  The product containing 
fractions (11-23) were concentrated to give pyran 1.91 (33.2 mg, 75%) as a clear oil. Rf = 
0.44 (20% EtOAc/hexanes); +7.3 (c =1.28, CHCl3); 500 MHz 
1H NMR (CDCl3) 
 7.70-7.65 (m, 4H), 7.45 (m, 10H), 7.30 (m, 1H), 7.17 (d, J = 8.6 Hz, 2H), 6.84 (d, J = 
8.6 Hz, 2H), 6.18 (s, 1H), 6.17-6.12 (m, 1H), 5.96 (d, J = 15.2 Hz, 1H), 5.94-5.89 (m, 
1H), 5.79 (d, J = 15.2 Hz, 1H), 5.61 (s, 1H), 5.40 (dd, J = 15.9, 5.8 Hz, 1H), 4.81 (s, 2H), 
4.71 (d, J = 10.8 Hz, 2H), 4.64 (s, 2H), 4.62 (s, 1H), 4.54 (s, 1H), 4.39 (Aq, J = 10.4 Hz, 
 = 31.2 Hz, 2H), 4.13-4.04 (m, 2H), 3.93-3.78 (m, 3H), 3.79 (s, 3H), 3.67 (s, 3H), 
3.58-3.41 (m, 5H), 3.31 (s, 3H), 2.40-2.31 (m, 1H), 2.24 (t, J = 11.7 Hz, 2H), 2.19-2.10 
(m, 3H), 2.03-1.85 (m, 6H), 1.82-1.73 (m, 3H), 1.67-1.53 (m, 6H), 1.49-1.42 (m, 2H), 
1.17 (d, J = 6.7 Hz, 3H), 1.12 (s, 3H), 1.11 (s, 3H), 1.06 (s, 9H), 0.92 (t, J = 6.9 Hz, 3H), 
0.88 (s, 9H), 0.08 (d, J = 7.8, 6H); 125 MHz 13C NMR (CDCl3)  166.8, 165.9, 159.4, 
153.2, 146.9, 146.9, 145.6, 145.2, 138.5, 138.3, 136.0, 135.9, 134.2, 134.2, 131.3, 129.9, 
129.8, 129.7, 128.7, 128.2, 128.0, 127.4, 118.8, 117.4, 114.1, 109.1, 108.8, 102.9, 93.4, 
79.3, 75.2, 75.2, 75.1, 75.0, 72.9, 72.2, 71.8, 70.4, 69.6, 68.5, 60.7, 55.6, 51.9, 51.4, 46.2, 
43.1, 42.7, 41.6, 41.3, 41.0, 40.6, 38.9, 38.1, 35.4, 33.4, 27.3, 27.2, 26.2, 24.3, 22.2, 19.5, 
18.4, 14.2, 14.0, -3.7, -4.3; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 51.8, 51.3, 27.2, 26.1, 
24.2, 14.0, 13.9, -3.8, -4.4; CH2 δ 109.1, 108.8, 93.4, 72.2, 69.6, 60.7, 43.1, 42.6, 41.4, 





128.7, 128.1, 128.0, 127.4, 118.8, 117.4, 114.1, 79.3, 75.2, 75.1, 75.1, 75.0, 72.9, 71.7, 
70.4, 68.5; C0 δ 166.8, 165.9, 159.4, 153.2, 146.9, 145.6, 145.2, 138.3, 134.2, 134.2, 
131.3, 129.8, 128.7, 102.9, 51.9, 46.2, 27.2, 19.5, 18.4, 14.2; IR (neat) 2933, 2857, 1720, 
1643, 1613, 1514, 1407, 1428, 1382, 1360, 1248, 1108, 1042 cm-1; HRMS (ESI/ APCI) 
calcd for C81H114O14NaSi2 (M+Na) 1389.7661, found 1389.7661. 
 





dienoate (1.92):  To a stirring solution of TBDPS ether 1.91 (50.8 mg, 0.037 mmol, 1 
equiv) in DMF (742 L) in a 4 mL reaction vial, at rt, was added a premixed solution of 1 
M TBAF in THF (37 L, 0.037 mmol, 1 equiv) and 1 M AcOH in DMF (37 L, 0.037 
mmol, 1 equiv).  The transfer was made complete by washing with DMF (2 × 50 L), 
and the solution was stirred for 20 h, then diluted with 40% EtOAc/hexanes (1 mL), and 
quenched with water (1 mL).  The aqueous layer was extracted with 40% EtOAc/hexanes 
(3 × 3 mL).  The combined organic layers were dried over Na2SO4, concentrated, and 




with 10% EtOAc/hexanes, collecting 10 × 75 mm test tube fractions.  The product 
containing fractions (11-23) were concentrated to give alcohol 1.92 (38 mg, 89%) as a 
clear oil. Rf = 0.20 (30% EtOAc/hexanes); +4.0 (c =1.00, CHCl3); 500 MHz 
1H 
NMR (CDCl3)  7.37-7.34 (m, 4H,) 7.31-7.48 (m, 1H), 7.26 (d, J = 8.8 Hz, 2H), 6.89 (d, 
J = 8.8 Hz, 2H), 6.24-6.15 (m, 2H), 5.98 (d, J = 16.2 Hz, 1H), 5.93 (s, 1H), 5.80 (d, J = 
14.7 Hz, 1H), 5.61 (s, 1H), 5.40 (dd, J = 15.5, 5.9 Hz, 1H), 4.82 (s, 2H), 4.75-4.71 (m, 
2H), 4.67-4.65 (m, 2H), 4.65-4.56 (m, 2H), 4.48 (Aq, J = 10.7 Hz,  = 20.1 Hz, 2H), 
4.15-4.05 (m, 2H), 3.92-3.84 (m, 2H), 3.80 (s, 3H), 3.76-3.67 (m, 3H), 3.68 (s, 3H), 3.57-
3.41 (m, 5H), 3.32 (s, 3H), 2.46-2.32 (m, 1H), 2.29-2.13 (m, 5H), 2.04-1.86 (m, 6H), 
1.83-1.68 (m, 2H), 1.68-1.56 (m, 6H), 1.47 (q, J = 7.5 Hz, 2H),  1.18 (d, J = 7.4 Hz, 3H), 
1.12 (d, J = 2.9 Hz, 6H), 0.93 (t, J = 7.1 Hz, 3H), 0.88 (s, 9H), 0.08 (d, J = 7.0 Hz, 6H); 
125 MHz 13C NMR (CDCl3)  166.8, 165.9, 159.7, 153.2, 146.9, 146.1, 144.8, 144.6, 
138.9, 138.2, 130.7, 129.8, 128.7, 128.2, 128.0, 127.3, 118.8, 117.4, 114.3, 109.0, 102.8, 
93.4, 79.6, 77.6, 77.4, 77.1, 75.6, 75.2, 75.2, 72.2, 71.7, 70.3, 69.7, 68.5, 60.6, 55.6, 52.0, 
51.4, 46.2, 43.0, 41.9, 41.6, 41.1, 41.0, 40.6, 38.8, 37.0, 35.4, 33.4, 26.2, 24.4, 24.2, 22.2, 
18.4, 14.1, -3.7, -4.3; 125 MHz DEPT (CDCl3) CH3 δ 55.6, 51.9, 51.3, 26.1, 24.3, 24.2, 
14.1, 14.0, -3.7, -4.3; CH2 δ 109.0, 93.4, 72.1, 69.6, 60.5, 43.0, 41.9, 41.6, 41.1, 41.0, 
40.5, 38.8, 36.9, 35.4, 33.4, 22.2; CH δ 146.9, 146.1, 138.9, 129.8, 128.7, 128.1, 128.0, 
127.3, 118.7, 117.4, 114.3, 79.6, 77.6, 75.6, 75.1, 71.7, 70.3, 68.5; C0 δ 166.8, 165.9, 
159.7, 153.2, 144.8, 144.6, 138.2, 130.7, 102.8, 77.1, 77.2, 46.2, 18.4; IR (neat) 3493, 
3070, 2936, 1719, 1642, 1514, 1463, 1435, 1381, 1359, 1302, 1249, 1108, 1043 1042 cm-











yl)-3-((4-methoxybenzyl)oxy)butanoic acid (1.93):  To a stirring of alcohol 1.92 (33.4 
mg, 0.029 mmol, 1 equiv) in CH2Cl2 (300 L) in a 4 mL reaction vial, at 0 C, was added 
i-Pr2NEt (36 L, 0.210 mmol, 7 equiv), DMSO (20 L, 0.290 mmol, 10 equiv), and 
SO3Pyr (18 mg, 0.12 mmol, 4 equiv) in a single portion.  This solution was stirred at 0 
C for 75 min, then quenched by the addition of saturated aqueous NaHCO3 solution (1 
mL).  The phases were separated, and aqueous layer was extracted with 40% 
EtOAc/hexanes (3 × 3 mL). The organic phases were combined, dried over Na2SO4 and 
concentrated under reduced pressure.  The resulting clear oil with run through a 1.5 × 2 
cm plug of silica with EtOAc, and concentrated to give the crude aldehyde (33.1 mg), 
which was carried on without characterization.  
To a stirring solution of the aforementioned aldehyde in 2-methyl-2-butene (400 L) 
and t-BuOH (400 L) in a 5 mL rb flask, at rt, was added a 1.25 M aqueous KH2PO4 
solution (140 L).  This solution was cooled to -10 C in an ethylene glycol/ CO2 bath, 




mixture was stirred vigorously for 1.5 h then quenched with a 0.05 M aqueous pH 4 
buffer solution (1 mL).  The phases were separated, and aqueous layer with extracted 
with Et2O (3 x 3 mL).  The combined organic layers were dried over Na2SO4, 
concentrated and purified by flash column chromatography using a 1.5 × 12.0 cm silica 
gel column, eluting with 3% MeOH/CH2Cl2, collecting 10 × 75 mm test tube fractions.  
The product containing fractions (4-13) were concentrated to give acid 1.93 (30.7 mg, 93 
%, 2 steps) as a clear oil. Rf = 0.32 (10% MeOH/ 40% EtOAc/ 50% hexanes); 
+12.9 (c =1.14, CHCl3); 500 MHz 
1H NMR (CDCl3)  7.37-7.34 (m, 4H), 7.32-7.27 (m, 
1H), 7.25 (d, J = 8.8 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 6.21-6.16 (m, 2H), 6.00 (d, J = 
15.9 Hz, 1H), 5.93 (s, 1H), 5.80 (d, J = 15.5 Hz, 1H), 5.62 (s, 1H), 5.41 (dd, J = 16.3, 6.4 
Hz, 1H), 4.85-4.80 (m, 2H), 4.75-4.70 (m, 2H), 4.67 (d, J = 3.8 Hz, 2H), 4.65-4.58 (m, 
2H), 4.57 (d, J = 10.5 Hz, 1H), 4.45 (d, J = 10.5 Hz, 1H), 4.16-4.04 (m, 3H), 3.87 (dt, J = 
10.9, 6.3 Hz, 1H), 3.80 (s, 3H), 3.81-3.78 (m, 1H), 3.68 (s, 3H), 3.58-3.39 (m, 5H), 3.32 
(s, 3H), 2.62 (t, J = 5.2 Hz, 2H), 2.29-2.20 (m, 2H), 2.19-2.12 (m, 2H), 2.05-1.87 (m, 
4H), 1.83-1.66 (m, 4H), 1.64-1.55 (m, 2H), 1.50-1.42 (m, 2H), 1.28-1.25 (m, 3H), 1.18 
(d, J = 6.5 Hz, 3H), 1.12 (s, 3H), 1.11 (s, 3H), 0.93 (t, J = 71. Hz, 3H), 0.88 (s, 9H), 0.09-
0.07 (m, 6H); 125 MHz 13C NMR (CDCl3)  166.9, 165.9, 159.7, 153.3, 147.0, 146.1, 
144.7, 144.5, 139.2, 138.1, 130.4, 129.9, 129.8, 128.8, 128.8, 128.7, 128.2, 128.0, 127.2, 
118.7, 117.4, 114.3, 114.2, 109.1, 102.8, 93.3, 79.7, 77.6, 77.4, 77.1, 75.2, 75.2, 75.1, 
73.2, 72.5, 71.8, 70.3, 69.6, 68.5, 55.6, 52.0, 51.5, 46.2, 43.0, 42.0, 41.4, 41.1, 41.0, 40.6, 
40.3, 38.8, 35.4, 33.4, 30.0, 26.3, 26.2, 24.3, 24.3, 22.2, 18.4, 14.1, 14.0, 1.4, -3.7, -4.3; 
125 MHz DEPT (CDCl3) CH3 δ 55.6, 52.0, 51.5, 26.2, 24.3, 24.3, 14.1, 14.0, -3.9, -4.4; 





30.0, 22.2; CH δ 147.0, 146.1, 139.2, 129.8, 128.7, 128.2, 128.0, 127.2, 118.7, 117.4, 
114.2, 79.7, 75.2, 75.1, 73.1, 71.7, 70.2, 68.5; CH0 δ 166.9, 165.9, 159.7, 153.4 144.7, 
144.5, 138.1, 130.4, 129.8, 128.8, 128.7, 128.7, 114.2, 102.8, 77.6, 77.4, 77.1, 46.2, 26.2, 
18.4, 1.4; IR (neat) 2933, 2856, 1716, 1643, 1614, 1514, 1463, 1435, 1381, 1360, 1303, 
1249, 1173, 1107, 1082, 1041, 836 cm-1; HRMS (ESI/ APCI) calcd for C65H94O15NaSi 
(M+Na) 1165.6518, found 1165.6520. 
 




tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-12-yl octa-2,4-dienoate (1.73):54  To 
a stirring solution of TBS ether 1.93 (11.6 mg, 0.0101 mmol, 1 equiv) in a solution of 9:1 
THF/Pyr in a 2 mL plastic vial, at rt, was added HFPyr (20%, 253 L, 25 mL/mmol of 
silyl ether) using a needleless plastic syringe.  This solution was stirred for 2 days then 
quenched by pipetting into a stirring mixture of EtOAc (20 mL) and brine (20 mL).  The 
phases were separated, the organic layer was washed with brine (2 × 10 mL), dried over 





To a stirring solution of the aforementioned seco-acid in THF (373 L) in a 2 mL 
vial, at 0 C, was added Et3N (8.5 L, 0.061 mmol, 6 equiv) and a 1 M solution of 
trichlorobenzyl chloride (30 L, 0.030 mmol, 3 equiv) in THF. After 5 min, the reaction 
mixture was warmed to rt and stirring was continued for an additional 3 h.  The reaction 
mixture was diluted with a solution of 3:1 toluene/THF (6 mL) and taken up into a 10 mL 
gas-tight syringe.  This solution was added by syringe pump to a stirring solution of 
DMAP (25 mg, 0.20 mmol, 20.0 equiv) in toluene (6.7 mL) in 50 mL rb flask, at 40 °C, 
over a period of 12 h. The residual contents of the syringe were rinsed into the flask with 
toluene (0.5 mL) and stirring was continued for an additional 2 h. The reaction mixture 
was cooled to rt, diluted with 30% EtOAc/hexanes (10 mL) and washed with water (3 × 
10 mL) and with brine (10 mL).  The organic phase was dried over Na2SO4, concentrated, 
and purified by flash column chromatography with a 0.5 × 6.0 cm silica gel column, 
eluting with 10% EtOAc/hexanes, collecting 6.0 × 50 mm test tube fractions.  The 
product containing fractions (11-26) were combined and concentrated under reduced 
pressure to provide macrolactone 1.73 as a white foam (5.4 mg, 52 % over 2 steps): Rf = 
0.44 (30% EtOAc/hexanes); 500 MHz 1H NMR (CDCl3)  7.41-7.33 (m, 4H), 7.31-7.24 
(m, 2H), 7.21 (d, J = 8.8 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H), 6.24 (d, J = 15.8 Hz, 1H), 
6.18-6.14 (m, 2H), 5.98 (d, J = 1.7 Hz, 1H), 5.77 (d, J = 15.6 Hz, 1H), 5.59 (ddd, J = 11.6 
4.3, 2.5 Hz, 1H), 5.33 (dd, J = 15.8, 8.6 Hz, 1H), 5.25 (s, 1H), 4.83 (Aq, J = 7.3 Hz,  
= 12.0 Hz, 2H), 4.76-4.73 (m, 2H), 4.71 (s, 2H), 4.65 (Aq, J = 12.0 Hz,  = 15.7 Hz, 
2H), 4.49 (s, 2H), 4.22-4.15 (m, 1H), 3.99-3.92 (m, 2H), 3.75 (s, 3H), 3.73-3.70 (m, 2H), 
3.68 (s, 3H), 3.35-3.47 (m, 1H), 3.40-3.33 (m, 2H), 3.11 (s, 3H), 3.11-3.06 (m, 1H), 2.59 




2.22-1.82 (m, 12H), 1.79-1.72 (m, 1H), 1.56 (dd, J = 13.8, 6.9 Hz, 1H), 1.50-1.41 (m, 
3H), 1.09 (s, 3H), 1.08 (s, 3H), 1.07 (d, J = 6.9 Hz, 3H), 0.92 (t, J = 6.9, 3H); 125 MHz 
13C NMR (CDCl3)  172.2, 167.0, 165.6, 159.3, 151.7, 146.7, 145.9, 144.6, 144.5, 142.0, 
138.1, 131.0 , 129.6, 128.6, 128.6, 128.1, 127.8, 125.5, 119.4, 118.7, 113.9, 109.1, 109.0, 
103.5, 93.7, 81.5, 76.5, 76.4, 76.3, 75.3, 75.3, 73.2, 72.1, 70.7, 69.8, 67.3, 55.4, 52.8, 
51.3, 45.3, 44.2, 43.1, 42.0, 41.5, 41.1, 41.0, 35.3, 34.7, 31.0, 29.9, 26.3, 22.0, 20.3, 15.2, 
13.9. 
 
   Preparation of Merle 23:54  To a stirring solution of 
protected Merle 23 (2.0 mg, 0.0020 mmol, 1 equiv) in CH2Cl2 (440 μl) in a 4 mL reaction 
vial, at 0 C, was added 1 M aqueous pH 7 buffer (300 μL), and DDQ (4.0 mg, 0.020 
mmol, 10 equiv).  After 2 h the reaction mixture was quenched by the addition of 
saturated aqueous NaHCO3 solution (1 mL), the phases were separated, and the aqueous 
layer was extracted with CH2Cl2 (3 × 3mL).  The combined organic layers were washed 
with brine (2 × 1 mL), dried over Na2SO4, concentrated, and used without further 
purification. 
 To the aforementioned analog in a 4 mL reaction vial was added a 0.25 M 
solution of LiBF4 (270 µL, 0.0900 mmol, 45.0 equiv) in 25:1 CH3CN/H2O.  The reaction 




the reaction mixture was poured into a stirring solution of EtOAc (5 mL), and quenched 
with saturated aqueous NaHCO3 solution (5 mL).  The layers were separated and the 
aqueous phase was extracted with EtOAc (3 × 5 mL).  The combined organic phases 
were dried over Na2SO4, concentrated, and purified by flash column chromatography 
with a 0.5 × 6 cm silica gel column, eluting with 35% EtOAc/hexanes, collecting 6 × 50 
mm test tube fractions. The product containing fractions (9-18) were combined and 
concentrated under reduced pressure to provide Merle 23 (1.4 mg, 93%, 2 steps) as a 
white foam: Rf = 0.13 (30% EtOAc/hexanes). 500 MHz 
1H NMR (CDCl3)  6.18-6.15 
(m, 2H), 6.02 (d, J = 1.7 Hz, 1H), 5.80 (dd, J = 15.2, 6.4 Hz, 2H), 5.33 (dd, J = 15.8, 8.6 
Hz, 1H), 5.27 (s, 1H), 5.26-5.22 (m, 1H), 5.21 (s, 1H), 4.75-4.69 (m, 4H), 4.47 (d, J = 
11.7 Hz, 1H), 4.26-4.18 (m, 1H), 4.11-3.99 (m, 2H), 3.86-3.80 (m, 1H), 3.76-3.65 (m, 
1H), 3.68 (s, 3H), 3.56 (ddd, J = 11.1, 7.5, 2.3 Hz, 1H), 3.53-3.46 (m, 1H), 3.41 (dd, J = 
11.1, 11.1 Hz, 1H), 2.53-2.41 (m, 3H), 2.19-1.80 (m, 12H), 1.65-1.42 (m, 8H), 1.24 (d, J 
= 6.7 Hz, 3H), 1.14 (s, 3H), 1.01 (s, 3H), 0.93 (t, J = 7.4, 3H); 125 MHz 13C NMR 
(CDCl3)  172.4, 167.3, 165.8, 152.3, 146.5, 145.6, 144.0, 143.5, 138.9, 129.9, 128.6, 
119.8, 118.9, 109.3, 108.7, 99.2, 80.2, 79.7, 77.8, 76.5, 74.2, 73.9, 70.5, 68.8, 64.7, 51.3, 















ylidene)acetate (1.96):33 This compound was prepared from ketone 1.87 in same manner 
as 1.88 using acetic anhydride at 0 °C for 3h. (84% yield, 2 steps, as a clear oil).  Rf = 
0.46 (30% EtOAc/hexanes); 500 MHz 1H NMR (CDCl3)  7.39-7.34 (m, 4H), 7.33-7.29 
(m, 1H), 7.21 (d, J = 8.3 Hz, 2H), 6.84 (d, J = 8.3 Hz, 2H), 6.00 (d, J = 15.9 Hz, 1H), 
5.89 (s, 1H), 5.46-5.32 (m, 2H), 4.86 (ABq, J = 7.1 Hz,  = 4.1 Hz, 2H), 4.71-4.65 (m, 
2H), 4.62 (d, J = 10.8 Hz, 1H), 4.42 (d, J = 10.8 Hz, 1H), 4.15-4.09 (m, 3H), 4.08-4.00 
(m, 1H), 3.90 (ddd, J = 10.2, 4.6, 2.0 Hz, 1H), 3.79 (s, 3H), 3.69 (s, 3H), 3.52 (dd, J = 
15.4, 2.7 Hz, 1H), 3.24 (s, 3H), 2.30 (ddd, J = 14.1, 11.7, 1.6 Hz, 1H), 2.03 (s, 3H), 1.92 
(ddd, J = 14.3, 9.8, 1.8 Hz, 1H), 1.73 (ddd, J = 13.3, 10.3, 2.6 Hz, 1H), 1.23 (d, J = 6.4, 
3H), 1.11 (s, 6H), 0.90 (s, 9H), 0.05 (s, 6H); 125 MHz 13C NMR (CDCl3)  169.5, 166.7, 
159.4, 152.5, 138.4, 138.1, 130.8, 129.5, 129.5, 129.4, 128.7, 128.2, 128.0, 127.9, 124.6, 
117.7, 114.1, 114.0, 102.9, 93.6, 77.0, 72.7, 72.3, 72.2, 69.7, 68.6, 64.7, 55.5, 55.5, 51.8, 







methylpent-3-en-2-yl)-2-methoxytetrahydro-4H-pyran-4-ylidene)acetate (1.110):33  
To a stirring solution of TBS-ether 1.96 (110 mg, 0.140 mmol, 1 equiv) in a 5:4:1 
solution of THF/ MeOH/ pyridine in a plastic bottle, at 0 C, was added HFPyr (20%, 
1.1 mL).  The mixture was stirred at 0 C for 10 min, then at rt for 2 h, and then quenched 
by pipetting it into a stirring mixture of 50% EtOAc/hexanes (10 mL) and saturated 
aqueous NaHCO3 solution (10 mL).  The phases were separated and the aqueous layer 
was extracted with 50% EtOAc/hexanes (3 × 10 mL).  The combined organic layers were 
dried over Na2SO4, concentrated, and purified by flash column chromatography using a 
1.5 × 5.0 cm silica gel column, eluting with 30% EtOAc/hexanes, collecting 10 × 75 mm 
test tube fractions.  The product containing fractions (6-27) were combined and 
concentrated under reduced pressure to provide pure alcohol 1.110 (85 mg, 91% yield) as 
a clear oil: Rf = 0.29 (50% EtOAc/hexanes); 500 MHz 
1H NMR (CDCl3)  7.39-7.34 (m, 
4H), 7.34-7.29 (m, 1H), 7.21 (d, J = 8.9 Hz, 2H), 6.84 (d, J = 8.9 Hz, 2H), 5.99 (d, J = 
16.0 Hz, 1H), 5.88 (s, 1H), 5.50 (dt, J = 15.6, 5.8 Hz, 1H), 5.43 (s, 1H), 4.86 (ABq, J = 
96. Hz,  = 7.0 Hz, 2H), 4.68 (s, 2H), 4.62 (d, J = 10.9 Hz, 1H), 4.42 (d, J = 10.9 Hz, 
1H), 4.14 (dt, J = 12.7, 6.4 Hz, 1H), 4.09-4.02 (m, 3H), 3.90 (ddd, J = 9.9, 4.3, 1.7 Hz, 
1H), 3.79 (s, 3H), 3.70 (s, 3H), 3.47 (dd, J = 15.7, 2.4 Hz, 1H), 3.23 (s, 3H), 2.34 (ddd, J 




= 13.0, 10.0 2.1 Hz, 1H), 1.53 (s, 1H), 1.22 (d, J = 6.4 Hz, 3H), 1.13 (s, 3H), 1.10 (s, 3H); 
125 MHz 13C NMR (CDCl3)  169.7, 166.8, 159.4, 159.4, 152.5, 139.8, 138.1, 138.1, 
130.7, 129.5, 129.5, 128.7, 128.0, 128.0, 125.1, 117.5, 114.1, 114.0, 102.7, 93.6, 76.9, 




5-oxopent-3-en-2-yl)dihydro-2H-pyran-4(3H)-ylidene)acetate (1.97):33 To a stirring 
solution of alcohol 1.110 (85 mg, 0.127 mmol, 1 equiv) in CH2Cl2 (4.2 mL), at rt, was 
added powdered 4 Å  molecular sieves (110 mg), followed by TPAP (4.00 mg, 0.013 
mmol, 0.1 equiv) and NMO (45.0 mg, 0.381 mmol, 3 equiv) in a single portion.  After 1 
h the reaction mixture was diluted with EtOAc (10 mL), and filtered through a 3 cm pad 
of florisil washing with copious amounts of EtOAc.  The filtrate was concentrated to a 
dark oil, and purified by flash column chromatography using a 1.5 × 3.0 cm silica gel 
column, eluting with 30% EtOAc/hexanes, and collecting 10 × 75 mm test tube fractions.  
The product containing fractions (2-8) were combined and concentrated under reduced 
pressure to provide 1.97 (79 mg, 93% yield) as a clear oil: Rf = 0.54 (50% 
EtOAc/hexanes); 500 MHz 1H NMR (CDCl3)  9.52 (d, J = 7.9 Hz, 1H), 7.38-7.34 (m, 
4H), 7.33-7.28 (m, 2H), 7.21 (d, J = 9.7 Hz, 2H), 6.84 (d, J = 9.1 Hz, 2H), 5.94 (dd, J = 




4.67 (s, 2H), 4.63 (d, J = 11.0 Hz, 1H), 4.40 (d, J = 11.0 Hz, 1H), 4.17 (dt, J = 10.8, 6.1 
Hz, 1H), 4.14-4.06 (m, 1H), 3.89 (ddd, J = 10.1, 4.7, 2.0 Hz, 1H), 3.79 (s, 3H), 3.70 (s, 
3H), 3.54 (dd, J = 16.6, 3.1 Hz, 1H), 3.26 (s, 3H), 2.37 (ddd, J = 14.2, 12.0, 1.8 Hz, 1H), 
1.98 (ddd, J = 14.4, 9.7, 2.0 Hz, 1H), 1.91 (s, 3H), 1.78 (ddd, J = 14.1, 10.3, 2.8 Hz, 1H), 
1.24 (d, J = 6.6 Hz, 3H), 1.16 (s, 3H), 1.14 (s, 3H); 125 MHz 13C NMR (CDCl3)  194.8, 
169.0, 167.1, 166.4, 159.5, 151.4, 138.0, 130.5, 129.5, 128.7, 128.0, 127.9, 127.0, 118.1, 
114.2, 114.1, 102.6, 93.6, 77.6, 77.3, 77.0, 76.7, 72.3, 71.8, 71.5, 69.8, 69.2, 55.5, 51.6, 




methyl-5-oxopent-3-en-2-yl)dihydro-2H-pyran-4(3H)-ylidene)acetate (1.98):  To a 
stirring solution of PMB ether 1.97 (79 mg, 0.118 mmol, 1 equiv) in CH2Cl2 (3.0 mL) 
and water (30 μL) in a 10 mL rb flask, at rt, was added DDQ (40.0 mg, 0.177 mmol, 1.5 
equiv) in a single portion.  The reaction solution was stirred at rt for 30 min, then 
pippeted directly onto a 1.5 × 10.0 silica gel column eluting with 25% EtOAc/hexanes, 
and collecting 10 × 74 mm test tube fractions.  The product containing fractions (19-45) 
were combined and concentrated under reduced pressure to provide the crude alcohol (61 
mg, 94% yield) as a yellow oil, which was used immediately in the next step. 




(82.0 L, 0.708 mmol, 6 equiv) was added followed by TBSOTf (68.0 L, 0.295 mmol, 
2.5 equiv).  After 30 min the reaction mixture was quenched first with MeOH (200 L), 
and then with a saturated aqueous NaHCO3 solution (1 mL).  The layers were separated 
and the aqueous layer was extracted with CH2Cl2 (3 × 5 mL). The combined organic 
layers were dried over Na2SO4, concentrated, and purified by flash column 
chromatography using a 1.5 × 7.5 cm silica gel column, eluting with 15% 
EtOAc/hexanes, collecting 10 × 75 mm test tube fractions.  The product containing 
fractions (4-11) were combined and concentrated under reduced pressure to provide 1.98 
(70.5 mg, 96% yield or 90% yield over 2 steps) as a clear oil: Rf = 0.60 (40% 
EtOAc/hexanes); +2.0 (c =2.0, CHCl3); 500 MHz 
1H NMR (CDCl3)  9.50 (d, J 
= 7.6 Hz, 1H), 7.33-7.30 (m, 4H), 7.28-7.24 (m, 2H), 5.92 (dd, J = 15.8, 7.6 Hz, 1H), 
5.89 (s, 1H), 5.48 (s, 1H), 4.78 (Aβq, J = 6.9 Hz,  = 7.0 Hz, 2H), 4.61 (s, 2H), 4.12-
4.06 (m, 2H), 3.85 (dt, J = 10.7, 6.3 Hz, 2H), 3.67 (s, 3H), 3.53 (ddd, J = 16.0, 2.8, 0.8 
Hz, 1H), 3.38 (s, 3H), 2.35 (ddd, J = 15.6, 11.6, 1.8 Hz, 1H), 2.03 (ddd, J = 14.2, 8.7, 2.5 
Hz, 1H), 1.91 (s, 3H), 1.16 (d, J = 6.4 Hz, 3H), 1.15 (s, 3H), 1,13 (s, 3H), 0.86 (s, 9H), 
0.07 (s, 3H), 0.05 (s, 3H); 125 MHz 13C NMR (CDCl3)  194.8, 169.1, 167.1, 166.5, 
151.6, 138.0, 128.7, 128.7, 128.1, 128., 127.3, 118.2, 102.6, 93.4, 75.3, 71.2, 70.5, 69.6, 
69.3, 52.1, 51.5, 47.6, 38.8, 33.1, 26.1, 26.0, 23.9, 22.0, 21.5, 18.4, 13.9, -2.7, -3.7, -4.4; 
125 MHz DEPT (CDCl3) CH3 δ 52.1, 51.5, 26.1, 26.0, 23.9, 22.0, 21.5, 13.9, -2.7, -3.7, -
4.4; CH2 δ 93.4, 69.6, 38.8, 33.1; CH δ 194.8, 167.1, 128.7, 128.0, 127.3, 118.2, 75.3, 
71.2, 70.5, 69.3; C δ 169.1, 166.5, 151.6, 138.0, 102.6, 47.6, 18.4; IR (neat) 2953, 2933, 
2890, 2858, 2721, 1751, 1721, 1689, 1465, 1436 cm-1; HRMS (ESI/ APCI) calcd for 










(1.99): To a stirring solution of aldehyde 1.98 (49.0 mg, 0.074 mmol, 1 equiv) and silane 
1.56 (57.0 mg, 0.080 mmol, 1.1 equiv) in E2O (1.85 mL) in a 10 mL rb flask, at -78 C, 
was added a 1.0 M TMSOTf solution (96 L, 0.096mmol, 1.3 equiv) in THF dropwise by 
syringe.  After 4 h the reaction mixture was quenched first with i-Pr2NEt (0.2 mL), stirred 
for 10 min, and then quenched with a saturated aqueous NaHCO3 solution (1 mL).  The 
mixture was warmed to rt, the phases were separated, and the aqueous layer was 
extracted with Et2O (3 x 10 mL).  The combined organic layers were dried over Na2SO4, 
concentrated, and purified by flash column chromatography using a 1.5 × 9.0 cm silica 
gel column, eluting with 5% EtOAc/hexanes, collecting 10 × 75 mm test tube fractions.  
The product containing fractions (6-19) were concentrated to give bis-pyran 1.99 (67.0 
mg, 70%) as a clear oil. Rf = 0.59 (30% EtOAc/hexanes); +5.0 (c =1.0, CHCl3); 
500 MHz 1H NMR (CDCl3)  7.72-7.66 (m, 4H), 7.47-7.33 (m, 10H), 7.32-7.28 (m, 1H), 
7.19 (d, J = 8.3 Hz, 2H), 6.86 (d, J = 8.3 Hz, 2H), 5.97 (d, J = 16.1 Hz, 2H), 5.91 (s, 1H), 





(s, 2H), 4.64 (s, 1H), 4.56 (s, 1H), 4.42 (Aβq, J = 10.8 Hz,  = 8.2 Hz, 2H), 4.14-4.05 
(m, 2H), 3.96-3.90 (m, 1H), 3.89-3.68 (m, 5H), 3.80 (s, 3H), 3.69 (s, 3H), 3.61-3.43 (m, 
4H), 3.32 (s, 3H), 2.55-2.34 (m, 1H), 2.33-2.13 (m, 4H), 2.08 (s, 3H), 2.06-1.87 (m, 6H), 
1.85-1.74 (m, 2H), 1.72-1.56 (m, 3H), 1.18 (d, J = 6.8 Hz, 3H), 1.11 (d, J = 3.7 Hz, 6H), 
1.07 (s, 9H), 0.89 (s, 9H), 0.10 (s, 3H), 0.08 (s, 3H); 125 MHz 13C NMR (CDCl3)  
169.5, 166.7, 159.3, 153.0, 145.0, 144.4, 138.3, 138.1, 135.9, 134.1, 134.1, 131.2, 129.8, 
129.6, 128.6, 128.0, 127.9, 127.0, 117.1, 114.0, 109.1, 108.7, 102.7, 93.3, 79.1, 77.6, 
77.3, 77.0, 75.1, 75.1, 74.9, 72.9, 72.2, 71.7, 70.3, 69.6, 68.5, 60.6, 55.5, 51.7, 51.4, 46.2, 
43.1, 42.6, 41.5, 41.2, 41.0, 40.5, 38.8, 38.0, 33.6, 27.2, 26.2, 24.3, 24.0, 21.5, 20.9, 19.4, 
18.4, 14.1, -3.8, -4.4; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 51.7, 51.4, 27.2, 26.2, 24.3, 
24.0, 20.9, 14.0, -3.8, -4.4, CH2 δ 109.1, 108.7, 93.3, 72.2, 69.6, 60.6, 43.1, 42.6, 41.5, 
41.2, 41.0, 40.5, 38.8, 38.0, 33.6; CH δ 138.3, 138.1, 135.9, 129.8, 129.6, 128.6, 128.0, 
127.9, 127.0, 117.0, 114.0, 79.1, 75.1, 75.0, 74.9, 72.9, 71.7, 70.3, 68.5; C δ 169.5, 166.7, 
159.3, 153.0, 145.0, 144.4, 138.1, 134.1, 134.1, 131.2, 102.7, 77.6, 77.3, 77.0, 46.2, 21.5, 
19.4, 18.4; IR (neat) 2937, 2890, 2858, 1748, 1721, 1653, 1513, 1465; cm-1; HRMS (ESI/ 









yl)-2-methoxydihydro-2H-pyran-4(3H)-ylidene)acetate (1.100): To a stirring solution 
of TBDPS ether 1.99 (44.0 mg, 0.034 mmol, 1 equiv) in DMF (683 L) in a 4 mL 
reaction vial, at rt, was added a premixed solution of 1 M TBAF in THF (34 L, 0.034 
mmol, 1 equiv) and 1 M AcOH in DMF (34 L, 0.034 mmol, 1 equiv).  The transfer was 
made complete by washing with DMF (2 × 50 L), and the reaction mixture was stirred 
for 20 h before being diluted with 40% EtOAc/hexanes (1 mL), and quenched with water 
(1 mL).  The aqueous layer was extracted with 40% EtOAc/hexanes (3 x 3 mL).  The 
combined organic layers were dried over Na2SO4, concentrated, and purified by flash 
column chromatography using a 1.5 × 6.0 cm silica gel column, eluting with 25% 
EtOAc/hexanes, collecting 10 × 75 mm test tube fractions.  The product containing 
fractions (4-9) were concentrated to give alcohol 1.100 (28 mg, 78%) as a clear oil. Rf = 
0.27 (30% EtOAc/hexanes); +9.0 (c =1.00, CHCl3); 500 MHz 
1H NMR (CDCl3) 
 7.37-7.32 (m, 4H), 7.32-7.28 (m, 1H), 7.26 (d, J = 9.4 Hz, 2H), 6.88 (d, J = 9.4 Hz, 
2H), 5.98 (d, J = 16.0 Hz, 1H), 5.90 (s, 1H), 5.55 (s, 1H), 5.41 (dd, J = 16.0, 5.8 Hz, 1H), 
4.80 (s, 2H), 4.73 (s, 2H), 4.66 (s, 1H), 4.64 (s, 2H), 4.59 (s, 1H), 4.48 (Aβq, J = 10.9 Hz, 
 = 16.5 Hz, 2H), 4.13-4.04 (m, 2H), 3.93-3.82 (m, 2H), 3.80 (s, 3H), 3.76-3.69 (m, 
2H), 3.69 (s, 3H), 3.56-3.40 (m, 4H), 3.32 (s, 3H), 2.37 (ddd, J = 15.8, 11.7, 1.5 Hz, 1H), 
2.28-2.15 (m, 4H), 2.08 (s, 3H), 2.06-1.87 (m, 8H), 1.82-1.55 (m, 6H), 1.17 (d, J = 6.8 
Hz, 3H), 1.10 (d, J = 5.1 Hz, 6H), 0.08 (s, 9H), 0.84 (s, 3H), 0.07 (s, 3H); 125 MHz 13C 
NMR (CDCl3)  169.6, 166.7, 159.6, 153.0, 144.7, 144.5, 138.6, 138.2, 130.7, 129.8, 
128.7, 128.1, 127.9, 127.0, 117.1, 114.2, 109.1, 109.0, 102.7, 93.3, 79.4, 75.5, 75.5, 75.2, 





41.0, 40.6, 38.8, 37.0, 33.6, 26.2, 24.3, 24.0, 21.6, 18.4, 14.0, -3.8, -4.4; 125 MHz DEPT 
(CDCl3) CH3 δ 55.6, 51.7, 51.4, 26.2, 24.3, 24.0, 21.6, 14.0, -3.8, -4.4; CH2 δ 109.1, 
109.0, 93.3, 72.1, 69.6, 60.5, 43.0, 41.9, 41.5, 41.1, 41.0, 40.6, 38.8, 37.0, 33.6; CH δ 
138.6, 129.8, 128.7, 128.1, 127.9, 127.0, 117.1, 114.2, 79.4, 75.5, 75.5, 75.2, 75.1, 75.0, 
71.8, 70.4, 68.8; C δ 169.6, 166.7, 159.6, 153.0, 144.7, 144.5, 138.2, 130.7, 102.7, 46.2, 
18.4; IR (neat) 3482, 3070, 2938, 2858, 1748, 1721, 1654, 1613, 1514, 1463 cm-1; HRMS 






pyran-2-yl)-3-((4-methoxybenzyl)oxy)butanoic acid (1.101):  To a stirring of alcohol 
1.100 (32.4 mg, 0.031 mmol, 1 equiv) in CH2Cl2 (300 L) in a 1 mL reaction vial, at 0 
C, was added i-Pr2NEt (38 L, 0.21 mmol, 7 equiv), DMSO (22 L, 0.31 mmol, 10 
equiv), and SO3Pyr (20 mg, 0.12 mmol, 4 equiv) in a single portion.  After 75 min the 
mixture was quenched with saturated aqueous NaHCO3 solution (1 mL). The phases were 
separated, and the aqueous layer was extracted with 40% EtOAc/hexanes (3 × 3 mL).  




pressure.  The resulting clear oil was run through a 1.5 × 4.5 cm plug of silica eluting 
with 20% EtOAc/hexanes, and concentrated to give the crude aldehyde (24.5 mg), which 
was carried on immediately without characterization.  
To a stirring solution of the aforementioned aldehyde in 2-methyl-2-butene (400 L) 
and t-BuOH (400 L) in a 5 mL rb flask, at rt, was added a 1.25 M aqueous KH2PO4 
solution (140 L).  This solution was cooled to -10 C in an ethylene glycol/ CO2 bath, 
and NaClO2 (15 mg, 0.14 mmol, 5 equiv) was added in a single portion.  The reaction 
mixture was stirred vigorously for 1.5 h then quenched with a 0.05 M aqueous pH 4 
buffer solution (1 mL).  The phases were separated, and aqueous layer was extracted with 
Et2O (3 × 3 mL).  The combined organic layers were dried over Na2SO4, concentrated, 
and purified by flash column chromatography using a 1.5 × 10.0 cm silica gel column, 
eluting with 3% MeOH/CH2Cl2, collecting 10 × 75 mm test tube fractions.  The product 
containing fractions (5-11) were concentrated to give acid 1.101 (31.0 mg, 75%, 2 steps) 
as a clear oil. Rf = 0.48 (10% MeOH/ 40% EtOAc/ 50% hexanes).  Decomposition of this 
acid could be observed within a few hours so it was used immediately in the next reaction 








tetraoxatetracyclo[21.3.1.13,7.111,15]nonacos-8-en-13-ylidene)acetate (1.102):  To a 
stirring solution of TBS ether 1.101 (31.0 mg, 0.029 mmol, 1 equiv) in a solution of 9:1 
THF/Pyr in a 2 mL plastic vial, at rt, was added 20% HFPyr (729 L, 25 mL/mmol of 
silyl ether) using a needleless plastic syringe.  This solution was stirred for 2 days then 
quenched by pipetting into a stirring solution of EtOAc (20 mL) and brine (20 mL).  The 
phases were separated and organic layer was washed with a brine (2 × 10 mL), dried over 
Na2SO4, and concentrated to give the seco-acid as a yellow oil that was used without 
further purification. 
To a stirring solution of the aforementioned seco-acid in THF (1.0 L) in 2 mL vial, 
at 0 C, was added Et3N (24 L, 0.174 mmol, 6 equiv) and a 1 M solution of 
trichlorobenzoyl chloride (87 L, 0.030 mmol, 3 equiv) in THF. After 5 min, the solution 
was warmed to rt and stirring was continued for an additional 3 h.  The reaction mixture 
was diluted with toluene (9 mL) and taken up into a 10 mL gas-tight syringe.  This 
solution was added by syringe pump to a stirring solution of DMAP (71 mg, 0.58 mmol, 
20.0 equiv) in toluene (19 mL) in a 100 mL rb flask, at 40 °C, over a 12 h period. The 
residual contents of the syringe were rinsed into the flask with toluene (1 mL) and stirring 
was continued for an additional 2 h. The reaction mixture was cooled to rt, diluted with 
30% EtOAc/hexanes (50 mL) and washed with water (3 × 20 mL) and brine (20 mL).  
The organic phase was dried over Na2SO4, concentrated under reduced pressure, and 
purified by flash column chromatography using a 1.5 × 5.5 cm silica gel column, eluting 
with 10% EtOAc/hexanes, collecting 10 × 75 mm test tube fractions.  The product 




provide macrolactone 1.102 as a clear oil (15.6 mg, 58% over 2 steps): Rf = 0.40 (30% 
EtOAc/hexanes); +32 (c = 0.2, CHCl3); 500 MHz 
1H NMR (CDCl3)  7.40-7.32 
(m, 5H), 7.21 (d, J = 8.3 Hz, 2H), 6.82 (d, J = 8.3 Hz, 2H), 6.23 (d, J = 16.3 Hz, 1H), 
5.95 (s, 1H), 5.60-5.54 (m, 1H), 5.34 (dd, J = 15.6, 8.5 Hz, 1H), 5.16 (s, 1H), 4.82 (Aβq, 
J = 7.7 Hz,  = 10.8 Hz, 2H), 4.76 (s, 2H), 4.71 (s, 2H), 4.64 (Aβq, J = 11.8 Hz,  = 
17.0 Hz, 2H), 4.48 (s, 2H), 4.22-4.14 (m, 1H), 4.00-3.91 (m, 2H), 3.75 (s, 3H), 3.70 (s, 
3H), 3.73-3.65 (m, 2H), 3.54-3.47 (m, 2H), 3.40-3.32 (m, 2H), 3.09 (s, 3H), 2.58 (dd, J = 
15.0, 1.8 Hz, 1H), 2.47 (dd, J = 15.4, 9.8 Hz, 2H), 2.31 (d, J = 13.2 Hz, 1H), 2.22-1.82 
(m, 11H), 2.06 (s, 3H), 1.78-1.71 (m, 2H), 1.09 (d, J = 5.1 Hz, 6H), 1.06 (d, J = 6.2 Hz, 
3H); 125 MHz 13C NMR (CDCl3)  172.3, 169.4, 167.0, 159.4, 155.4, 144.6, 141.9, 
138.2, 131.0, 129.7, 128.7, 127.1, 127.9, 125.8, 119.6, 114.0, 109.2, 109.1, 103.4, 93.8, 
81.6, 76.6, 76.5, 76.4, 75.4, 74.0, 73.2, 72.2, 70.8, 69.9, 67.4, 55.5, 53.7, 52.9, 51.5, 45.3, 
44.3, 43.2, 42.0, 41.6, 41.2, 41.1, 34.8, 31.1, 26.4, 21.8, 20.3, 15.3; 125 MHz DEPT 
(CDCl3) CH3 δ 55.5, 52.9, 51.5, 26.4, 21.8, 20.3, 15.3; CH2 δ 109.2, 109.1, 93.8, 72.2, 
69.9, 44.3, 43.2, 42.0, 41.6, 41.2, 41.1, 34.8, 31.1; CH δ 141.9, 129.7, 128.7, 128.1, 
127.9, 125.8, 119.6, 114.0, 81.6, 76.6, 76.5, 76.4, 75.4, 74.0, 73.2, 70.8, 67.4; C δ 172.3, 
169.4, 167.0, 159.4, 155.4, 144.6, 138.2, 131.0, 103.4, 53.7, 45.3; IR (neat) 3070, 3027, 
1722, 1652, 1514, 1435, 1370, 1300, 1234, 1156, 1089, 1042 cm-1; HRMS (ESI/ APCI) 






 Preparation of Merle 35:  To a stirring solution of protected 
Merle 35 (1.5 mg, 0.0017 mmol, 1 equiv) in CH2Cl2 (340 µL) in a 2 mL vial, at 0 C, was 
added 1 M aqueous pH 7 buffer solution (190 µL), and DDQ (4.0 mg, 0.020 mmol, 10 
equiv).  After 2 h the reaction mixture was quenched with saturated aqueous NaHCO3 
solution (1 mL).  The phases were separated, and the aqueous layer was extracted with 
CH2Cl2 (3 × 3 mL).  The organic layers were combined, washed with brine (2 × 1 mL), 
dried over Na2SO4, concentrated, and used without further purification. 
To the aforementioned analogue in a 4 mL reaction vial was added a 0.25 M solution 
of LiBF4 (306 µL, 0.077 mmol, 45.0 equiv) in 25:1 CH3CN/H2O.  The reaction vial was 
sealed and the mixture was allowed to stir at 80 ºC for 10 h.  After cooling to rt the 
reaction mixture was poured into a stirring solution of EtOAc (5 mL), and quenched with 
saturated aqueous NaHCO3 solution (5 mL).  The phases were separated and the aqueous 
phase was extracted with EtOAc (3 × 5 mL).  The combined organic phases were dried 
over Na2SO4, concentrated, and purified by flash column chromatography using a 0.5 × 6 
cm silica gel column, eluting with 20% EtOAc/hexanes, collecting 6 × 50 mm test tube 
fractions. The product containing fractions (14-19) were combined and concentrated 
under reduced pressure to provide Merle 35 (1.0 mg, 82%, 2 steps) as white foam: Rf = 
0.33 (50% EtOAc/hexanes); -7.0 (c =0.13, CHCl3); 500 MHz 
1H NMR (CDCl3)  





(s, 1H), 5.22 (ddd, J = 12.1, 5.7, 3.0, 1H), 5.14 (s, 1H), 4.78-4.69 (m, 4H), 4.47 (d, J = 
12.0 Hz, 1H), 4.22 (ddd, J = 13.5, 11.4, 2.6 Hz, 1H), 4.10-3.99 (m, 2H), 3.82 (ddd, J = 
12.5, 12.5, 5.2 Hz, 1H), 3.71 (d, J = 1.9 Hz, 1H), 3.69 (s, 3H), 3.56 (ddd, J = 11.1, 7.5, 
2.1 Hz, 1H), 3.53-3.46 (m, 1H), 3.44-3.37 (m, 1H), 2.52-2.41 (m, 2H), 2.19-1.80 (m, 8H), 
1.68-1.40 (m, 8H), 1.27 (s, 3H), 1.24 (d, J = 6.4 Hz, 3H), 1.15 (s, 3H), 1.02 (s, 3H); 125 
MHz 13C NMR (CDCl3)  175.5, 169.6, 167.3, 152.1, 144.1, 143.6, 138.9, 130.2, 120.0, 
109.3, 108.8, 99.2, 80.2, 79.8, 77.9, 76.6, 74.7, 74.0, 70.6, 68.9, 64.8, 51.3, 45.1, 43.5, 
42.9, 42.5, 41.7, 41.1, 41.0, 40.4, 36.2, 31.6, 25.1, 21.8, 20.1; 125 MHz DEPT (CDCl3) 
CH3 δ 51.3, 25.1, 21.8, 20.1; CH2 δ 109.3, 108.8, 43.5, 42.9, 42.5, 41.7, 41.1, 41.0, 40.4, 
36.2, 31.6; CH δ 138.9, 130.2, 120.0, 80.2, 79.8, 77.9, 76.6, 74.7, 74.0, 70.6, 68.9, 64.8; 
C δ 172.5, 169.6, 167.3, 152.1, 144.1, 143.6, 99.2; HRMS (ESI/ APCI) calcd 699.3356 
for C36H52O12Na (M+Na), found 699.3365. 
 









MeOH (0.9 mL) in a 4 mL vial, at rt, was added K2CO3 (6 mg, 0.045 mmol, 10 equiv).  
The reaction mixture was stirred at rt for 45 min, and then quenched by pipetting into a 
mixture of CH2Cl2 (5 mL) and saturated aqueous NH4Cl solution (5 mL).  The phases 
were separated, and the aqueous layer was extracted with CH2Cl2 (3 × 5 mL).  The 
organic layers were combined, washed with brine (2 × 3 mL), dried over Na2SO4, and 
concentrated.  The crude alcohol was used without further purification. 
To a stirring solution of the aforementioned alcohol in a 1 mL conical vial, at rt, was 
added CH2Cl2 (45 μL), followed by succinic anhydride (5 mg, 0.045 mmol, 10 equiv) and 
DMAP (7 mg, 0.54 mmol, 12 equiv).  The reaction mixture was stirred at rt for 20 h, and 
then quenched by pipetting into a mixture of EtOAc (5 mL) and a 0.5 M aqueous pH 4 
acetate buffer solution (5 mL).  The phases were separated and the aqueous phase was 
extracted with EtOAc (3 × 5 mL).  The combined organic phases were dried over 
Na2SO4, concentrated, and purified by flash column chromatography using a 0.5 × 6 cm 
silica gel column, eluting with 3% MeOH/CH2Cl2, collecting 6 × 50 mm test tube 
fractions. The product containing fractions (4-5) were combined and concentrated under 
reduced pressure to provide acid 1.103 (4.0 mg, 90%, 2 steps) as a clear oil: Rf = 0.53 
(2:1 toluene/dioxane and 3% AcOH); +3.2 (c =0.2, CHCl3); 500 MHz 
1H NMR 
(CDCl3)  7.41-7.32 (m, 4H), 7.32-7.26 (m, 1H), 7.20 (d, J = 8.7 Hz, 2H), 6.82 (d, J = 8.7 
Hz, 2H), 6.25 (d, J = 15.9 Hz, 1H), 5.93 (d, J = 2.0 Hz, 1H), 5.58 (ddd, J = 12.2, 4.6, 2.6 
Hz, 1H), 5.35 (dd, J = 16.1, 9.2 Hz, 1H), 5.18 (s, 1H), 4.82 (Aβq, J = 13.6 Hz,  = 12.0 
Hz, 2H), 4.78-4.74 (m, 2H), 4.71 (s, 2H), 4.65 (Aβq, J = 14.3 Hz,  = 21.3 Hz, 2H), 
4.47 (s, 2H), 4.21-4.15 (m, 2H), 4.00-3.93 (m, 2H), 3.75 (s, 3H), 3.73-7.67 (m, 2H), 3.69 





(m, 1H), 2.38-2.29 (m, 1H), 2.23-1.83 (m, 9H), 1.79-1.70 (m, 1H), 1.67-1.60 (m 1H), 
1.56 (ddd, J = 14.4, 7.7, 1.3 Hz, 1H), 15.0-1.40 (m, 1H), 1.10 (s, 3H), 1.09 (s, 3H), 1.06 
(d, J = 6.6 Hz, 3H); 125 MHz 13C NMR (CDCl3)  172.3, 170.7, 167.0, 159.4, 151.2, 
144.6, 144.6, 141.9, 138.2, 131.1, 129.7, 128.7, 128.2, 127.9, 125.8, 119.7, 114.0, 109.2, 
109.1, 103.4, 93.8, 81.6, 76.6, 76.5, 76.5, 75.5, 74.5, 73.3, 72.2, 70.8, 69.9, 67.4, 55.5, 
52.9, 51.4, 45.3, 44.3, 43.2, 42.0, 41.6, 41.2, 41.2, 41.1, 34.7, 31.0, 30.0, 29.7, 26.5, 23.0, 
20.4, 15.2, 14.4, 1.3; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 52.9, 51.4, 26.5, 15.2, 1.3; 
CH2 δ 109.2, 109.1, 93.8, 72.2, 69.9, 44.3, 43.2, 42.0, 41.6, 41.2, 41.2, 41.1, 34.7, 31.0, 
31.0, 29.7; CH δ 141.9, 129.7, 128.7, 128.2, 127.9, 125.8, 119.7, 114.0, 81.6, 77.5, 76.6, 
76.5, 75.5, 74.5, 73.3, 70.8, 67.4; C δ 172.3, 170.7, 167.0, 159.4, 151.2, 144.6, 144.6, 
138.2, 131.1, 23.0, 20.4, 14.4; IR (neat) 2934, 1726, 1608, 1382, 1247, 1152, 1041 cm-1; 
HRMS (ESI/ APCI) calcd 1011.4717 for C55H72O16Na (M+Na), found 1011.4731. 
 
 Preparation of Merle 36: To a stirring solution of 
carboxylate 1.103 (3.5 mg, 0.0035 mmol, 1 equiv) in CH3CN (350 μL) in a 1 ml vial, at 0 
ºC, was added a 1 M solution of i-Pr2NEt (7.1 μL, 0.0071 mmol, 2 equiv) in CH3CN, and 
a 1 M solution of BOMCl (5 μL, 0.005 mmol, 1.3 equiv) in CH3CN.  After 30 min the 
reaction mixture was quenched by the addition of saturated aqueous NaHCO3 solution (5 




mL).  The organic layers were combined, dried over Na2SO4, filtered, and concentrated.  
The crude product was taken on without purification. 
To a stirring solution of the aforementioned product in CH2Cl2 (500 μL) in a 4 mL 
reaction vial, at 0 ºC, was added 1 M aqueous pH 7 buffer solution (278 μl), and DDQ 
(6.0 mg, 0.026 mmol, 10 equiv).  After 2 h the reaction was quenched with a saturated 
aqueous NaHCO3 solution (1 mL).  The phases were separated, and the aqueous layer 
was extracted with CH2Cl2 (3 × 5 mL).  The organic layers were combined, washed with 
brine (2 × 1 mL), dried over Na2SO4, filtered, and concentrated.  The crude product was 
used without further purification. 
To the aforementioned protected analog in a 4 mL reaction vial was added a 0.25 M 
solution of LiBF4 (450 µL, 0.113 mmol, 45.0 equiv) in 25:1 CH3CN/H2O.  The reaction 
vial was sealed and the mixture was allowed to stir at 80 ºC for 12 h.  After cooling to rt 
the reaction mixture was poured into a stirring solution of EtOAc (5 mL), and quenched 
with saturated aqueous NaHCO3 solution (5 mL).  The phases were separated and the 
aqueous phase was extracted with EtOAc (3 × 5 mL).  The combined organic phases 
were dried over Na2SO4, filtered, and concentrated. Purification was accomplished using 
a 10 × 20 cm preparatory chromatography plate eluting with 5% EtOAc/hexanes. The 
dominant band was cut out, stirred with EtOAc for 20 min, filtered, and concentrated 
under reduced pressure to provide Merle 36 (1.0 mg, 39%, 3 steps) as a clear oil: Rf = 
0.25 (10% MeOH/ 40% EtOAc/ 50% hexanes); -15.0 (c = 0.07, CHCl3); 500 
MHz 1H NMR (CDCl3)  5.98 (d, J = 1.9 Hz, 1H), 5.79 (d, J = 15.9 Hz, 1H), 5.33 (dd, J 
= 15.9, 8. Hz, 1H), 5.29 (s, 1H), 5.22 (ddd, J = 12.1, 5.7, 2.9 Hz, 1H), 5.16 (s, 1H), 4.78-





(m, 2H), 3.82 (t, J = 6.5 Hz, 1H), 3.73-3.67 (m, 1H), 3.69 (s, 3H), 3.56 (ddd, J = 10.5, 
7.3, 2.2 Hz, 1H), 3.53-3.46 (m, 1H), 3.44-3.37 (m, 1H), 2.80-2.57 (m, 4H), 2.53-2.40 (m, 
2H), 2.19-1.79 (m, 14H), 1.67-1.58 (m, 2H), 1.52 (d, J = 14.9 Hz, 1H), 1.26 (s, 3H), 1.24 
(d, J = 6.2 Hz, 3H), 1.16 (s, 3H); 125MHz 13C NMR (CDCl3)  174.7, 172.5, 170.9, 
167.3, 151.8, 144.1, 143.6, 138.9, 130.1, 120.2, 109.4, 108.8, 99.2, 80.2, 79.8, 77.9, 76.6, 
75.1, 74.0, 70.6, 69.0, 64.8, 51.4, 45.1, 43.4, 42.9 42.5, 41.6, 41.1, 41.0, 40.4, 36.1, 31.5, 
30.0, 28.5, 25.0, 20.1, 14.4, 1.3; 125 MHz DEPT (CDCl3) CH3 δ 51.4, 25.0, 20.1, 1.3; 
CH2 δ 109.4, 108.8, 43.4, 42.9, 42.5, 41.6, 41.1, 41.0, 40.4, 36.1, 31.5, 30.0, 28.5; CH δ 
138.9, 130.1, 120.2, 80.2, 79.8, 77.9, 76.6, 75.1, 74.0, 70.6, 69.0, 64.8; C δ 174.7, 172.5, 
170.9, 167.3, 151.8, 144.1, 143.6, 99.6, 45.1, 14.4; IR (neat) 3254, 2923, 1735, 1718, 
1231 cm-1; HRMS (ESI/ APCI) calcd 757.3411 for C38H54O14Na (M+Na), found 
757.3420. 
 
  Preparation of 6-(dimethylamino)hexanoic acid:  To a stirring solution 
of 6-aminohexanoic acid (1.49 g, 11.4 mmol, 1 equiv) in a 37% aqueous formaldehyde 
solution (2.10 mL, 28.4 mmol, 2.5 equiv) in a 25 mL 2 neck rb flask equipped with a 
reflux condenser, at rt, was added 90% aqueous formic acid (2.30 mL, 56.8 mmol, 5 
equiv).  The reaction mixture was heated at reflux for 16 h, cooled to rt, transferred to a 
100 mL rb flask, and diluted with water (5 mL).  This aqueous solution was shell frozen 
then lyophilized to give a thick orange sludge that was taken up in acetone (10 mL), 
acidified with 1 M HCl (2 mL), and left in a -20 ºC freezer overnight.  The precipitate 




hydrochloride salt (1.61 g, 8.27 mmol, 73%) and as an off white solid: Mp = 104 ºC (108 
ºC lit);  500 MHz 1H NMR (D2O)  3.12 (dd, J = 8.6, 8.4 Hz, 2H), 2.86 (s, 6H), 2.36 (t, J 
= 7.6 Hz, 2H), 1.73 (ddt, J = 15.3, 9.7, 5.8 Hz, 2H), 1.63 (quintet, J = 7.3 Hz, 2H), 1.38 
(d, J = 7.3 Hz, 2H); 125MHz 13C NMR (D2O)  57.8, 42.7, 34.3, 25.2, 24.1, 23.8. 
 





(1.104):  To a stirring solution of macrolactone 1.102 (8.0 mg, 0.0079 mmol, 1 equiv) in 
MeOH (1.58 mL) in a 4 mL vial, at rt, was added K2CO3 (11 mg, 0.079 mmol, 10 equiv).  
After 45 min the reaction mixture was quenched by pipetting into a mixture of CH2Cl2 
(10 mL) and saturated aqueous NH4Cl solution (10 mL).  The phases were separated, and 
the aqueous layer was extracted with CH2Cl2 (3 × 10 mL).  The organic layers were 
combined, washed with brine (2 × 10 mL), dried over Na2SO4, and concentrated.  The 
crude alcohol was used without further purification. 
The aforementioned alcohol was transferred to a 0.5 mL conical vial and dried under 
vacuum.  Meanwhile, to a stirring solution of 6-(dimethylamino)hexanoic acid (3.1 mg, 




nitrobenzoic anhydride (6.00 mg, 0.017 mmol, 2.2 equiv), and DMAP (0.20 mg, 0.0016 
mmol, 0.2 equiv).  This solution was stirred for 30 min at rt then added to the conical vial 
containing the alcohol washing with an additional 50 µL of CH2Cl2.  After 4 h, the 
reaction mixture was quenched by pipetting into a mixture of EtOAc (5 mL) and a 0.5 M 
aqueous pH 10 carbonate buffer solution (5 mL).  The phases were separated, and the 
aqueous layer was extracted with EtOAc (3 × 5 mL).  The combined organic layers were 
dried over Na2SO4, concentrated, and purified by flash column chromatography using a 
0.5 × 6 cm silica gel column, eluting with 5% MeOH/CH2Cl2, collecting 6 × 50 mm test 
tube fractions. The product containing fractions (4-16) were combined and concentrated 
under reduced pressure to provide amine 1.104 (5.2 mg, 63%, 2 steps) as clear oil: Rf = 
0.22 (10% MeOH/CHCl3); +29.5 (c =0.5, CHCl3); 500 MHz 
1H NMR (CDCl3)  
7.41-7.32 (m, 4H), 7.31-7.28 (m, 1H), 7.21 (d, J = 9.3 Hz, 2H), 6.82 (d, J = 9.3 Hz, 2H), 
6.22 (d, J = 15.5 Hz, 1H), 5.95 (s, 1H), 5.57 (ddd, J = 12.1, 4.7, 2.9 Hz, 1H), 5.34 (dd, J = 
15.8, 8.4 Hz, 1H), 5.17 (s, 1H), 4.82  (Aβq, J = 13.1 Hz,  = 11.0 Hz, 2H), 4.77-4.74 
(m, 2H), 4.71 (s, 2H), 4.64 (Aβq, J = 20.1 Hz,  = 16.3 Hz, 2H), 4.48 (s, 2H), 4.21-4.14 
(m, 1H), 3.99-3.92 (m, 2H), 3.81-3.65 (m, 3H), 3.74 (s, 3H), 3.69 (s, 3H), 3.53-3.47 (m, 
1H), 3.36 (dddd, J = 10.8, 10.8, 2.8, 2.0 Hz, 1H), 3.09 (s, 3H), 2.57 (dd, J = 15.8, 2.6 Hz, 
1H), 2.47 (dd, J = 15.8, 9.9 Hz, 1H), 2.34-2.27 (m, 2H), 2.22 (s, 6H), 2.21-2.05 (m, 4H), 
2.01-1.91 (m, 3H), 1.91-1.82 (m, 3H), 1.78-1.71 (m, 1H), 1.68-1.59 (m, 3H), 1.56 (dd, J 
= 13.5, 7.0 Hz, 1H), 1.52-1.41 (m, 3H), 1.36-1.28 (m, 3H), 1.26 (s, 2H), 1.09 (s, 3H), 
1.07 (s, 3H), 1.06 (d, J = 7.0 Hz, 3H); 125 MHz 13C NMR (CDCl3)  172.3, 172.1, 167.1, 
159.4, 151.5, 144.6, 144.6, 141.9, 138.2, 131.1, 129.7, 128.7, 128.2, 127.9, 125.8, 119.6, 





67.3, 59.8, 55.5, 52.9, 51.4, 45.7, 45.3, 44.3, 43.1, 42.0, 41.6, 41.2, 41.2, 41.0, 34.8, 31.1, 
30.0, 27.5, 27.2, 26.5, 24.8, 20.3, 15.3; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 52.9, 51.4, 
45.7, 26.5, 20.3, 15.3; CH2 δ 109.2, 109.1, 93.8, 72.2, 69.9, 59.8, 44.3, 43.1, 42.0, 41.6, 
41.2, 41.2, 41.0, 34.8, 31.1, 30.0, 27.5, 27.2, 24.8; CH δ 414.9, 129.7, 128.7, 128.2, 
127.9, 125.8, 119.6, 114.0, 81.6, 76.6, 76.5, 76.4, 75.4, 73.9, 73.3, 70.8, 67.3; C δ 172.3, 
172.1, 167.1, 159.4, 151.5, 144.6, 144.6, 138.2, 131.1, 103.4, 45.3; IR (neat) 2938, 1734, 
1653, 1514, 1456 cm-1; HRMS (ESI/ APCI) calcd 1030.5886 for C59H84NO14Na (M+Na), 
found 1030.5902. 
 
 Preparation of Merle 37:  To a stirring solution of protected 
Merle 37 (5.0 mg, 0.005 mmol, 1 equiv) in CH2Cl2 (980 µl) in a 2 mL reaction vial, at 0 
C, was water (10 µl), and DDQ (5.6 mg, 0.024 mmol, 5 equiv).  After 2 h the reaction 
mixture was quenched with a saturated aqueous NaHCO3 solution (1 mL).  The phases 
were separated, and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL).  The 
organic layers were combined, washed with brine (2 × 5 mL), dried over Na2SO4, and 
concentrated. The crude product was used without further purification. 
To the aforementioned analog in a 4 mL reaction vial was added a 0.25 M solution of 
LiBF4 (882 µL, 0.220 mmol, 45.0 equiv) in 25:1 CH3CN/H2O.  The reaction vial was 
sealed and the mixture was allowed to stir at 80 ºC for 10 h. After cooling to rt the 




10% MeOH/CHCl3. Further purification was accomplished using a 10 × 20 cm 
preparatory chromatography plate eluting with 20% MeOH/CHCl3. The dominant band 
was cut out, stirred with 20% MeOH/CHCl3 for 20 min, filtered, and concentrated under 
reduced pressure to provide Merle 37 (1.2 mg, 32%, 2 steps) as a white foam: Rf = 0.21 
(20% MeOH/CHCl3); +17.0 (c = 0.10, CHCl3); 500 MHz 
1H NMR (CDCl3)  
5.98 (s, 1H), 5.78 (d, J = 16.2 Hz, 2H), 5.33 (d, J = 16.2 Hz, 2H), 5.27 (s, 1H), 5.22 (ddd, 
J = 11.9, 5.4, 2.9 Hz, 1H), 5.14 (s, 1H), 4.75-4.69 (m, 4H), 4.47 (d, J = 12.0 Hz, 1H), 
4.25-4.17 (m, 1H), 4.08-3.99 (m, 2H), 3.82 (dd, J = 6.3, 5.7 Hz, 1H), 3.72-3.67 (m, 1H), 
3.69 (s, 3H), 3.59-3.52 (m, 1H), 3.52-3.46 (m, 1H), 3.44-.337 (m, 1H), 3.01 (d, J = 7.6 
Hz, 2H), 2.53-2.36 (m, 2H), 2.41 (s, 6H), 2.36-2.23 (m, 2H), 2.19-1.91 (m, 8H), 1.91-
1.80 (m, 2H), 1.71-1.56 (m, 4H), 1.44 (d, J = 14.3 Hz, 1H), 1.41-1.33 (m, 4H), 1.26 (s, 
3H), 1.24 (d, J = 6.5 Hz, 3H), 1.14 (s, 3H), 1.01 (s, 3H); 125 MHz 13C NMR (CDCl3)  
172.4, 172.0, 167.3, 152.1, 144.1, 143.6, 138.9, 130.2, 120.0, 109.4, 108.8, 99.2, 80.2, 
79.8, 77.9, 76.6, 74.7, 73.9, 70.4, 69.0, 64.8, 51.4, 46.1, 45.1, 43.5, 42.9, 42.5, 41.6, 41.1, 
41.1, 40.4, 36.1, 34.6, 31.7, 30.0, 26.7, 25.2, 24.5, 20.1, 20.0; 125 MHz DEPT (CDCl3) 
CH3 δ 51.4, 25.2, 20.1, 20.0; CH2 δ 109.4, 108.8, 46.1, 43.5, 42.9, 42.5, 41.6, 41.1, 41.1, 
40.4, 36.1, 34.6, 31.7, 30.0, 26.7, 24.5; CH δ 138.9, 130.2, 120.0, 80.2, 79.8, 77.9, 76.6, 
74.7, 73.9, 70.4, 69.0, 64.8; C δ 172.4, 172.0, 167.3, 152.1, 144.1, 143.6, 99.2, 45.1; IR 
(neat) 3455, 3326, 2975, 2939, 2858, 1735, 1653, 1465 cm-1; HRMS (ESI/ APCI) calcd 
776.4580 for C42H65NO12Na (M+Na), found 776.4593. 
 
HPLC Conditions:  HPLC was conducted using Rainnin Dynamax model SD-200 





refractive index detector.  10 μL aliquots of a 1-mg/mL stock sample solution in 
acetonitrile were injected, eluting with thoroughly degassed 80% acetonitrile/water at a 
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DEVELOPMENT OF AN AROMATIC A-, B-RING SYSTEM 
 
Evaluation A-, B-ring Structure Function Relationships 
To date, the combination of the Keck and Wender groups have synthesized over 100 
analogues.  The Wender group has focused primarily on determining structural features 
that contribute to high affinity binding, while the Keck group has chosen to explore the 
structural features that endow bryostatin 1 with its unique biological profile. 
Wender’s initial work identified a heteroatom triad on the C-ring that was required 
for high affinity binding.  The A- and B-rings were then hypothesized to function merely 
as a “spacer domain” that held those atoms in the correct spatial orientation.  The 
synthesis of Merle 23 by the Keck group and subsequent biological evaluation by the 
Blumberg group has demonstrated that the A- and B-rings are not merely a “spacer 
domain’ but that in fact they endow bryostatin 1 with its unique biology.  Merle 23 
differs from bryo 1 in that the C7 acetate, C8 gem dimethyl, C9 alcohol and C13 
exocyclic enoate have all been replaced by exocyclic olefins at C7 and C13 (Figure 2.1).  
These changes resulted in Merle 23 displaying a biological profile distinct from that of 





Figure 2.1. Structural comparison of Merle 23 and Bryo 1 
 
In order to better understand the role of the A-, B-ring functionality in determining a 
bryostatin like response, the Keck group undertook the task of examining each of the four 
positions by systematically reinstalling each of the four missing functional groups on 
Merle 23 or by deleting them from bryo 1.  These efforts resulted in the synthesis of 
seven new analogues that possess some combination of the natural bryostatin 
functionality (Figure 2.2).  All analogues were initially tested in the U937 proliferation 
and attachment assay, in which Merle 23 was PMA like, for either bryo 1 like or PMA 
like behavior.  Adding the C7 acetate, Merle 271, to the Merle 23 bis-pyran ring system 
failed to induce a switch to bryo 1 like behavior, but the combination of the C7 acetate 
with the C13 enoate, Merle 332, did.  Merle 283, which lacks only the B-ring enoate while 
maintaining the entire A-ring, behaved very similar to Bryo 1; however, if the B -ring is 
completely omitted (Merle 29u)4 the compound reverts to PMA like behavior.  
Furthermore, replacing the B-ring with a more flexible ester linkage resulted in an 
analogue that would spontaneously undergo ring expansion to make Merle 29d.  Merle 29 











chromatography, but during cell assays, conversion of Merle 29u to Merle 29d was 
observed in the form of decreasing biological potency.  Merle 305, which is missing the 
C9 ketal exhibited bryo 1 like activity, and Merle 326, with only the gem-dimethyl added 
back, was PMA like.  The synthesis of this set of analogues revealed that the structural 
requirements for bryo like behavior are more complex than just a single functional group 
being responsible.  However, there does exist a clear trend in that analogues containing 
two or more polar moieties tend to be bryo 1 like provided that both A- and B-rings rings 
are present. 
 
The polarity hypothesis 
Our current understanding is that bryostatins and analogues bind to PKC mainly 
though interactions with the C-ring while the A- and B-rings form a hydrophobic surface 
on the protein.  The entire assemble then undergoes translocation during which time 
interactions of the hydrophobic surface with membranes, other PKC domains, and other 
proteins are critical for determining the biological response.  By systematically removing 
functional groups from bryostatin or adding them to Merle 23, the Keck group was able 
to show that, while no single group dictated biological outcome in U937 cells, there was 
a dependence on the overall polarity of the A-, B-ring region as determined by ClogP 



























































































































































































































Transcriptional Response of A-, B-ring Analogues 
To better understand the subtle biological differences between the set of A- and B-
ring analogues, they were examined with regard to their transcriptional response in both 
U937 and LNCaP cells.7 Figure 2.4 represents the mean increase in gene induction for 
SERPINB2, TNFα, CXCL8, CCL2, TRAF1, and BIRC3 at 8 h following exposure to 
1000 nM of the indicated compounds in both cell lines. In spite of the fact that all 
analogues are bryo 1 like in the LNCaP proliferation assay, they show a range of activity 
from PMA like to almost bryo 1 like in the transcription assay.  This trend correlates well  
 
 




with the analogues ClogP value giving some validation to the polarity hypothesis.  
Additionally, just as was observed in Chapter 1, the LNCaP cells have a much larger 
scope of activation presumably making them less sensitive to PKC activation and 
explaining why all analogues show bryo 1 like proliferation.  Contrastingly, the U397 
cells appear to have a distinct break at about a two-fold increase in activation that 
correlates well with which analogues are PMA like in the proliferation and attachment 
assay (Figure 2.5). 
 
 





The analogues were also tested for their ability to induce TNFα secretion in both 
LNCaP and U937 cells (Figure 2.6).  TNFα secretion is of particular interest as it has 
been identified as an important contributor to PMA induced cell growth inhibition in 
LNCaP cells.8 All analogues induce dramatically less TNFα secretion than PMA at 
concentrations of 1, 10, 100, and 1000 nM, which is consistent with their bryo 1 like 
behavior with regard to growth inhibition.  Mirroring the qPCR results, the U937 cells 
show a difference between the PMA like analogues Merle 23 and 32 and the bryo 1 like 
analogues Merle 28, 30, and 33.  
The qPCR transcriptional studies and TNFα secretion analysis support the idea that 
modulating the polarity across the A- and B-rings will endow analogues with a variety of 
biological responses that span the range from PMA to bryo 1.  The new goal thus became 
to develop a method by which polarity could be adjusted in a more simplistic way than 
altering all four of the groups examined earlier.   
 
Design and Synthesis of Merle’s 34 and 38 
The initial concept for a more adaptable A-, B-ring ‘functional domain’ was based on 
attaching esters of varying carbon chain length at the C7 and C13 positions to control 
lipophilicity.  This approach had the added advantage of being directly amenable to the 
group’s well-established pyran annulation chemistry.  The first analogue chosen to test 
the feasibility of this strategy was Merle 34, which has a calculated partition coefficient 
(ClogP) equal to 1.36 resulting from a C7 acetate and C13 propionate.   Merle 38 was 
also targeted because it would come from an intermediate in the Merle 34 synthesis, and 
























Dr. Rudra designed and executed the synthesis of these two analogues. From a 
retrosynthetic perspective Merle 34 and 38 were envisioned to come from the convergent 
union of A-ring β-hydroxyallyl silane 2.3 and fully functionalized C-ring 2.2 described in 
Chapter 1 (Figure 2.7).  The A-ring subunit would then come from bis-TMS protected 
2.4, which is derived from the previously used intermediate 2.5. 
Starting from intermediate 2.5, available in 18 total steps following the route 
originally developed by Dr. Li (Chapter 1, Figure 1.56), Dr. Rudra first cleaved the C7 
olefin with ozone and reduced the resulting ketone to an alcohol with NaBH4 (Figure 
2.8).  Alcohol 2.6 was obtained as a single diastereomer resulting from axial attack of the 
hydride.  Protection with TMSCl was followed by a Bunnelle reaction9 accessed β-
hydroxyallyl silane 2.3. 
 
 




The A- and C-ring portions were joined using a pyran annulation reaction forming the 
B-ring and providing the full carbon skeleton (Figure 2.9).  The C1 TBDPS group was 
removed and the compound advanced to macrolactone 2.8 as previously described for 
other analogues.  At this point, the B-ring olefin could be cleaved by the slow addition of 
O3 in a solution of CH2Cl2 and the ketone was reduced with NaBH4 to the equatorial 
alcohol in the 7:1 mixture of diastereomers.  Merle 34 was accessed by esterification of 
the C13 alcohol with propionic anhydride followed by global deprotection, while Merle 
38 resulted from the global deprotection of intermediate 2.9 (Figure 2.10). 
Merle 34 and 38 have binding affinities of 16.2 and 13.2 nM respectively, which 
implies that C13 substituents with an (S) configuration have a negative effect on binding.   
 
 





Figure 2.10. Completion of Merle 34 and 38 
 
Contrastingly, loss of binding is not observed in a series of dioxirane B-ring analogues 
made by the Wender group with various substituents in the (S) configuration.10 When 
tested in the U937 assay, both analogues were intermediate between PMA and bryo 1, 
and both were approximately 100-fold less potent than bryo 1 and other analogues.  
Merle 34 was remarkably similar to Merle 33, the C7 acetate and C13 enoate analogue, 
except for being less potent.  These results suggest that having an sp3 center at C13 is 
disadvantageous for binding and biological potency; however, the opposite C13 




Results and Discussion 
Design of aromatic A- and B-ring analogues 
Based on our modest success with using esters and alcohols at C7 and C13 we were 
encourage to continue trying to modulate polarity on the A- and B-rings, and thereby, 
control the resulting biology.  A significant shortcoming of previous approaches was 
that they required many steps, making each analogue a significant challenge.  We 
therefore sought to discover a new strategy that would facilitate the rapid assembly of 
highly diverse A- and B-rings from simple building blocks in a convergent or ‘Lego’ 
like fashion.      
Switching from pyran rings to aromatic rings was an attractive way to simplify the 
synthesis of A-, B-ring analogues (Figure 2.11).  Aromatic rings would have several 
advantages.  First, they do not contain any stereocenters, which will greatly simplify 
their synthesis.  Second, there are numerous diverse aromatic building blocks 
commercially available that would require minimal functional group manipulations. 
Finally, they can be easily diversified further through cross-coupling methodologies 
should any of the ‘X’ labeled position be an aryl triflate or halide.   
 
 




Synthesis of Merle 40 
To test the ability of aromatic rings to act as surrogates for the natural pyran rings 
we set out to synthesize the simplest and most unadorned A-, B-ring system (Figure 
2.12).  The new analogue, Merle 40, was believed to be obtainable by splitting the 
molecule in half using a Heck reaction between B-ring bromide 2.14 and C-ring olefin 
2.12, and using a Yamaguchi esterification between a C26 alcohol and a C1 acid.  This 
strategy was intended to be flexible allowing the Heck and esterification reactions to be 
done in either order.   The sole top-half stereocenter at C3 would come from a catalytic 
asymmetric allylation (CAA) and the A-, and B-rings would be joined using a Suzuki 
cross coupling reaction.  The fully functionalized C-ring was to come from known 
glycal 2.1311 through a series of regio- and stereo-specific oxidations. At the outset, we 
were aware that due to the low reactivity of the C16-C17 olefin, particularly in cross 
metathesis reactions,12 that this was a rather aggressive and likely challenging approach; 
however, since the majority of the chemistry leading to olefin 2.12 was already 
developed it was worth pursuing.    
Synthesis of the top half commenced by coupling B-ring benzyl bromide 2.15 with 
the Molander salt derived from 3-formylbenzeneboronic acid (Figure 2.13).13 Aldehyde 
2.17 was homo-elongated using a Wittig reaction with triphenyl-(methoxymethyl)-
phosphonium chloride followed by acidic work-up of the resulting enol-ether to give to 
homobenzyl aldehyde.14 Aldehyde 2.18 was highly unstable necessitating its immediate 
use in the subsequent CAA reaction, which accessed alcohol 2.19 in modest yields but 
excellent enantioselectivity. The BOM group was chosen so that only one global 





Figure 2.12.  First generation retrosynthesis 
 
2.19 was cleaved with ozone and oxidized to the acid15 completing the synthesis of the 
desired A-, B-ring system in merely 7 total steps compared to the 19 required for the 
simplest of the bis-pyran analogues. 
The route to the C-ring, originally developed up through ketone 2.27 by Dr. 
Troung,11 started with chiral alcohol 2.21 that had been synthesized in excess of 70 
grams in chapter 1 (Figure 2.14).  TBS protection of the free alcohol was followed by 
hydroformylation using Buchwald’s ligand 2.26.16 Prenyl indium addition17 installed 





Figure 2.13. Synthesis of aromatic A-, B-rings 
 
Removal of the C23 TBS ether and cyclizing under dehydrating conditions accessed 
glycal 2.13. 
Glycal 2.13 was first oxidized with MMPP in MeOH so that the epoxide was 
opened in-situ and trapped exclusively as the anomeric methyl ketal (Figure 2.15).    
The free alcohol at C20 was immediately oxidized to the ketone using Dess-Martin 
conditions.19 The exocyclic enoate was installed through an aldol addition and in-situ 
elimination resulting in a single olefin isomer that was dictated by developing A-1,3 
strain with the vicinal ketone.20 The final two steps were the reduction of the C20 
ketone and esterification of the free alcohol with acetic anhydride.  The acetate ester 
was chosen because it had already been demonstrated that the acetate can be removed 














Having successfully synthesized both fragments, focus was directed towards 
coupling them.  Although this route was designed to be flexible allowing the Heck and 
esterification reactions to be conducted in either order, we suspected that the Heck 
would work better if performed first.  Rather than screening catalyst conditions on the 
valuable fully functionalized C-ring, bromobenzene and intermediate 2.27 were used as 
a model reaction (Figure 2.16).  We were pleased to discover that the first set of 
conditions attempted were very effective at carrying out this reaction with good yield 
and the product was obtained exclusively as the E-isomer.22 
Unfortunately, this result did not translate to the desired substrate for which multiple 
problems were observed (Figure 2.17).  The first issue discovered was that the fully 
functionalized C-ring was slightly unstable to prolonged exposure to strong bases at 
elevated temperature leading to internalization of the exocyclic enoate 2.31.  Similar 
sensitivities to basic conditions have also been reported by Wender10 and Evans.20 The 
Heck reaction also failed to proceed when simplified C-ring 2.27 was used.  Recovery 
of the de-brominated B-ring indicates that oxidative addition is occurring but the 
reaction is stalling out during the migratory insertion step.  This failure was rationalized 
as being due to the increased sterics, compared to bromobenzene, as well as the C1 acid  
 
 





Figure 2.17. Heck reaction with Jeffery conditions 
 
possibly acting as a chelating ligand effectively blocking a necessary coordination site 
on palladium. 
At this point, performing the esterification first followed by an intramolecular Heck 
was explored.  Removal of the PMB protecting group followed by coupling using 
Shiina’s reagent23 afforded 2.33 in excellent yield (Figure 2.18).  The Heck reaction 
under Jeffery conditions again only produced the de-brominated product along with  
significant C-ring isomerization/decomposition. Exchanging K2CO3 for less basic 
KHCO3 or KOAc failed to remedy stability issues, and oxidative addition failed with 






Jeffery w/ K2CO3, KOAc, KHCO3  Debromination/ C-ring isomerization 
Jeffery w/ amine basses No oxidative addition 
Pd(P(t-Bu)3)2, Et3N, DMF No oxidative addition 
Pd(OAc)2, SPHOS, Et3N Debromination 
Pd(P(t-Bu)3)2, Pd2(dba)3, Cy2NMe, 
Toluene, rt 
Trace product/ debrominated 
 
Figure 2.18. Attempted intramolecular Heck reaction 
 
failure to undergo oxidative addition.  By now it had become apparent that the triphenyl 
phosphine ligands were not electron donating enough to accomplish this reaction under 
mildly basic conditions.  Using Pd(P(t-Bu)3)2 with Et3N in DMF gave no reaction.  
Using the Buchwald ligand SPHOS24 and Et3N the catalyst underwent oxidative 
addition to give the de-brominated product, with minimal decomposition or 
isomerization.  Unfortunately, changing the base, temperature, and solvent failed to 
facilitate the insertion step with this catalyst.  In 2001, the Fu group reported the use of 
Pd/P(t-Bu)3 in a 1:1 ratio, and Cy2NMe as a versatile catalyst for the Heck reaction of 




product formation was finally observed albeit only in trace amounts.  Heating, long 
reaction times, and high catalyst loadings did not provide any improvement.  A possible 
explanation for observing minimal product formation but complete de-bromination is 
that migratory insertion is taking place but that the compound cannot adapt a 
conformation that would allow for β-hydride elimination and therefore undergoes β-aryl 
elimination instead. 
An attractive alternative to the Heck reaction would be use either a Stille or Suzuki 
cross coupling reaction.  Both reaction types would extend the reaction one carbon 
further away from the C18 gem-dimethyl alleviating the need to have a bulky Pd 
species at C17.  However, since both the Stille and Suzuki reactions would require 
additional functional group manipulations to access a vinyl stannane or borane the Heck 
was given one final consideration.  Based on previous results, the intermolecular 
reaction was going to be necessary as well as not having C1 at the acid oxidation state.  
Additionally, the C3 BOM group was replaced with a TES group because it would still 
be labile to the LiBF4 deprotection conditions, but could also be removed selectively 
should the need arise.  Following protection of the C3 alcohol with TESCl the terminal 
olefin 2.34 was cleaved with O3, and reduced to the primary alcohol (Figure 2.19).  
Both the Jeffery and Fu conditions were attempted on this substrate.  The Jeffery 
conditions gave no product but the Fu conditions gave the product in yields consistently 
in the 70% range along with recovery of unreacted C-ring.  Increasing reaction times or 
using up to a three-fold excess of the bromide failed to drive the reaction any further.  
Considering the complexity of these substrates and the known inert nature of the C16-





Figure 2.19. Successful Heck reaction 
 
rt in only 16 h avoided all of the C-ring stability issues previous observed using harsher 
conditions. 
Completion of the analog from this stage only required five steps (Figure 2.20).  
Oxidation of alcohol 2.36 to the acid over 2 steps provided carboxylate 2.37.  Removal 
of the PMB ether with DDQ gave an intermediate seco-acid, which required extensive 
purification prior to macrolactonization due to decomposition if any DDQ side products 
were present when forming the mixed anhydride.26 Macrolatonization proceeded in 
good yield to provide analogue precursor 2.38. Unfortunately, exposure of 2.38 to our 
standard LiBF4 at 80 °C deprotection conditions completely destroyed the compound 
yielding no usable material.  This is not the first analogue to be unstable under these 
conditions.  Dr. Kraft and Dr. Chavez both encountered similar issues while trying to 
remove the BOM group from Merle 29 and 31 (Figure 2.21), respectively.  Dr. Kraft 















followed by cleavage of a C3 BPS with HFPyr and the C19 methyl ketal with LiBF4 at 
50 °C.4 Conducting the reactions in this order resulted in the major product being the 
ring expanded compound Merle 29d. However, doing the hydrogenation last 
decomposed the analogue.  Dr. Chavez was able to deprotect the BOM group with 
BF3OEt2/DMS in dichloromethane after first cleaving a C3 PMB with DDQ and 
hydrolyzing the methyl ketal with LiBF4 at 50 °C. 
Transfer hydrogenation27 of the new bis-aromatic analog resulted in reduction of the 
C16-C17 olefin along with considerable decomposition (Figure 2.22).  Removal of the 
TES and methyl ketal was accomplished efficiently with aqueous HF in acetonitrile; 
however, exposure to the previously used BF3OEt2 conditions provided only the 
eliminated product 2.41.  Bromocatechol borane at -78 °C28 was also tried to no avail.  
 
 




Considering that the C21 exocyclic enoate would not be stable to dissolving metal 
conditions and that screening for a specific ‘goldilocks’ Lewis acid or hydrogenation 
catalyst would be time consuming and not likely to yield a successful result, attention 
was focused on removing the BOM at an earlier stage. 
The major challenge associated with earlier removal of the BOM was selectivity in 
the presence of the PMB and methyl ketal groups.  This immediately ruled out using 
Lewis acidic or hydrogenation conditions.  The only example of selectivity favoring 
BOM cleavage over PMB was with the use of Lithium 4,4’-ditertbutylbiphenyl 
(LiDBB) by Roush and co-workers;29 however, for our purposes this reaction would 
need to be done prior to installment of C21 enoate.  To accommodate all these 
constraints glycal 2.13 was chosen as the best place to attempt BOM removal (Figure 
2.23).  The dissolving metal reaction proceeded in modest yield along with recovered 
starting material and a product lacking both the BOM and PMB.  Nevertheless, the free 
alcohol could be protected as the TBS ether 2.42 and advanced.   
Strangely, the epoxidation/ methanolysis/ oxidation sequence provided the methyl 
ketal as a 2.5:1 mixture of diastereomers rather than the near exclusive axial methyl 
ketal that was observed with a BOM group at C26.  Presumable, the axial methyl ketal 
is the thermodynamic product.  Therefore, the observed mixture likely resulted from 
kinetic control.  Inserting a thermodynamic isomerization step with monochloroacetic 
acid rectified the problem giving 2.43 as the sole product without loss of yield after 
Dess-Martin oxidation.20   Installation of the C21 enoate and C20 acetate proceeded 
smoothly to give the C26 TBS C-ring 2.44.  Heck coupling of the new C-ring did not 





Figure 2.23. Replacing BOM with TBS 
 
Alcohol 2.45 was oxidized to the acid, the PMB group removed, and the compound 
was cyclized using Yamaguchi conditions26 as described previously (Figure 2.24). 
Aqueous HF had previously been used to successfully remove the TES and methyl 
ketal.  However, trying to remove all three protecting groups under these conditions 
gave a mixture of three products in approximately equal proportion.  The eliminated 
product 2.41 could be separated by column chromatography, and the ring expanded 
compound 2.47 could be separated by successive elution on a TLC plate with 30% 
acetone/benzene.  Unfortunately, the desired analogue was not stable to successive 
elution on a preparatory plate resulting in decomposition and reintroduction of the 





Figure 2.24. Attempted deprotection 
 
To avoid the ring expanded compound, deprotection of the TES and methyl ketal 
first followed by cleavage of the TBS under buffered HFPyr conditions was attempted 
(Figure 2.25).  Complete removal of the ketal required 2 h at which point the reaction 
was quenched, and this fortuitously yielded only two products.  Along with the TBS 
protected compound 2.48, Merle 40 was obtained contaminated with only trace amounts 
of 2.47.  Deprotection of 2.48 with the buffered conditions required >24 h and resulted 
in a 1:1 mixture of Merle 40 and ring expanded 2.47. However, having obtained 







Figure 2.25. Successful deprotection of Merle 40 
 
Biological evaluation of Merle 40 
Surprisingly, Merle 40 displayed a Ki = to 971 nM.  Such a result was entirely 
unexpected considering that the entire C-ring ‘binding domain’ was intact, and that 
even if the analogue was undergoing ring expansion during the assay that should only 
result in a minor loss in binding similar to what was seen for Merle 29u and d.  Merle 
40 also displayed a dramatic loss in biological potency in U937 cells, where no 
response was observed until 20 μM was applied (Figure 2.26).  The lack of potency is 
represented even more dramatically in Toledo cells, which experience growth inhibition 
in response to both PMA and bryo 1 (Figure 2.27).  In Toledo cells, Merle 40 is four 

















Figure 2.27. Growth inhibition of Toledo cells. 
 
Despite Merle 40’s lack of potency and therefore limited potential as a medicinal 
compound it does provide the opportunity to learn more about the subtleties of bryo 1’s 
structure function relationships.  The two most distinct differences are the lack of the 
internal hydrogen-bonding network, present in bryo 1 and other analogues, and the 
aromatic rings being flat and more rigid than pyrans.  Simple plastic models indicated 
that Merle 40 was at least capable of adapting a near identical conformation as seen in 
the bryo 1 crystal structure without considerable strain.  Bryostatins and analogues are 
known to have highly rigid structures due to a strong internal hydrogen-bonding 
network (Figure 2.28).30 The loss of this network may allow for greater flexibility and 





Figure 2.28. Bryostatin 1 crystal structure 
 
Support for hydrogen bonding being required to maintain a proper binding 
conformation can be found by comparison with other known analogues (Figure 2.29).  
The binding affinity of Wender’s analogue 2.49 drops from 3.4 nM to 297 nM when the 
C3 hydroxyl is removed in compound 2.50.  This is the same order of magnitude in 
binding loss that was observed with Merle 40, and was hypothesized, using computer 
modeling, to be a direct result of the internal hydrogen-bonding network not holding the 
C-ring in the proper conformation.31 Similarly bryostatin 16, which lacks the C19 
hemiketal, also losses binding affinity by two orders of magnitude.  The H-bonding 
network may also be very important for preorganizing the ligand thus minimizing the 
entropy of binding, and without this preorganization entropy becomes a significant 
factor.   To further explore the conformational changes in Merle 40 that resulted in such 
a dramatic change in binding we are currently pursuing both crystallizing the analogue 






Figure 2.29. Ki of analogues lacking the internal H-bonding network 
 
Future direction 
In addition to evaluating the conformational differences between Merle 40 and high 
affinity PKC ligands, two new analogues have been proposed to further probe the role 
of the internal hydrogen-bonding network (Figure 2.30).  Analogue 2.51 will utilize a 
pyran A-ring so that the role of the B-ring can be more directly examined.  Based on our 
experience with Merle 29u and d, this analogue is expected to still suffer from a 
propensity to ring expand but may restore high affinity binding.  If binding is in fact 
restored then the second analogue 2.52, which contains a pyridine B-ring, could be used 
to directly explore the role of the hydrogen-bonding network with regard to compound 





Figure 2.30. Proposed analogues 
 
pyridine analogue 2.52 may still succeed at solving both the binding and ring 
expansion/ C19 elimination problems.  Should 2.52 not resolve these issues then it is 
unlikely that anything other than a pyran type heterocycle could be used as the B-ring; 
however, if the pyridine is an acceptable modification then the project could move 
forward by replacing both the A- and B-rings with substituted pyridines. 
 
Conclusion 
In order to develop a simplified platform upon which the polarity hypothesis could 
be rigorously tested a new analogue, Merle 40 was synthesized.  The C-ring portion was 
accessed in only 19 steps, and the novel A-, B-ring system was constructed in a mere 7 
steps.  The two fragments were combined through a Heck insertion, which is the only 
example of the C16-C17 olefin, of a fully functionalized C-ring, being utilized with 
good yield.  Unfortunately Merle 40 is not a stable compound and is not a good ligand 
for PKC with a Ki = 971 nM.  In spite of its shortcomings Merle 40 does however 
provide a great opportunity to learn more about the structural features that make 




structural analysis will likely be highly valuable for the future design of simplified 
analogues.  Based on this work as well as the work of former Keck group members and 
other groups our understanding of bryostatin structure function relationships has been 
advanced considerably (Figure 2.31).  
 
Experimental Section 
General experimental procedures  
Diisopropylamine, diisopropylethylamine, pyridine, triethylamine, EtOAc, and 
CH2Cl2 were distilled from CaH2.  Reagent grade DMF, DMSO and acetone were 
purchased, stored over 4Å molecular sieves and used without further purification. Et2O, 
THF, and toluene were distilled from Na under an atmosphere of N2. MeOH was 
distilled from dry Mg turnings. The titer of n-BuLi was determined by the method of 
Eastham and Watson.2 TiCl4 was distilled prior to use. Zn was activated with aqueous 
HCl solution prior to use. All other reagents were used without further purification.  
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Yields were calculated for material judged homogenous by thin layer chromatography 
and nuclear magnetic resonance (NMR).  Thin layer chromatography was performed on 
Merck Kieselgel 60 Å F254 plates or Silicycle 60Å F254 eluting with the solventindicated, 
visualized by a 254 nm UV lamp, and stained with an ethanolic solution of 12-
molybdophosphoric acid, or an aqueous potassium permanganate solution. Flash 
column chromatography was performed with Silicycle Flash Silica Gel 40 – 63 µm or 
Silicycle Flash Silica Gel 60 – 200 µm, slurry packed with hexanes in glass columns. 
Glassware for reactions was oven dried at 125 C and cooled under a dry atmosphere 
prior to use.  Liquid reagents and solvents were introduced by oven-dried syringes 
through septum-sealed flasks under a nitrogen atmosphere.  Nuclear magnetic 
resonance spectra were acquired at 300, 500 MHz for 1H and 75, 125 MHz for 13C.  
Chemical shifts for proton nuclear magnetic resonance (1H NMR) spectra are reported 
in parts per million relative to the signal of residual CDCl3 at 7.27 ppm. Chemicals 
shifts for carbon nuclear magnetic resonance (13C NMR and DEPT) spectra are reported 
in parts per million relative to the centerline of the CDCl3 triplet at 77.23 ppm.  
Chemical shifts of the unprotonated carbons (‘C’) for DEPT spectra were obtained by 
comparison with the 13C NMR spectrum.  The abbreviations s, d, dd, ddd, dddd, dq, t, 
and m stand for the resonance multiplicity singlet, doublet, doublet of doublets, doublet 
of doublet of doublets, triplet and multiplet, respectively.  Optical rotations (Na D line) 
were obtained using a microcell with 1 dm path length.  Specific rotations ([α] , Unit: 
°cm2/g) are based on the equation α = (100· α)/(l·c) and are reported as unit-less 
numbers where the concentration c is in g/l00 mL and the path length l is in decimeters.  




of Chemistry at The University of Utah on a double focusing high-resolution mass 
spectrometer.  Compounds were named using ChemDraw 12.0.0. 
 
Experimental procedures for Merle 40 
 Preparation of 3-(3-bromobenzyl)benzaldehyde 2.17: To a stirring 
biphasic solution of 1-bromo-3-(bromomethyl)benzene (1.15 g, 4.59 mmol, 1 equiv) 
and potassium tetrafluoroborate salt 2.16 (0.975 g, 4.59 mmol, 1 equiv) in a 4:3:2 
mixture of toluene/EtOH/H2O (46 mL) in a 100 mL rb flask equipped with a reflux 
condenser, at rt, was added Na2CO3 (0.937 g, 9.18 mmol, 2 equiv) and Pd(PPh3) (0.132 
g, 0.115 mmol, 0.025 equiv).  The reaction mixture was stirred at reflux (80 °C oil bath) 
for 2 h, cooled to rt, and then partitioned between EtOAc (50 mL) and water (50 mL).  
The phases were separated and the aqueous layer was extracted with EtOAc (3 × 20 
mL).  The combined organic layers were dried over Na2SO4, concentrated and purified 
by flash column chromatography using a 3.5 × 8.0 cm silica gel column, eluting with 
5% EtOAc/hexanes, collecting 13 × 100 mm test tube fractions.  The product containing 
fractions (22-49) were combined and concentrated under reduced pressure to provide 
2.17 (0.955 g, 75% yield) as a clear oil: Rf = 0.42 (20% EtOAc/hexanes); 500 MHz 
1H 
NMR (CDCl3)  10.0 (s, 1H), 7.75 (d, J = 7.2 Hz, 1H), 7.71 (s, 1H), 7.51-7.43 (m, 2H), 
7.39-7.33 (m, 2H), 7.18 (t, J = 7.2 Hz, 1H), 7.13 (d, J = 7.2 Hz, 1H), 4.03 (s, 2H); 125 
MHz 13C NMR (CDCl3)  192.5, 142.7, 141.6, 137.0, 135.3, 132.1, 130.5, 130.0, 129.9, 
129.6, 128.5, 127.8, 123.0, 41.4; 125 MHz DEPT (CDCl3) CH3 δ none; CH2 δ 41.4; CH 




123.0;  IR (neat) 3050, 3026, 2911, 2900, 2780, 1725, 1590, 1560, 1478 cm-1; HRMS 
(ESI/ APCI) calcd 296.9891 and 298.9871 for C14H11BrONa found 296.9892 and 
298.9875.  
 
  Preparation of 2-(3-(3-bromobenzyl)phenyl)acetaldehyde 2.18: 
To a stirring solution of potassium tert-butoxide (283 mg, 2.52 mmol, 2 equiv) in THF 
(25 mL) in a 50 mL rb flask, at 0 °C, was added (methoxymethyl) 
triphenylphosphonium chloride (775 mg, 2.52 mmol, 2 equiv).  The mixture 
immediately turned deep red and was stirred for 2 h.  To this solution, at 0 °C, was 
added aldehyde 2.17 (347 mg, 1.26 mmol, 1 equiv) dropwise by syringe, and stirring 
was continued for 30 min.  The reaction mixture was quenched with a saturated aqueous 
NH4Cl solution (15 mL).  The phases were separated and the aqueous layer was 
extracted with EtOAc (3 × 20 mL).  The combined organic layers were dried over 
Na2SO4, and concentrated to provide the crude enol ether as 1.4:1 mixture of E/Z 
isomers, which was used without purification. 
To a stirring solution of the aforementioned enol ether in THF (25 mL) in a 50 mL 
rb flask, at rt, was added a 1 M aqueous HCl solution.  The homogenous solution was 
stirred for 24 h at rt, then quenched with saturated aqueous NaHCO3 solution (15 mL).  
The phases were separated and the aqueous layer was extracted with EtOAc (3 × 20 
mL).  The combined organic layers were dried over Na2SO4, concentrated, and purified 
by flash column chromatography using a 2.0 × 7.0 cm silica gel column, eluting with 




fractions (9-25) were combined and concentrated under reduced pressure to provide 
2.18 (266 mg, 73% yield) as a clear oil: Rf = 0.39 (20% EtOAc/hexanes); 500 MHz 
1H 
NMR (CDCl3)  9.75 (s, 1H), 7.43-7.29 (m, 3H), 7.22-7.07 (m, 4H), 7.05 (s, 1H), 3.96 
(s, 2H), 3.67 (s, 2H); 125 MHz 13C NMR (CDCl3)  199.6, 143.3, 141.3, 132.5, 132.2, 
130.4, 130.3, 129.6, 129.5, 128.3, 127.9, 127.8, 122.9, 50.7, 41.6; 125 MHz DEPT 
(CDCl3) CH3 δ none; CH2 δ 50.7, 41.6; CH δ 199.6, 132.2, 130.4, 130.3, 129.6, 129.5, 
128.3, 127.9, 127.8, 122.9; C δ 143.3, 141.3, 132.5, 122.9; ;  IR (neat) 3056, 3026, 
2909, 2824, 2725, 1946, 1723, 1591, 1567, 1475, 1426, 1311, 1183, 1071, 777, 704 cm-
1; HRMS (ESI/ APCI) calcd 311.0047 and 313.0027 for C15H13BrONa found 311.0047 
and 313.0032. 
 
 Preparation of (S)-1-(3-(3-bromobenzyl)phenyl)pent-4-en-2-ol 
2.19:  To a stirring solution of (S)-Binol (106 mg, 0.369 mmol, 0.4 equiv) and 
powdered 4 Å molecular sieves (369 mg) in CH2Cl2 (3.69 mL) in a 25 ml 2-neck rb 
flask, at rt, was added a 1.0 M solution of Ti(i-OPr)4 (171 μL, 0.2 equiv) in CH2Cl2 and 
a freshly prepared 0.1 M solution of TFA (28 μL, 1.3 equiv) in CH2Cl2.  This 
suspension was heated at 40 °C for 1 h, during which time a deep red color developed. 
After cooling to rt. aldehyde 2.18 (266 mg, 0.922 mmol, 1 equiv) in CH2Cl2 (500 μL) 
was added via cannula. An additional aliquot of CH2Cl2 (200 μL) was used to complete 
the transfer, and the mixture was cooled to -78 °C.  After 30 min, allyl tributylstannane 




min at -78 °C. Stirring was discontinued, the reflux condenser was replaced with a 
septa, and the flask was stored in a -20 °C.  After 3 days the reaction mixture was 
quenched, at -20 °C by the addition of saturated aqueous NaHCO3 solution (0.5 mL) 
then filtered through a 3 cm pad of celite® into a 50 mL Erlenmeyer flask.  Saturated 
aqueous NaHCO3 solution (10 mL) was added along with additional CH2Cl2 (10 mL), 
and the biphasic solution was stirred for 1 h.  The layers were separated and the aqueous 
layer was extracted with CH2Cl2 (3 × 10 mL).  The combined organic layers were 
washed with brine (2 × 5 mL), dried over Na2SO4, concentrated to a red oil, and 
purified by flash column chromatography using a 2.0 × 10.0 cm silica gel column, 
eluting with 8% EtOAc/hexanes, and collecting 10 × 75 mm test tube fractions.  The 
product containing fractions (21-38) were combined and concentrated under reduced 
pressure to provide 2.19 (189 mg, 62% yield) as a yellow oil: Rf = 0.25 (20% 
EtOAc/hexanes); +15.0 (c =1.0, CHCl3) @ 95% ee; 500 MHz 
1H NMR (CDCl3) 
 7.39-7.35 (m, 2H), 7.31-7.28 (m, 1H), 7.21-7.17 (m, 1H), 7.17-7.11 (m, 2H), 7.10-
7.06 (m, 2H), 5.90 (dddd, J = 13.1, 11.2, 7.4, 7.1 Hz, 1H), 5.21-5.16 (m, 2H), 3.97 (s, 
2H), 3.91 (ddd, J = 15.1, 7.5, 4.6 Hz, 1H), 2.83 (dd, J = 13.7, 4.9 Hz, 1H), 2.73 (dd, J = 
13.7, 8.1 Hz, 1H), 2.40-2.34 (m, 1H), 2.29-2.22 (m, 1H), 1.73 (s, OH); 125 MHz 13C 
NMR (CDCl3)  143.7, 140.7, 139.0, 134.9, 132.2, 130.3, 130.3, 129.5, 129.1, 127.8, 
127.7, 127.4, 122.8, 118.5, 71.9, 43.5, 41.7, 41.5; 125 MHz DEPT (CDCl3) CH3 δ none; 
CH2 δ 118.5, 43.5, 41.7, 41.5; CH δ 134.9, 132.2, 130.3, 130.3, 129.5, 129.1, 127.8, 
127.7, 127.4, 71.9; C δ 143.7, 140.7, 139.0, 122.8; IR (neat) 3402, 3058, 3016, 2918, 
1640, 1606, 1592, 1567, 1486 cm-1; HRMS (ESI/ APCI) calcd 353.0517 and 355.0497 






Mosher ester analysis32 confirms (S) orientation of the C3 alcohol 
 
Preparation of (S)-((1-(3-(3-bromobenzyl)phenyl)pent-4-en-2-
yl)oxy)triethylsilane 2.34:  To a stirring solution of alcohol 2.19 (222 mg, 0.670 mmol, 
1 equiv) in CH2Cl2 (6.7 mL) in a 25 mL rb flask, at rt, was added Et3N (280 μL, 2.01 
mmol, 3 equiv) followed by TESCl (169 μL, 1.01 mmol, 1.5 equiv).  After 7 h the 
reaction mixture was quenched with water (10 mL), the phases were separated, and the 
aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The combined organic layers 
were dried over Na2SO4, concentrated, and purified by flash column chromatography 
using a 2.0 × 8.0 cm silica gel column, eluting with 10% EtOAc/hexanes, and collecting 
10 × 75 mm test tube fractions.  The product containing fractions (6-16) were combined 
and concentrated under reduced pressure to provide 2.34 (285 mg, 95% yield) as a clear 
oil: Rf = 0.71 (30% EtOAc/hexanes); +8.9 (c =1.0, CHCl3); 500 MHz 
1H NMR 
(CDCl3)  7.36-7.32 (m, 2H), 7.21 (t, J = 8.2 Hz, 1H), 7.16 (t, J = 7.5 Hz, 1H), 7.14-
7.11 (m, 1H), 7.07-6.99 (m, 3H), 5.87 (dddd, J = 17.3, 10.3, 7.4, 7.4 Hz, 1H), 5.08-5.01 























1H), 2.65 (dd, J = 13.9, 5.3 Hz, 1H), 2.28-2.17 (m, 2H), 0.87 (t, J = 7.9 Hz, 9H), 0.50-
0.40 (m, 6H); 125 MHz 13C NMR (CDCl3)  143.8, 140.1, 139.9, 135.2, 132.1, 130.6, 
103.1, 129.4, 128.6, 128.0, 127.8, 126.9, 122.7, 117.4, 73.5, 43.7, 42.0, 41.7, 7.1, 5. 0; 
125 MHz DEPT (CDCl3) CH3 δ 7.1; CH2 δ 117.4, 43.7, 42.0, 41.7, 5.0; CH δ 135.2, 
132.1, 130.6, 130.1, 129.4, 128.6, 128.0, 127.8, 126.9, 73.5; C δ 143.8, 140.1, 139.9, 
122.7; IR (neat) 2953, 2911, 2875, 1640, 1594, 1568, 1475, 1424 cm-1; HRMS (ESI/ 
APCI) calcd 467.1382 and 469.1361 for C24H33BrOSiNa found 467.1389 and 469.1367. 
 
 Preparation of (R)-4-(3-(3-bromobenzyl)phenyl)-3-
((triethylsilyl)oxy)butan-1-ol 2.35:  Into a stirring solution of olefin 2.34 (155 mg, 
0.348 mmol, 1 equiv) in CH2Cl2 (6.9 mL) in a 50 mL rb flask, at - 78 °C, was bubbled a 
steady stream of O3 until a faint blue color developed, approximately 3 min.  Flushing 
with O2 for 15 min purged excess ozone, then PPh3 (183 mg, 0.696 mmol, 2 equic) was 
added, and the reaction mixture was allowed to warm to rt as it stirred for 3 h.  This 
solution of crude aldehyde was cooled to 0 °C, and ethanol (3.5 mL) was added 
followed by NaBH4 (6.6 mg, 0.17 mmol, 0.5 equiv).  After 1 h the mixture was 
quenched with saturated aqueous NaHCO3 solution (10 mL), the phases were separated, 
and the aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The combined organic 
layers were dried over Na2SO4, concentrated and purified by flash column 
chromatography using a 2.0 × 7.0 cm silica gel column, eluting with 10% 




fractions (10-29) were combined and concentrated under reduced pressure to provide 
2.35 (137 mg, 88% yield) as a clear oil: Rf = 0.42 (30% EtOAc/hexanes); -2.0 (c 
=1.0, CHCl3); 500 MHz 
1H NMR (CDCl3)  7.36-7.32 (m, 2H), 7.22 (t, J = 7.5 Hz, 1H), 
7.16 (t, J = 6.9 Hz, 1H), 7.13-7.10 (m, 2H), 7.05-7.01 (m, 2H), 6.98 (s, 1H), 4.13 (ddd, J 
= 12.9, 6.3 Hz, 1H), 3.93 (s, 2H), 3.86 (ddd, J = 12.3, 8.2, 4.3 Hz, 1H), 3.75-3.69 (m, 
1H), 2.87 (dd, J = 13.3, 6.0 Hz, 1H), 2.75 (dd, J = 13.1, 7.1 Hz, 1H), 2.44 (s, 1H), 1.81-
1.74 (m, 1H), 1.65-1.58 (m, 1H), 0.93 (t, J = 8.2 Hz, 9H), 0.55 (ddd, J = 15.0, 7.4, 4.1 
Hz, 6H); 125 MHz 13C NMR (CDCl3)  143.6, 140.4, 139.2, 132.1, 130.3, 130.1, 129.4, 
128.8, 127.8, 127.1, 122.8, 73.4, 60.5, 43.9, 41.7, 37.9, 7.0, 5.1; 125 MHz DEPT 
(CDCl3) CH3 δ 7.1; CH2 δ 60.5, 43.9, 41.7, 37.9, 5.0; CH δ 132.1, 130.3, 130.1, 129.4, 
128.8, 127.8, 127.8, 127.1, 73.4; C δ 143.6, 140.4, 139.2, 122.8; IR (neat) 3386, 2951, 
2910, 2875, 1593, 1568, 1474 cm-1; HRMS (ESI/ APCI) calcd 471.1331 and 473.1310 
for C23H33BrO2SiNa found 471.1339 and 473.1323. 
 
 Preparation of (5R,6R,8S)-8-allyl-6-((4-methoxybenzyl)oxy)-
5,10,10,11,11-pentamethyl-1-phenyl-2,4,9-trioxa-10-siladodecane 2.22:11 To a 
stirring solution of alcohol (3.71 g, 9.26 mmol, 1 equiv), and imidazole (2.52 g, 37.1 
mmol, 4 equiv), in DMF (46 mL), in a 100 mL rb flask, at rt, was added TBSCl (2.79 g, 
18.5 mmol, 2 equiv).  This solution was stirred for 20 h, quenched with water (20 mL), 
and then diluted with 30% EtOAc/hexanes (50 mL).  The phases were separated and the 
aqueous layer was extracted with 30% EtOAc/hexanes (3 × 20 mL).  The combined 





separated by flash column chromatography using a 5.0 × 19.0 cm silica gel column, 
eluting with 3% EtOAc/hexanes, collecting 13 × 100 mm test tube fractions.  The 
product containing fractions (83-290) were combined and concentrated under reduced 
pressure to provide 2.22 (3.95 g, 83% yield) as a pure diastereomer and as a clear oil: Rf 
= 0.27 (5% EtOAc/ 35% toluene/ 60% hexanes); 500 MHz 1H NMR (CDCl3)  7.37-
7.34 (m, 4H), 7.32-7.28 (m, 1H), 7.26 (d, J = 8.7 Hz, 2H), 6.87 (d, J = 8.7 Hz, 2H), 5.83 
(dddd, J = 13.4, 13.4, 6.8, 7.2 Hz, 1H), 5.04 (dd, J = 13.7, 2.0 Hz, 2H), 4.81 (Aβq, J = 
7.3 Hz, Δν = 9.6 Hz, 2H), 4.63 (Aβq, J = 11.8 Hz, Δν = 18.7 Hz, 2H), 4.59 (d, J = 10.9 
Hz, 1H), 4.47 (d, J = 10.9 Hz, 1H), 4.05-3.93 (m, 2H), 3.80 (s, 3H), 3.66 (ddd, J = 8.4, 
4.5, 3.0 Hz, 1H), 2.31-2.25 (m, 2H), 1.69-1.58 (m, 2H), 1.18 (d, J = 6.7 Hz, 3H), 0.90 
(s, 9H), 0.08 (s, 3H), 0.06 (s, 3H); 125 MHz 13C NMR (CDCl3)  159.4, 138.3, 135.0, 
131.3, 129.4, 128.7, 128.1, 127.9, 117.3, 114.1, 93.5, 78.2, 73.2, 72.2, 69.6, 69.4, 55.6, 
43.2, 37.6, 26.2, 18.4, 15.4, -3.5, -4.1. 
 
 Preparation of (5S,7R,8R)-8-((benzyloxy)methoxy)-5-((tert-
butyldimethylsilyl)oxy)-7-((4-methoxybenzyl)oxy)nonanal 2.23:11  To a stirring 
solution of olefin 2.22 (3.01 g, 5.85 mmol, 1 equiv) in THF (11.7 mL) in a high 
pressure Parr reaction vessel, at rt and open to air, was added phosphite ligand 2.26 (92 
mg, 0.12 mmol, 0.02 equiv), and Rh(acac)(CO)2 (8.0 mg, 0.03 mmol, 0.005 equiv).  
The pressure gage was secured and the reaction vessel was purged with N2 three times 




to 60 psi with CO2/H2, and heated at 60 °C for 20 h.  Pressure was carefully released, 
and then the solution was transferred to a 100 mL rb flask rinsing with copious amounts 
of EtOAc, and then concentrated.  Purification was accomplished by flash column 
chromatography using a 5.0 × 14.0 cm silica gel column, eluting with 10% 
EtOAc/hexanes, collecting 13 × 100 mm test tube fractions.  The product containing 
fractions (89-190) were combined and concentrated under reduced pressure to provide 
2.23 (3.03 g, 95% yield) as a clear oil: Rf = 0.30 (20% EtOAc/hexanes); 500 MHz 
1H 
NMR (CDCl3)  9.74 (s, 1H), 7.38-7.34 (m, 4H), 7.33-7.29 (m, 1H), 7.25 (d, J = 8.5 Hz, 
2H), 6.87 (d, J = 8.5 Hz, 2H), 4.81 (Aβq, J = 7.4 Hz, Δν = 12.0 Hz, 2H), 4.64 (Aβq, J = 
12.0 Hz, Δν = 18.9 Hz, 2H), 4.60 (d, J = 10.8 Hz, 1H), 4.45 (d, J = 10.8 Hz, 1H), 4.03 
(ddd, J = 12.8, 6.4, 4.8 Hz, 1H), 3.95-3.88 (m, 1H), 3.80 (s, 3H), 3.64 (ddd, J = 9.3, 4.7, 
2.5 Hz, 1H), 2.40 (ddd, J = 8.9, 7.3, 1.6 Hz, 2H), 1.75-1.46 (m, 6H), 1.19 (d, J = 6.3 Hz, 
3H), 0.90 (s, 9H), 0.60 (s, 6H); 125 MHz 13C NMR (CDCl3)  202.8, 159.4, 138.2, 
131.2, 129.4, 128.7, 128.1, 128.0, 114.1, 93.5, 78.3, 73.0, 72.2, 69.6, 69.6, 55.6, 44.3, 
37.8, 37.4, 26.2, 18.4, 17.5, 15.2, -3.6, -4.1. 
 
 Preparation of (8S,10R,11R)-11-((benzyloxy)methoxy)-8-
((tert-butyldimethylsilyl)oxy)-10-((4-methoxybenzyl)oxy)-3,3-dimethyldodec-1-en-
4-ol 2.24:11  To a stirring solution of aldehyde 2.23 (3.03 g, 5.56 mmol, 1 equiv) and 
indium powder (1.92 g, 16.7 mmol, 3 equiv) in DMF (28 mL) in a 100 ml rb flask, at rt, 




mixture was quenched by the addition of saturated aqueous NaHCO3 solution (10 mL).  
The phases were separated and the aqueous layer was extracted with a 30% 
EtOAc/hexanes solution (2 × 10 mL).  The aqueous layer was acidified with a 1 M 
aqueous HCl solution (5 mL) and extracted once more.  The combined organic layers 
were dried over Na2SO4, concentrated and purified by flash column chromatography 
using a 5.0 × 10.0 cm silica gel column, eluting with 10-20% EtOAc/hexanes, 
collecting 18 × 150 mm test tube fractions.  The product containing fractions (8-45) 
were combined and concentrated under reduced pressure to provide 2.24 (3.32 g, 97% 
yield) as a clear oil: Rf = 0.54 (30% EtOAc/hexanes); 500 MHz 
1H NMR (CDCl3)  
7.37-7.34 (m, 4H),7.32-7.28 (m, 1H), 7.25 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 
5.81 (dd, J = 16.9, 10.5 Hz, 1H), 5.09 (d, J = 10.5 Hz, 1H), 5.05 (d, J = 17.8 Hz, 1H), 
4.81 (Aβq, J = 6.9 Hz, Δν = 10.4 Hz, 2H), 4.63 (Aβq, J = 11.4 Hz, Δν = 19.6 Hz, 2H), 
4.59 (d, J = 11.0 Hz, 1H), 4.47 (d, J = 11.0 Hz, 1H), 4.05-3.98 (m, 1H), 3.95-3.87 (m, 
1H), 3.80 (s, 3H), 3.65 (ddd, J = 11.5, 4.0, 2.8 Hz, 1H), 3.23 (dd, J = 9.9, 6.4 Hz, 1H), 
1.71-1.42 (m, 8H), 1.38-1.26 (m, 1H), 1.18 (d, J = 6.2 Hz, 3H), 1.00 (s, 6H), 0.89 (s, 
9H), 0.06 (dd, J = 5.5, 2.6 Hz, 6H); 125 MHz 13C NMR (CDCl3)  159.4, 145.7, 138.3, 
131.3, 129.4, 128.7, 128.1, 127.9, 114.0, 113.5, 93.5, 78.5, 78.5, 78.4, 78.4, 73.3, 72.2, 
70.1, 69.9, 69.6, 55.6, 41.9, 38.6, 38.6, 37.7, 32.0, 31.9, 26.3, 23.4, 22.6, 22.5, 22.3, 








2.53:11  To a stirring solution of alcohol 2.24 (3.32 g, 5.40 mmol, 1 equiv) in CH2Cl2 
(54 mL) in a 100 mL rb flask, at 0 °C, was added i-Pr2NEt (6.60 mL, 37.8 mmol, 7 
equiv), DMSO (3.85 mL, 54.0 mmol, 10 equiv), and SO3Pyr (3.44 g, 21.6 mmol, 4 
equiv) in a single portion. The reaction mixture was stirred at 0 °C for 1 h, then 
quenched with saturated aqueous NaHCO3 solution (30 mL).  The phases were 
separated and the aqueous layer was extracted with CH2Cl2 (3 × 30 mL).  The combined 
organic layers were dried over Na2SO4, concentrated and the purified by flash column 
chromatography using a 5.0 × 12.0 cm silica gel column, eluting with 10% 
EtOAc/hexanes, and collecting 18 × 150 mm test tube fractions.  The product 
containing fractions (11-43) were combined and concentrated under reduced pressure to 
provide 2.53 (2.84 g, 89% yield) as a faint yellow oil: Rf = 0.48 (20% EtOAc/hexanes); 
500 MHz 1H NMR (CDCl3)  7.37-7.33 (m, 4H), 7.32-7.28 (m, 1H), 7.25 (d, J = 8.5 
Hz, 2H), 6.87 (d, J = 8.5 Hz, 2H), 5.90 (dd, J = 17.3, 11.4 Hz, 1H), 5.13 (dd, J = 13.8, 
3.0 Hz, 2H), 4.81 (Aβq, J = 7.4 Hz, Δν = 10.3 Hz, 2H), 4.63 (Aβq, J = 11.8 Hz, Δν = 
21.5 Hz, 2H), 4.59 (d, J = 11.4 Hz, 1H), 4.45 (d, J = 11.4 Hz, 1H), 4.01 (ddd, J = 12.3, 
5.8, 4.8 Hz, 1H), 3.92-3.86 (m, 1H), 3.80 (s, 3H), 3.64 (ddd, J = 9.1, 4.6, 2.4 Hz, 1H), 
2.42 (ddd, J = 7.0, 7.0, 3.7 Hz, 2H), 1.68 (ddd, J = 14.0, 8.5, 2.6 Hz, 1H), 1.61-1.52 (m, 
3H), 1.47-1.40 (m, 2H), 1.21 (s, 6H), 1.18 (d, J = 6.6 Hz, 3H), 0.89 (s, 9H), 0.05 (s, 
3H), 0.05 (s, 3H); 125 MHz 13C NMR (CDCl3)  213.1, 159.4, 142.9, 138.3, 131.3, 
129.8, 128.7, 128.1, 127.9, 114.5, 114.0, 93.5, 78.3, 73.2, 72.2, 69.8, 69.6, 55.6, 51.0, 




  Preparation of (8S,10R,11R)-11-((benzyloxy)methoxy)-8-
hydroxy-10-((4-methoxybenzyl)oxy)-3,3-dimethyldodec-1-en-4-one 2.25:11  To a 
stirring solution of silyl ether 2.53 (488 mg, 0.796 mmol, 1 equiv) in THF (3.98 mL) in 
a 25 mL rb flask, at rt, was added a 1.0 M solution of TBAF (3.19 mL, 3.19 mmol, 4 
equiv) in THF.  The reaction was stirred for 20 h, and then another aliquot of TBAF (1 
mL) was added.  After an additional 6 h the reaction was quenched with saturated 
aqueous NH4Cl  solution (10 mL).  The phases were separated and the aqueous layer 
was extracted with EtOAc (3 × 10 mL).  The combined organic layers were dried over 
Na2SO4, concentrated and purified by flash column chromatography using a 2.5 × 9.0 
cm silica gel column, eluting with 30% EtOAc/hexanes, and collecting 10 × 75 mm test 
tube fractions.  The product containing fractions (21-61) were combined and 
concentrated under reduced pressure to provide 2.25 (368 mg, 93% yield) as a clear oil: 
Rf = 0.16 (30% EtOAc/hexanes); 500 MHz 
1H NMR (CDCl3)  7.38-7.33 (m, 4H), 
7.32-7.28 (m, 1H), 7.25 (d, J = 9.1 Hz, 2H), 6.86 (d, J = 9.1 Hz, 2H), 5.91 (dd, J = 17.5, 
10.4 Hz, 1H), 5.14 (ddd, 14.7, 3.8, 0.9 Hz, 2H), 4.84 (Aβq, J = 13.6 Hz, Δν = 11.3 Hz, 
2H), 4.63 (s, 2H), 4.61 (d, J = 11.1 Hz, 1H), 4.50 (d, J = 11.1 Hz, 1H), 4.00 (ddd, J = 
6.3, 6.3, 5.4 Hz, 1H), 3.80 (s, 3H), 3.75-3.68 (m, 2H), 2.53-2.41 (m, 2H), 1.65-1.59 (m, 
4H), 1.41-1.34 (m, 2H), 1.22 (s, 6H), 1.19 (d, J = 6.5 Hz, 3H); 125 MHz 13C NMR 
(CDCl3)  213.5, 159.6, 142.8, 138.1, 130.7, 130.0, 129.9, 128.7, 128.1, 128.0, 114.5, 





  Preparation of (S)-2-((2R,3R)-3-((benzyloxy)methoxy)-2-((4-
methoxybenzyl)oxy)butyl)-6-(2-methylbut-3-en-2-yl)-3,4-dihydro-2H-pyran 2.13:11  
To a stirring solution of hydroxyketone 2.25 (192 mg, 0.385 mmol, 1 equiv) in benzene 
(7.7 mL) in a 25 mL rb flask, at rt, was added 4 Å molecular sieves (5) and CSA (6.0 
mg, 0.02 mmol, 0.05 equiv).  The flask was fitted with an efficient reflux condenser 
then heated in a 85 °C oil bath.  After 3 h the solution was cooled to rt, quenched with 
pyridine (200 μL), concentrated, and purified by flash column chromatography using a 
2.0 × 8.5 cm silica gel column, eluting with 8% EtOAc/hexanes, and collecting 10 × 75 
mm test tube fractions.  The product containing fractions (11-30) were combined and 
concentrated under reduced pressure to provide 2.13 (163 mg, 88% yield) as a clear oil: 
Rf = 0.60 (30% EtOAc/hexanes); 500 MHz 
1H NMR (CDCl3)  7.38-7.34 (m, 4H), 
7.33-7.29 (m, 1H), 7.26 (d, J = 8.9 Hz, 2H), 6.87 (d, J = 8.9 Hz, 2H), 5.94 (dd, J = 18.5, 
11.0 Hz, 1H), 5.02 (dd, J = 17.6, 1.5 Hz, 1H), 4.94 (dd, J = 10.7, 1.5 Hz, 1H), 4.84 
(Aβq, J = 6.7 Hz, Δν = 5.6 Hz, 2H), 4.65 (Aβq, J = 11.8 Hz, Δν = 7.2 Hz, 2H), 4.62 (d, 
J = 10.9, 1H), 4.58 (dd, J = 4.6, 2.8 Hz, 1H), 4.53 (d, J = 10.9 Hz, 1H), 4.05-3.94 (m, 
2H), 3.86 (ddd, J = 10.7, 5.1, 2.3 Hz, 1H), 3.80 (s, 3H), 2.14-2.05 (m, 1H), 2.03-1.91 
(m, 1H), 1.90-1.73 (m, 2H), 1.61 (ddd, J = 14.5, 10.6, 2.5 Hz, 1H), 1.56-1.46 (m, 1H), 
1.21 (d, J = 6.5 Hz, 3H), 1.18 (s, 3H), 1.17 (s, 3H); 125 MHz 13C NMR (CDCl3)  
159.5, 159.1, 146.5, 138.2, 131.2, 130.0, 129.8, 128.7, 128.1, 127.9, 114.1, 114.0, 






 Preparation of tert-butyl(((2R,3R)-3-((4-methoxybenzyl)oxy)-
4-((S)-6-(2-methylbut-3-en-2-yl)-3,4-dihydro-2H-pyran-2-yl)butan-2-
yl)oxy)dimethylsilane 2.42:  To a stagnant solution of 4,4-ditertbutylbiphenyl (1.0 g, 
3.75 mmol) in THF (7.5 mL) in a 25 mL rb flask under an Ar atmosphere, at 0 °C, was 
added freshly cut Li wire, washed with hexanes then Et2O (~60 mg).  This solution was 
maintained at 0 °C in an ultrasonication bath for 2 h resulting in a deep blue/green 
solution.  The 0.5 M LiDBB solution was then added dropwise to a stirring solution of 
BOM ether 2.13 (224 mg, 0.466 mmol, 1 equiv) in THF (4.6 mL) in a 25 mL rb flask, at 
-78 °C, until a deep blue color persisted.  After 1 h the reaction mixture was quenched 
by the addition of saturated aqueous NH4Cl solution (5 mL) then warmed to rt.  The 
phases were separated and the aqueous layer was extracted with EtOAc (3 × 10 mL).  
The combined organic layers were dried over Na2SO4, concentrated and purified by 
flash column chromatography using a 2.0 × 12.0 cm silica gel column, eluting first with 
100 mL of 5% EtOAc/hexanes to wash off 4,4-ditertbutylbiphenyl, then with 20% 
EtOAc/hexanes, and collecting 10 × 75 mm test tube fractions.  The product containing 
fractions (58-85) were combined and concentrated under reduced pressure to provide 
the pure alcohol (95 mg, 57% yield) as a clear oil: Rf = 0.33 (30% EtOAc/hexanes) 
To a stirring solution of the aforementioned alcohol in CH2Cl2 (2.64 mL) in a 25 mL 
rb flask, at rt, was added TBSCl (80.0 mg, 0.528 mmol, 2 equiv), and imidazole (72.0 
mg, 1.06 mmol, 4 equiv).  This solution was stirred for 20 h, and then quenched with 
water (5 mL).  The phases were separated and the aqueous layer was extracted with 




concentrated, and purified by flash column chromatography using a 1.5 × 10.0 cm silica 
gel column, eluting with 5% EtOAc/hexanes, and collecting 10 × 75 mm test tube 
fractions.  The product containing fractions (3-11) were combined and concentrated 
under reduced pressure to provide 2.42 (94 mg, 75% yield) as a clear oil: Rf = 0.66 
(30% EtOAc/hexanes); +29.4 (c =1.0, CHCl3); 500 MHz 
1H NMR (CDCl3)  
7.27 (d, J = 8.9 Hz, 2H), 6.89 (d, J = 8.9 Hz, 2H), 5.97 (dd, J = 17.6, 10.7 Hz, 1H), 5.04 
(dd, J = 17.5, 1.3 Hz, 1H), 4.95 (dd, J = 10.8, 1.5 Hz, 1H), 4.59 (d, J = 10.5 Hz, 1H), 
4.58 (s, 3H), 4.51 (d, J = 10.5 Hz, 1H), 4.01-3.95 (m, 2H), 3.81 (s, 3H), 3.75 (ddd, J = 
11.1, 4.8, 1.8 Hz, 1H), 2.10 (dddd, J = 6.7, 9.9, 9.9, 2.5 Hz, 1H), 2.03-1.94 (m, 1H), 
1.85 (ddd, J = 14.5, 10.7, 1.9 Hz, 1H), 1.78-1.71 (m, 1H), 1.51 (ddd, J = 14.0, 11.1, 2.9 
Hz, 2H), 1.20 (s, 3H), 1.18 (s, 3H), 1.12 (d, J = 6.3 Hz, 3H), 0.91 (s, 9H), 0.07 (s, 6H); 
125 MHz 13C NMR (CDCl3)  159.4, 159.3, 146.6, 131.5, 129.5, 114.0, 110.9, 93.1, 
79.1, 73.1, 71.8, 68.4, 55.5, 41.6, 35.0, 28.6, 26.1, 25.8, 25.4, 20.9, 18.3, 17.7, -4.5, -
4.6; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 26.1, 25.8, 25.4, 17.7, -4.5, -4.6; CH2 δ110.9, 
73.1, 35.0, 28.6, 20.9; CH δ 146.6, 129.5, 114.0, 93.1, 79.1, 71.8, 68.4; C δ 159.4, 
159.3, 131.5, 41.6, 18.3; IR (neat) 2956, 2929, 2856, 1663, 1613, 1587, 1515, 1463 cm-
1; HRMS (ESI/ APCI) calcd 497.3036 for C28H46O4SiNa found 497.3059. 
 
 Preparation of (2S,6S)-6-((2R,3R)-3-((tert-
butyldimethylsilyl)oxy)-2-((4-methoxybenzyl)oxy)butyl)-2-methoxy-2-(2-
methylbut-3-en-2-yl)dihydro-2H-pyran-3(4H)-one 2.43:  To a stirring solution of 





°C, was added MeOH (1.0 mL), NaHCO3 (33.0 mg, 0.392 mmol, 2 equiv), and MMPP 
(196 mg, 0.392 mmol, 2 equiv).  After 1 h the reaction mixture was quenched with 
saturated aqueous NaHCO3 solution (5 mL), warmed to rt, and the phases were 
separated.  The aqueous layer was extracted with EtOAc (3 × 10 mL).  The combined 
organic layers were thoroughly dried over MgSO4, and concentrated to give the crude 
alcohol as a clear oil, which was used without purification. 
To a stirring solution of the aforementioned crude alcohol in MeOH (20 mL) in a 50 
mL rb flask, at 0 °C, was added monochloroacetic acid (19.0 mg, 0.198 mmol, 1 equiv).  
This solution was stirred for 45 min, and then quenched with saturated aqueous 
NaHCO3 solution (20 mL).  The phases were separated and the aqueous layer was 
extracted with 50% EtOAc/hexanes (3 × 20 mL).  The combined organic layers were 
thoroughly dried over MgSO4, and concentrated to give a crude alcohol as a clear oil, 
which was used without purification. 
To a stirring solution of Dess-Martin periodinane (168 mg, 0.396 mmol, 2 equiv) in 
CH2Cl2 (1.2 mL) in a 25 rb flask, at 0 °C, was added pyridine (160 μL, 1.98 mmol, 10 
equiv).  The aforementioned alcohol was added as a solution in CH2Cl2 (0.5 mL) via 
cannula.  An additional 0.5 mL aliquot of CH2Cl2 was used to complete the transfer.  
The solution was warmed to rt, stirred for 4 h, and then quenched by the addition of 
saturated aqueous NaHCO3 solution (5 mL).  The phases were separated and the 
aqueous layer was extracted with CH2Cl2 (3 × 5 mL).  The combined organic layers 
were dried over Na2SO4, concentrated and purified by flash column chromatography 
using a 1.5 × 10.0 cm silica gel column, eluting with 5% EtOAc/hexanes, and collecting 




combined and concentrated under reduced pressure to provide 2.43 (69 mg, 68% yield 
over 3 steps) as a clear oil: Rf = 0.60 (30% EtOAc/hexanes); +21.1 (c =1.0, 
CHCl3); 500 MHz 
1H NMR (CDCl3)  7.23 (d, J = 8.9 Hz, 2H), 6.87 (d, J = 8.9 Hz, 
2H), 6.21 (dd, J = 17.7, 10.8 Hz, 1H), 5.02 (dd, J = 9.3, 1.4 Hz, 1H), 4.99 (dd, J = 2.6, 
1.4 Hz, 1H), 4.61 (d, J = 10.8 Hz, 1H), 4.44 (d, J = 10.8 Hz, 1H), 4.19-4.09 (m, 2H), 
3.80 (s, 3H), 3.77 (ddd, J = 10.9, 4.6, 2.1 Hz, 1H), 3.28 (s, 3H), 2.54-2.40 (m, 2H), 
1.97-1.90 (m, 3H), 1.57 (ddd, J = 14.2, 11.0, 3.2 Hz, 1H), 1.16 (s, 3H), 1.12 (d, J = 5.9 
Hz, 3H), 1.11 (s, 3H), 0.91 (s, 9H), 0.09 (s, 6H); 125 MHz 13C NMR (CDCl3)  207.5, 
159.4, 144.5, 131.0, 129.4, 114.1, 112.6, 104.0, 78.9, 72.0, 69.4, 67.1, 55.5, 52.2, 45.1, 
37.7, 35.1, 30.5, 26.0, 22.5, 22.3, 18.3, 17.1, -4.5, -4.6; 125 MHz DEPT (CDCl3) CH3 δ 
55.5, 52.2, 26.0, 22.5, 22.3, 17.1, -4.5, -4.6; CH2 δ 112.6, 72.0, 37.7, 35.1, 30.5; CH δ 
144.5, 129.4, 114.1, 78.9, 69.4, 67.1; C δ 207.5, 159.4, 131.0, 104.0, 45.1, 18.3; IR 
(neat) 2954, 2890, 1725, 1612, 1514, 1463 cm-1; HRMS (ESI/ APCI) calcd 543.3118 
for C29H48O6SiNa found 543.3125. 
 
 Preparation of (E)-methyl 2-((2S,6S)-6-((2R,3R)-3-((tert-
butyldimethylsilyl)oxy)-2-((4-methoxybenzyl)oxy)butyl)-2-methoxy-2-(2-
methylbut-3-en-2-yl)-3-oxodihydro-2H-pyran-4(3H)-ylidene)acetate 2.54:  To a 
stirring solution of ketone 2.43 (69 mg, 0.133 mmol, 1 equiv) in MeOH (1.33 mL) in a 
15 mL rb flask, at rt, was added K2CO3 (92 mg, 0.663 mmol, 5 equiv) followed by a 3.0 





equiv).  The solution rapidly developed a vibrant yellow color, and after 1 h it was 
quenched with saturated aqueous NH4Cl solution (5 mL).  The phases were separated 
and the aqueous layer was extracted with Et2O (3 × 5 mL).  The combined organic 
layers were dried over Na2SO4, concentrated and purified by flash column 
chromatography using a 1.5 × 12.0 cm silica gel column, eluting with 12% 
EtOAc/hexanes, and collecting 10 × 75 mm test tube fractions.  The product containing 
fractions (4-13) were combined and concentrated under reduced pressure to provide 
2.54 (64 mg, 81% yield) as an intense yellow oil: Rf = 0.59 (30% EtOAc/hexanes); 
-75.3 (c =1.0, CHCl3); 500 MHz 
1H NMR (CDCl3)  7.20 (d, J = 8.6 Hz, 2H), 
6.85 (d, J = 8.6 Hz, 2H), 6.58 (s, 1H), 6.05 (dd, J = 17.8, 11.2 Hz, 1H), 4.97 (dd, J = 
5.3, 1.1 Hz, 1H), 4.95 (dd, J = 12.0, 1.4 Hz, 1H), 4.60 (d, J = 11.3 Hz, 1H), 4.42 (d, J = 
11.3 Hz, 1H), 4.21-4.11 (m, 2H), 3.79 (s, 3H), 3.80-3.75 (m, 1H), 3.76 (s, 3H), 3.31 
(ddd, 18.8, 1.9, 1.9 Hz, 1H), 3.27 (s, 3H), 2.88 (ddd, J = 18.8, 12.7, 3.4 Hz, 1H), 2.01 
(ddd, J = 14.5, 9.4, 1.9 Hz, 1H), 1.68 (ddd, J = 13.8, 10.3, 2.9 Hz, 1H), 1.13 (d, J = 6.9 
Hz, 3H), 1.10 (s, 3H), 1.05 (s, 3H), 0.91 (s, 9H), 0.09 (s, 6H); 125 MHz 13C NMR 
(CDCl3)  197.7, 166.3, 159.4, 148.4, 143.4, 130.9, 129.2, 123.1, 114.1, 113.4, 104.7, 
78.6, 71.6, 69.1, 67.1, 55.5, 52.3, 52.0, 45.8, 36.3, 35.0, 26.0, 22.3, 21.9, 18.2, 17.0, -
4.4, -4.6; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 52.3, 52.0, 26.0, 22.3, 17.1, -4.4, -4.6; 
CH2 δ 113.4, 71.6, 36.3, 35.0; CH δ143.4, 129.2, 123.1, 114.1, 78.6, 69.1, 67.1; C δ 
197.7, 166.3, 159.4, 148.4, 130.9, 104.7, 45.8, 18.2; IR (neat) 2955, 2931, 2858, 1725, 







 Preparation of (E)-methyl 2-((2S,3S,6S)-3-acetoxy-6-((2R,3R)-
3-((tert-butyldimethylsilyl)oxy)-2-((4-methoxybenzyl)oxy)butyl)-2-methoxy-2-(2-
methylbut-3-en-2-yl)dihydro-2H-pyran-4(3H)-ylidene)acetate 2.44:  To a stirring 
solution of ketone 2.54 (32.0 mg, 0.054 mmol, 1 equiv) in MeOH (3.6 mL) in a 15 mL 
rb flask, at rt, was added CeCl37H2O (404 mg, 1.08 mmol, 20 equiv).  This suspension 
was stirred until complete solvation of the cerium, then cooled to -42 °C, and NaBH4 
(20 mg, 0.54 mmol, 10 equiv) was added in a single portion.  After 1 h the reaction 
mixture was quenched by the addition of saturated aqueous NH4Cl solution (5 mL), 
then warmed to rt.  The phases were separated and the aqueous layer was extracted with 
40% EtOAc/hexanes (3 × 10 mL).  The combined organic layers were dried over 
MgSO4, and concentrated to give the crude alcohol as a clear oil. 
To a stirring solution of the aforementioned crude alcohol in CH2Cl2 (1.8 mL) in a 
10 mL rb flask, at 0 °C, was added pyridine (65 μL, 0.81 mmol, 15 equiv), DMAP (6.7 
mg, 0.05 mmol, 1 equiv), and acetic anhydride (26.0 μL, 0.270 mmol, 5 equiv).  After 3 
h the reaction mixture was quenched by the addition of saturated aqueous NaHCO3 
solution (5 mL), and warmed to rt.  The phases were separated and the aqueous layer 
was extracted with 40% EtOAc/hexanes (3 × 10 mL).  The combined organic layers 
were dried over Na2SO4, concentrated and purified by flash column chromatography 
using a 1.5 × 11.0 cm silica gel column, eluting with 8% EtOAc/hexanes, and collecting 
10 × 75 mm test tube fractions.  The product containing fractions (10-40) were 




as a clear oil: Rf = 0.58 (30% EtOAc/hexanes); -8.8 (c =1.0, CHCl3); 500 MHz 
1H NMR (CDCl3)  7.21 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 6.25 (dd, J = 
17.6, 11.1 Hz, 1H), 5.89 (s, 1H), 5.36 (s, 1H), 4.86 (d, J = 17.6 Hz, 1H), 4.81 (d, J = 
11.1 Hz, 1H), 4.60 (d, J = 11.1 Hz, 1H), 4.41 (d, J = 11.1 Hz, 1H), 4.13 (dq, J = 4.5, 6.2 
Hz, 1H), 4.01 (dddd, J = 13.8, 13.8, 2.8, 2.8 Hz, 1H), 3.80 (s, 3H), 3.78 (dd, J = 4.4, 2.5 
Hz, 1H), 3.69 (s, 3H), 3.51 (dd, J = 15.5, 2.2 Hz, 1H), 3.27 (s, 3H), 2.30 (ddd, J = 14.4, 
11.9, 1.5 Hz, 1H), 2.00 (s, 3H), 1.97 (dd, J = 13.7, 9.7 Hz, 1H), 1.65 (ddd, J = 14.0, 
11.2, 2.5 Hz, 1H), 1.14 (d, J = 6.0 Hz, 3H), 1.13 (s, 3H), 1.10 (s, 3H), 0.93 (s, 9H), 0.10 
(s, 6H); 125 MHz 13C NMR (CDCl3)  169.4, 166.7, 159.4, 152.6, 146.5, 131.0, 129.3, 
117.8, 114.0, 108.7, 102.9, 78.8, 72.4, 71.9, 68.6, 67.3, 55.5, 51.7, 51.3, 46.8, 35.4, 
32.6, 26.1, 24.5, 22.7, 21.6, 18.3, 17.2, -4.4, -4.6; 125 MHz DEPT (CDCl3) CH3 δ 55.5, 
51.7, 51.3, 26.1, 24.5, 22.7, 17.2, -4.4, -4.6; CH2 δ 108.7, 71.9, 35.4, 32.6; CH δ 146.5, 
129.3, 117.8, 114.0, 78.8, 72.4, 68.6, 67.3; C δ 169.4, 166.7, 159.4, 152.6, 131.0, 102.9, 
46.8, 18.3; IR (neat) 2954, 2856, 1748, 1721, 1667, 1613, 1514, 1464 cm-1; HRMS 
(ESI/ APCI) calcd 657.3435 for C34H54O9SiNa found 657.3434. 
 







yl)-2-methoxydihydro-2H-pyran-4(3H)-ylidene)acetate 2.45:  A 4 mL reaction vial 
was charged with a stir bar, olefin 2.44 (40.0 mg, 0.063 mmol, 1 equiv), bromide 2.35 
(34.0 mg, 0.076 mmol, 1.2 equiv), Pd2(dba)3 (1.40 mg, 0.0016 mmol, 0.025 equiv), and 
Pd(P(t-Bu)3)2 (1.60 mg, 0.0032 mmol, 0.05 equiv).  The vial was fitted with septum 
cap, evacuated, and refilled with N2.  Toluene (500 μL) was added followed by 
Cy2NMe (16.0 μL, 0.076 mmol, 1.2 equiv), and the solution was degassed by three 
consecutive freeze/vacuum (10 min) then thaw cycles.  After the final thaw the N2 line 
was removed, and the vial cap was wrapped with parafilm.  Within 30 min the solution 
transitioned from a deep purple color to very dark green indicating that it was 
progressing.  After 20 h, at rt, the almost black solution was pipeted directly on to a 1.5 
× 11.0 cm silica gel column, eluting first with 10% EtOAc/hexanes (100 mL), then with 
15% EtOAc/hexanes (100 mL), and finally with 20% EtOAc/hexanes, and collecting 10 
× 75 mm test tube fractions.  The recovered C-ring containing fractions (14-25) were 
combined and concentrated under reduced pressure to provide olefin 2.44 (17 mg, 42% 
yield).  The product containing fractions (40-72) were combined and concentrated under 
reduced pressure to provide 2.45 (31 mg, 49% yield) as a clear oil: Rf = 0.31 (30% 
EtOAc/hexanes); -6.9 (c =1.0, CHCl3); 500 MHz 
1H NMR (CDCl3)  7.25-7.16 
(m, 5H), 7.05-6.96 (m, 5H), 6.84 (d, J = 9.1 Hz, 2H), 6.58 (d, J = 16.9 Hz, 1H), 6.17 (d, 
J = 16.9 Hz, 1H), 5.85 (s, 1H), 5.48 (s, 1H), 4.59 (d, J = 11.3 Hz, 1H), 4.38 (d, J = 11.3 
Hz, 1H), 4.20-4.00 (m, 3H), 3.93 (s, 2H), 3.89-3.79 (m, 1H), 3.79 (s, 3h), 3.74-3.67 (m, 
2H), 3.64 (s, 3H), 3.46 (d, J = 15.8 Hz, 1H), 3.27 (s, 3H), 2.86 (dd, J = 13.1, 6.1 Hz, 
1H), 2.73 (dd, J = 13.1, 7.8 Hz, 1H), 2.44 (s, 1H), 2.36 (dd, J = 13.8, 13.8 Hz, 1H), 2.00 





2.3 Hz, 1H), 1.63-1.55 (m, 1H), 1.22 (s, 3H), 1.20 (s, 3H), 1.15 (d, J = 6.4 Hz, 3H), 
0.98-0.87 (m, 18H), 0.60-0.50 (m, 6H), 0.11 (d, J = 3.5 Hz, 6H); 125 MHz 13C NMR 
(CDCl3)  169.7, 166.7, 159.4, 152.8, 141.4, 141.4, 138.9, 138.5, 138.3, 130.9, 130.3, 
129.3, 128.8, 128.6, 127.6, 127.5, 127.5, 127.4, 127.1, 127.1, 123.5, 114.0, 102.9, 78.8, 
73.5, 71.9, 71.9, 68.5, 67.2, 60.5, 55.5, 51.4, 51.3, 46.5, 44.0, 42.0, 37.8, 35.3, 33.2, 
26.1, 26.0, 24.5, 23.2, 21.4, 18.3, 17.2, 7.1, 5.1, -4.4, -4.5; 125 MHz DEPT (CDCl3) 
CH3 δ 55.5, 51.4, 51.3, 26.1, 26.0, 24.5, 23.2, 21.4, 17.2, 7.1, -4.4, -4.5; CH2 δ 71.9, 
60.5, 44.0, 42.0, 37.8, 35.3, 33.2, 5.1; CH δ 138.5, 130.3, 129.3, 128.8, 128.6, 127.6, 
127.5, 127.5, 127.4, 127.1, 127.1, 123.5, 114.0, 78.8, 73.5, 71.9, 68.5, 67.2; C δ 169.7, 
166.7, 159.4, 152.8, 141.4, 141.4, 138.9, 138.3, 130.9, 102.9, 46.5, 18.3; IR (neat) 3476, 
2955, 1746, 1721, 1601, 1514, 1462 cm-1; HRMS (ESI/ APCI) calcd 1025.5606 for 
C57H86O11Si2Na found 1025.5616.  
 
  Preparation of (R)-4-(3-(3-((E)-3-((2S,3S,6S,E)-3-acetoxy-
6-((2R,3R)-3-((tert-butyldimethylsilyl)oxy)-2-((4-methoxybenzyl)oxy)butyl)-2-
methoxy-4-(2-methoxy-2-oxoethylidene)tetrahydro-2H-pyran-2-yl)-3-methylbut-1-
en-1-yl)benzyl)phenyl)-3-((triethylsilyl)oxy)butanoic acid 2.55:  To a stirring of 
alcohol 2.45 (12.0 mg, 0.012 mmol, 1 equiv) in CH2Cl2 (120 L) in a 2 mL reaction 




0.120 mmol, 10 equiv), and SO3Pyr (8.0 mg, 0.048 mmol, 4 equiv) in a single portion.  
This solution was stirred at 0 C for 45 min, and then quenched with a saturated 
aqueous NaHCO3 solution (1 mL).  The phases were separated, and aqueous layer was 
extracted with 40% EtOAc/hexanes (3 × 3 mL).  The combined organic layers were 
dried over Na2SO4, and concentrated under reduced pressure.  The resulting clear oil 
was run through a 1.5 × 4.5 cm plug of silica with 20% EtOAc/hexanes, and 
concentrated to give the crude aldehyde (11.0 mg). 
To a stirring solution of the aforementioned aldehyde in 2-methyl-2-butene (171 
L) and t-BuOH (171 L) in a 5 mL rb flask, at rt, was added a 1.25 M aqueous 
solution of KH2PO4 (60.0 L).  This solution was cooled to -10 C in an ethelene 
glycal/CO2 bath, and NaClO2 (80% by wt., 5.0 mg, 0.06 mmol, 5 equiv) was added in a 
single portion.  The reaction was stirred vigorously for 1.5 h, and then quenched with a 
0.05 M aqueous pH 4 buffer solution (1 mL).  The phases were separated, and aqueous 
layer was extracted with Et2O (3 × 3 mL).  The organic layers were combined, dried 
over Na2SO4, and concentrated.  Purification was accomplished by flash column 
chromatography using a 1.5 × 10.0 cm silica gel column, eluting with 30% 
EtOAc/hexanes, and collecting 10 × 75 mm test tube fractions.  The product containing 
fractions (2-8) were concentrated to give acid 2.55 (10.0 mg, 82%, 2 steps) as a clear oil 






  Preparation of Protected Merle 40 2.46:  To a stirring 
solution of PMB ether 2.55 (10.0 mg, 0.0098 mmol, 1 equiv) in CH2Cl2 (250 L) and 
water (2.5 L) in a 5 mL rb flask, at rt, was added DDQ (3.3 mg, 0.015 mmol, 1.5 
equiv).  After 30 min the reaction was pipeted directly onto a 1.5 × 8.0 cm silica gel 
column, eluting with 25% EtOAc/hexanes, and collecting 10 × 75 mm test tube 
fractions.  Product containing fractions (8-18) were concentrated to give seco-acid (7.0 
mg, 80%) as a clear oil. Rf = 0.61 (10% MeOH/ 40% EtOAc/ 50% hexanes). 
To stirring a solution of the aforementioned seco-acid in THF (260 L) in 2 mL 
vial, at 0 C, was added Et3N (6.5 L, 0.047 mmol, 6 equiv) and a 1.0 M solution of 
trichlorobenzoyl chloride (23 L, 0.023 mmol, 3 equiv) in THF. After 5 min, the 
mixture was warmed to rt and stirring was continued for an additional 3 h.  The reaction 
mixture was diluted with toluene (2.6 mL) and taken up into a 5 mL gas-tight syringe.  
This solution was added by syringe pump to a stirring solution of DMAP (19.0 mg, 
0.156 mmol, 20.0 equiv) in toluene (5.2 mL) at 40 °C over 12 h. The residual contents 
of the syringe were rinsed into the flask with toluene (1 mL) and stirring was continued 
for an additional 2 h. The reaction mixture was cooled to rt, diluted with 30% 
EtOAc/hexanes (25 mL) and washed with water (3 × 10 mL) and brine (10 mL).  The 
organic phase was dried over Na2SO4, and concentrated under reduced pressure.  




silica gel column, eluting with 5% EtOAc/hexanes, and collecting 6 × 50 mm test tube 
fraction.  The product containing fractions (4-13) were combined and concentrated 
under reduced pressure to provide macrolactone 2.46 as a clear oil (4.0 mg, 58% over 2 
steps) along with a compound resulting from elimination of the C19 methyl ketal (1.0 
mg, 14% yield). Data for protected Merle 40 2.46: Rf = 0.69 (30% EtOAc/hexanes); 
+ 5.0 (c =1.0, CHCl3); 500 MHz 
1H NMR (CDCl3)  7.24-7.12 (m, 5H), 7.06-
7.02 (m, 2H), 7.00 (d, J = 7.1 Hz, 1H), 6.24 (s, 2H), 5.90 (s, 1H), 5.32 (s, 1H), 5.05 (d, J 
= 9.3 Hz, 1H), 4.26 (ddd, J = 12.0, 6.5, 6.5 Hz, 1H), 4.00-3.95 (m, 1H), 3.93 (q, J = 
14.0 Hz, 2H), 3.76-3.68 (m, 1H), 3.60 (s, 3H), 3.50 (d, J = 15.1 Hz, 1H), 2.95 (s, 3H), 
2.82 (dd, J = 13.9, 4.8 Hz, 1H), 2.68 (dd, J = 13.9, 7.1 Hz, 1H), 2.24-2.16 (m, 2H), 
2.10-2.02 (m, 2H), 2.07 (s, 3H), 1.79 (ddd, J = 14.5, 10.1, 4.6 Hz, 1H), 1.25 (s, 3H), 
1.11 (s, 3H), 1.08 (d, J = 6.3 Hz, 3H), 0.93 (t, J = 8.2 Hz, 9H), 0.93 (s, 9H), .057 (q, J = 
8.2 Hz, 6H), 0.15 (s, 3H), 0.11 (s, 3H); 125 MHz 13C NMR (CDCl3)  170.7, 169.4, 
166.7, 152.0, 141.9, 141.9, 141.7, 138.5, 138.0, 137.5, 130.7, 128.6, 128.3, 127.9, 
127.8, 127.0, 126.9, 126.0, 125.3, 103.3, 72.2, 70.1, 68.8, 67.7, 51.5, 51.3, 45.9, 43.5, 
42.2, 41.4, 34.1, 31.8, 26.0, 24.3, 23.1, 21.5, 18.3, 17.8, 7.1, 5.0, -4.5, -4.6; 125 MHz 
DEPT (CDCl3) CH3 δ 51.5, 51.3, 26.0, 23.1, 21.5, 17.8, 7.1, -4.5, -4.6; CH2 δ 43.5, 
42.2, 41.4, 34.1, 5.1; CH δ 137.5, 130.7, 128.6, 128.3, 127.9, 127.8, 127.0, 126.9, 126.0, 
125.3, 72.2, 70.1, 68.8, 67.7; C δ 170.7, 169.4, 166.7, 152.0, 141.9, 141.7, 138.5, 138.0, 
103.3, 45.9, 18.3; IR (neat) 2954, 2884, 1743, 1719, 1661, 1602, 1472 cm-1; HRMS 






  and Preparation of Merle 40 and 2.48:  
To a stirring solution of analog precursor 2.46 (4.2 mg, 0.0048 mmol, 1 equiv) in 
CH3CN (432 L) and water (48 L) in a 2 mL plastic vial, at rt, was added a 48% 
aqueous HF solution (19 L) using a plastic ependorf pipet.  After 2 h the reaction 
mixture was quenched by the addition of a 1:1 mixture of EtOAc and a saturated 
aqueous NaHCO3 solution (1 mL).  The phases were separated and the aqueous layer 
was extracted with EtOAc (3 × 5 mL).  The combined organic layers were dried over 
Na2SO4, concentrated and purified by flash column chromatography using a 0.5 × 5.0 
cm silica gel column, eluting with 25% EtOAc/hexanes collecting 6 × 50 mm test tube 
fractions.  The C26 TBS protected Merle 40 containing fractions (14-20) were 
combined and concentrated to give 2.48 (2.4 mg, 67% yield) as a clear oil, and then the 
eluent was changed to 65% EtOAc/hexanes.  The product containing fractions (32-40) 
were combined and concentrated under reduced pressure to provide Merle 40 (0.5 mg, 
15% yield) as a clear oil.  
Data for 2.48. Rf = 0.72 (10% MeOH/ 40% EtOAc/ 50% hexanes); + 4.8 (c 
= 0.24, CHCl3); 500 MHz 
1H NMR (CDCl3)  7.27-7.23 (m, 2H), 7.20-7.11 (m, 3H), 
7.10-7.06 (m, 1H), 6.99-6.92 (m, 2H), 6.42 (d, J = 17.1 Hz, 1H), 6.37 (d, J = 17.1 Hz, 
1H), 5.99 (s, 1H), 5,31 (s, 1H), 5.14 (s, 1H), 5.08 (dd, J = 10.8, 4.4 Hz, 1H), 4.24-4.16 





3.65-3.57 (m, 2H), 2.93 (dd, J = 14.2, 5.7 Hz, 1H), 2.82 (d, J = 8.7 Hz, 1H), 2.69 (dd, J 
= 13.5, 3.4 Hz, 1H), 2.36 (dd, J = 16.2, 7.9 Hz, 1H), 2.23 (dd, J = 15.2, 3.8 Hz, 1H), 
2.09 (s, 3H), 1.91 (dd, J = 13.3, 13.3 Hz, 1H), 1.28 (s, 3H), 1.15 (s, 3H), 1.14 (d, J = 6.3 
Hz, 3H), 0.94 (s, 9H), 0.15 (s, 3H), 0.14 (s, 3H); 125 MHz 13C NMR (CDCl3)  171.3, 
169.5, 166.9, 151.7, 142.1, 141.9, 137.5, 136.6, 135.3, 131.2, 130.7, 128.8, 128.8, 
128.4, 127.6, 127.5, 127.0, 125.1, 119.9, 98.7, 74.5, 71.8, 68.2, 67.7, 65.7, 51.4, 45.9, 
43.1, 42.2, 39.2, 34.0, 31.4, 26.0, 24.6, 21.6, 20.7, 18.3, 17.9, -4.4, -4.5; 125 MHz 
DEPT (CDCl3) CH3 δ 51.4, 26.0, 24.6, 21.6, 20.7, 17.9, -4.4, -4.5; CH2 δ 43.1, 42.2, 
39.2, 34.0, 31.4; CH δ 135.3, 131.2, 130.7, 128.8, 128.8, 128.4, 127.6, 127.6, 127.5, 
127.0, 125.1, 119.9, 74.5, 71.8, 68.2, 67.7, 65.8; C δ 171.3, 169.5, 166.9, 151.7, 142.1, 
141.9, 137.5, 136.6, 98.7, 45.9, 18.3; IR (neat) 3492, 2930, 2857, 1722, 1660, 1462 cm-
1; HRMS (ESI/ APCI) calcd 773.3697 for C42H58O10SiNa found 773.6704. 
 
Data for Merle 40. Rf = 0.40 (10% MeOH/ 40% EtOAc/ 50% hexanes); -
11.0 (c = 0.5, CHCl3); 500 MHz 
1H NMR (CDCl3)  7.22-7.02 (m, 7H), 6.96 (d, J = 7.1 
Hz, 1H), 6.42 (d, J = 16.3 Hz, 1H), 6.39 (d, J = 16.3 Hz, 1H), 6.00 (s, 1H), 5.16 (s, 1H), 
5.12 (s, 1H) 5.08 (ddd, J = 8.7, 6.5, 1.9 Hz, 1H), 4.19-4.11 (m, 1H), 3.98-3.93 (m, 1H), 
3.93 (s, 2H), 3.91-3.81 (m, 1H), 3.69 (s, 3H), 3.66-3.61 (m, 1H), 2.88(d, J = 5.9 Hz, 
2H), 2.79 (s, 2H), 2.38 (dd, J = 15.8, 6.5 Hz, 1H), 2.27 (dd, J = 15.4, 5.0 Hz, 1H), 2.09 
(s, 3H), 1.93 (ddd, J = 14.5, 11.7, 2.2 Hz, 1H), 1.85-1.78 (m, 1H), 1.72 (d, J = 5.5 HZ, 
1H), 1.30 (s, 3H), 1.26 (s, 3H), 1.24 (d, J = 6.4 Hz, 3H); 125 MHz 13C NMR (CDCl3)  
172.1, 169.5, 166.9, 151.0, 142.4, 142.3, 137.5, 137.0, 135.5, 130.6, 129.0, 128.9, 





42.6, 42.3, 39.2, 36.6, 31.3, 24.7, 21.7, 20.8, 20.1; 125 MHz DEPT (CDCl3) CH3 δ 51.4, 
24.7, 21.7, 20.8, 20.1; CH2 δ 42.6, 42.3, 39.2, 36.6, 31.3; CH δ 135.5, 130.6, 129.0, 
128.9, 128.7, 127.4, 127.3, 126.9, 124.9, 120.1, 74.9, 74.3, 69.4, 69.1, 65.9; C δ 172.1, 
169.5, 166.9, 151.0, 142.4, 142.3, 137.5, 137.0, 98.7, 45.8; IR (neat) 3470, 3016, 2960, 
2888, 2840, 1746, 1730, 1600, 1510 cm-1; HRMS (ESI/ APCI) calcd 659.2832 for 
C36H44O10Na found 659.2841. 
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1H, 13C, AND DEPT SPECTRA FOR CHAPTER 2 
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